










A thesis submitted to Imperial College London for the degree of 





National Heart and Lung Institute 







The following tests on patients were carried out by myself and nurses in the asthma 
clinic at the Royal Brompton Hospital: lung function measurements, exhaled nitric 
oxide (FENO) measurement, skin prick testing, methacholine provocation test (PC20), 
weight, height, waist/hip measurement, bioelectrical impedance analysis (BIA), and 
skin fold measurements. 
Fibreoptic bronchoscopies were performed by me and previous research fellows in 
the Airways Disease Section at the National Heart and Lung Institute (NHLI), 
Imperial College London. 
The experiments carried out in this PhD were carried out using the latest equipment 
available to me at the NHLI. The staining of bronchoalveolar lavage cytospins with 
Oil red O (Chapter 4) and the staining of endobronchial biopsies with perilipin 
(Chapter 5) was performed by Dr. Jie Zhu. The multiplex assay (Chapter 7) was 
performed by Dr. Christos Rossios. 
The copyright of this thesis rests with the author and is made available under a 
Creative Commons Attribution Non-Commercial No Derivatives licence. Researchers 
are free to copy, distribute or transmit the thesis on the condition that they attribute it, 
that they do not use it for commercial purposes and that they do not alter, transform 
or build upon it. For any reuse or redistribution, researchers must make clear to 








Obesity is a risk factor for the development of asthma and plays a role in 
disease control, severity and airway inflammation. The relationship between asthma 
and adiposity is multifactorial and incorporates in-utero conditions, genetic factors, 
comorbidities and inflammation secondary to excess adipose tissue. Adipocytes 
produce cytokines, termed adipokines, which play an important role in systemic 
inflammation and have been correlated to the development of asthma and disease 
severity. Retrospective analysis of trials using inhaled corticosteroids and an in vitro 
study using alveolar macrophages has associated obesity with corticosteroid 
insensitivity in asthma.  
The first part of this study looked at data taken from a large cohort of well-
characterised severe asthmatics and compared patient demographics, disease 
characteristics, healthcare utilisation and medication according to body mass index 
(BMI). Lipid laden macrophages (LLMs) in bronchoalveolar lavage fluid (BALF) and 
perilipin as a marker of lipid droplets in endobronchial biopsies were analysed 
according to asthma severity and BMI. Finally, peripheral blood mononuclear cells 
(PBMCs) were used to study the effect of BMI on steroid sensitivity in patients with 
asthma using an in vitro model and the effects of adipokines (leptin, resistin and 
adiponectin) on the release of pro-inflammatory cytokines and corticosteroid 
response were assessed.  
Severe asthmatics are often overweight (29.3%) or obese (48.3%). Increasing 
BMI was associated with increasing medication use in terms of short-acting β2-
agonist (SABA) use per day, nebulisers and oral corticosteroid requirements (both 
maintenance and short burst therapy). In addition, obese severe asthmatics reported 
greater gastro-oesophageal reflux disease (GORD) and were less likely to be in full 
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time employment due to their asthma. LLMs are more prevalent in subjects with 
GORD which may explain the higher lipid laden macrophage index (LLMI) score 
seen in severe compared to mild/moderate asthmatics. Perilipin was expressed in 
the airway epithelium and submucosa in approximately half the study population. 
Greater expression was seen in the submucosa of asthmatic subjects compared to 
healthy controls. However, no significant correlations were noted in terms of asthma 
severity or BMI. Leptin, resistin and adiponectin were pro-inflammatory, in terms of 
CXCL8 release from PBMCs taken from asthmatics and healthy controls. PBMCs 
taken from severe asthmatics were less responsive to steroid suppression. 
Adiponectin induced IL-6, IL-10, CCL2, CCL3 and TNF-α release from PBMCs taken 
from asthmatics and healthy controls and IFN-γ, IL-1RA, CCL2, CCL3 and TNF-α 
release was suppressed by dexamethasone. Adiponectin induced CCL2 release and 
demonstrated relative corticosteroid insensitivity at dexamethasone 10-7 M in the 
severe asthma group. 
In conclusion, obesity related severe asthma is associated with more 
symptoms, a significant societal impact and patients are at risk of the many 
deleterious side effects of corticosteroid use. Leptin, resistin and adiponectin are pro-
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Chapter 1: Introduction 
1.1 Asthma 
The Global Initiative for Asthma (GINA, 2015) defined asthma as ‘a 
heterogeneous disease, usually characterised by chronic airway inflammation. It is 
defined by the history of respiratory symptoms such as wheeze, shortness of breath, 
chest tightness and cough that vary over time and in intensity, together with variable 
airflow limitation.’  
Asthma represents a spectrum of disorders characterised by airway 
obstruction. The main features include hyper-responsiveness of the airways to a 
wide variety of exogenous and endogenous stimuli and a specific pattern of mucosal 
inflammation involving activated mast cells, eosinophils and T lymphocytes. This is 
associated with altered responses of structural cells in the airway, including epithelial 
cells and airway smooth muscle cells (ASMCs) (Dichlberger et al., 2013, B, 2003) 
leading to changes in the airway wall and remodelling. 
Asthma can be divided into extrinsic asthma (atopic), intrinsic asthma (non-
atopic), and occupational asthma. Extrinsic asthma is associated with atopy and 
usually manifests in childhood or early adulthood. Atopy is defined as a genetic 
predisposition to produce immunoglobulin E (IgE) against common environmental 
allergens such as grass pollen, animal dander and house dust mite. IgE is a class of 
antibody, which has only been identified in mammals and is associated with type 1 
hypersensitivity reactions and the immune system response to parasitic (helminthic) 
infection (Amarasekera, 2011). The exact aetiology of intrinsic asthma is unknown. It 
usually occurs in patients after the age of 40 and is not related to atopy (Reed, 
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2010). Triggers such as respiratory infections, exercise, stress, air pollution and the 
inhalation of chemical irritants may cause bronchoconstriction.  
An association between asthma and obesity was first reported in adults in the 
1980’s (Seidell et al., 1986, Negri et al., 1988). The link has been a relatively recent 
suggestion, underpinned by a marked increase in the prevalence and incidence of 
both. 
1.1.1 An increasing problem 
Globally, there are more than 300 million people with asthma and this figure is 
expected to rise by a further 100 million by 2025 (Masoli et al., 2004). There are 
approximately 5.4 million people in the UK who are receiving medication for asthma 
and the number of adults with asthma in the UK has increased by 400,000 since the 
last audit of UK asthma in 2001 (UK, 2006). 
Despite significant advances in therapy over recent years, there are still over 
71,000 hospital admissions and 1400 deaths each year in the UK directly attributable 
to asthma (UK, 2004).  It is estimated that approximately 90 % of asthma deaths 
could have been prevented if the patient, carer or health care professional had acted 
differently (Asthma UK, 2014). The National Review of Severe Asthma Deaths 
(NRAD) assessed asthma deaths in the UK over a one year period (Royal College of 
Physicians, 2014). They found that where body mass index (BMI) data were 
available, 25% of cases were overweight (BMI 25 to 29.99) and 31% were obese or 
very obese (BMI ≥30). 
23 
 
There are over 4.1 million GP consultations each year and a GP with 2000 
patients will see approximately 85 people with asthma each year - each of these will 
consult three times on average (Surveys, 1995).   
The total cost of asthma to the National Health Service (NHS) is estimated at 
approximately £1 billion per year, which equates to about 1% of the total NHS 
budget, with hospital admissions comprising £45.8 million. The costs to the economy 
include lost productivity accounting for £1.23 billion with additional costs of £161 
million in benefits (UK, 2004). A real-world evaluation of the economic costs of 
persistent asthma in Europe found that the mean total cost per patient was €1,583. 
This cost ranged from €509 in controlled asthma to €2,281 in uncontrolled disease 
with increasing BMI and the presence of chronic cough or sputum production 
significantly increasing the total cost (Accordini et al., 2013).  
1.1.2 Severe asthma 
The majority of asthmatics can be well controlled using inhaled corticosteroids 
(ICS) and long-acting β2-agonists (LABAs). However, approximately 5% have a 
severe, refractory form of the disease (ATS, 2000). This group of patients is often 
difficult to treat, require significant attention and utilise 50% of the available NHS 
resources for asthma. Difficult to control asthma costs the NHS over £680 million a 
year (UK, 2004) and the average cost per patient with severe asthma is nearly six 
times that encountered with patients with mild asthma (Serra-Batlles et al., 1998). 
Furthermore, severe asthmatics are 20 times more likely to be admitted to hospital 




The ERS/ATS (Chung et al., 2014) defined severe asthma as asthma which 
requires treatment with guidelines suggested medications for GINA steps 4 – 5 
asthma (high dose ICS and LABA or leukotriene modifier/theophylline) for the 
previous year or systemic CS for ≥50% of the previous year to prevent it from 
becoming “uncontrolled” or which remains “uncontrolled” despite this therapy. 
Uncontrolled asthma is defined as at least one of the following:  
1) Poor symptom control: ACQ consistently >1.5, ACT <20 (or “not well 
controlled” by NAEPP/GINA guidelines)  
2) Frequent severe exacerbations: two or more bursts of systemic CS (>3 
days each) in the previous year  
3) Serious exacerbations: at least one hospitalisation, ICU stay or mechanical 
ventilation in the previous year  
4) Airflow limitation: after appropriate bronchodilator with FEV1 <80% 
predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of 
normal). 
1.2 Obesity 
The World Health Organisation (WHO) defines overweight and obesity as 
abnormal or excessive fat accumulation that presents a risk to health. The WHO has 
classified obesity as one of the eight principal causes of preventable chronic disease 
worldwide (WHO, 2005).  
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Obesity is strongly correlated with an increased risk of cardiovascular 
disease, stroke, peripheral vascular disease, renal failure, cancer, osteoarthritis, and 
Type 2 diabetes mellitus (Whitlock et al., 2009, Kopelman, 2000). 
The global epidemic of overweight and obesity - "globesity" - is rapidly 
becoming a major public health problem in many parts of the world. The WHO 
highlight that approximately 1.6 billion adults (≥15 years) were overweight in 2005 
with at least 400 million of these classified as obese. In 2014 this had risen to 1.9 
billion (39% of adults ≥18 years) and 600 million (13%) respectively. Their 
projections for 2015 are that these figures will increase to 2.3 billion and over 700 
million, respectively (WHO, 2011). 
1.2.1 Obesity in the UK 
The prevalence of obesity in England has increased markedly over recent 
years, placing a major burden on healthcare resources (Office, 2001). Between 1993 
and 2009 the proportion of the population who are obese (BMI ≥30) has increased 
from 13% of men and 16 % of women in 1993 to 22% and 24% in 2009, respectively 
(figure 1.1). Data from the 2009 Health Survey for England (HSE) revealed that 
61.3% of adults (aged 16 or over), and 28.3% of children (aged 2 to 10) in England 
were overweight or obese. Of these, 23% of adults and 14.4% of children were 
obese (Health, 2011). The Foresight report, entitled Tackling Obesities: Future 
Choices project, has predicted that if no action is taken by 2050 approximately 60% 




Figure 1.1. Changing prevalence of BMI in the United Kingdom and Northern 
Ireland (Organisation, 2011).  
 
1.2.2 The impact of obesity 
The global obesity epidemic has been referred to as ‘arguably the gravest and 
most poorly controlled public health threat of our time’ (Katz, 2005). Adult obesity 
has roughly doubled since 1980 and it is now a recognised disease and significant 
risk factor for fatal conditions including ischaemic heart disease, stroke, 
hypertension, diabetes and some types of cancer (Hughes and McGuire, 1997). The 
cost of obesity to the NHS is extremely difficult to accurately calculate. Estimates can 
help establish the economic magnitude of obesity but the overall complexity and 
associated comorbidities results in problems with validity (Bierl et al., 2013).  
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The NHS estimates that obesity contributes directly to about 1000 deaths 
every week. In 2011, 53% of obese men and 44% of obese women suffered with 
high blood pressure. Compared to 2001/2, hospital admissions relating to obesity 
rose by over 11 times (11,736 in total) in 2011/12 (NHS, 2013). The National Obesity 
Observatory (part of Public Health England) estimates that the NHS costs 
attributable to overweight and obesity are £1 billion and are projected to reach £9.7 
billion by 2050. The estimated total wider costs of raised BMI to society were £7.0 
billion in 2001 (2.9% of the total NHS spending) and this had increased to £15.8 
billion (6%) in 2007. Future predictions show that this figure is set to increase to 
£37.2 (11.9%) billion by 2025 (Olofsson et al., 2009, Pacheco et al., 2002).  
1.3 Asthma and obesity 
1.3.1 Epidemiology 
Over 50 cross-sectional and case-controlled studies have reported on the 
relationship between asthma and obesity since the 1990’s (Lugogo et al., 2010). The 
vast majority reported a greater prevalence of asthma in the obese. Data from 16 out 
of 17 prospective studies involving over 200,000 adults and children indicates that 
obesity antedates a diagnosis of asthma (Shore and Johnston, 2006, Beuther and 
Sutherland, 2007, Ford, 2005). These studies followed-up several hundred thousand 
subjects who were initially free of asthma for between two and 21 years. The results 
indicated that as BMI increases, the relative risk of developing asthma also 
increases. Additionally, obesity may increase disease severity in subjects who are 




1.3.2 Associations between asthma and obesity 
The marked increase in the prevalence and incidence of both asthma and 
obesity has led to an interest in a potential link between the two. In addition, recent 
studies have suggested that obese patients with asthma appear to have worse 
symptoms and a reduced response to their asthma medications (Sutherland et al., 
2010, Taylor et al., 2008). Additionally obesity is a risk factor for asthma attacks 
(Fitzpatrick et al., 2012). 
The link between the two appears to be multifactorial and is likely to involve a 
combination of in-utero conditions, genetic factors, comorbidities and inflammation 
secondary to the excess adipose tissue (figure 1.2) (Shore, 2008). 
 
FRC = functional residual capacity, GORD = gastro-oesophageal reflux disease 
Figure 1.2. Proposed mechanisms involved in the relationship between obesity 
and asthma (Shore, 2008). 
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A workshop report on obesity and asthma was organised by the American 
Thoracic Society in May 2010. The expert panel concluded that there is an urgent 
need for research to better understand the mechanisms of asthma in the obese, and 
to develop new therapies specifically targeted to this unique patient population 
(Dixon et al., 2010). 
1.3.3 Phenotyping asthma and obesity 
Asthma can be classified by severity based on a combination of lung function 
(FEV1), daytime and nocturnal symptoms, and the frequency of rescue 
bronchodilator therapy use (Asthma, 2008, Network, 2008, ATS, 2000, Chung et al., 
2014). However, this approach fails to take into consideration the heterogeneity of 
the disease that has been observed in different populations (Wenzel, 2006, Haldar et 
al., 2008). The identification of specific factors unique to different groups of 
asthmatics takes into account this heterogeneity and allows a classification system 
by phenotype. This method of classification may allow targeted management and 
treatment plans, leading to improved control, reduced exacerbations and potentially 
avoiding reductions in lung function (Kiley et al., 2007, Wenzel, 2005, Chung and 
Adcock, 2013).  
The Severe Asthma Research Program (SARP) (Moore et al., 2007) was 
established in 2001 and recruited 800 patients in less than four years. Participants 
underwent multiple investigations to characterise their asthma. The study set out to 
determine factors that differentiate severe asthma from those with mild disease. The 
initial data set revealed that there were differences in the severe asthma phenotype 
stratified by age of onset with a group of later-onset, less atopic subjects who 
reported frequent respiratory tract infections (Moore et al., 2007). Cluster analysis 
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was then applied to the database to identify five unique groups or clusters of 
individuals with asthma. The third cluster was composed of patients with a higher 
BMI (58 % with a BMI ≥ 30). This group were mainly older women (71 % female, 
mean age 50 years) with late onset non-atopic asthma (all older than 23 years, 64 % 
non-atopic) (Moore et al., 2010). 
1.3.4 Lung function in the obese 
Obesity leads to a reduction in the elastic properties of the chest wall with an 
associated reduction in functional residual capacity (FRC). Breathing at lower lung 
volumes correlates with increased airway responsiveness (Barros et al., 2006). The 
obese also tend to have lower tidal volumes (TV) and this may lead to a reduced 
capacity of the bronchodilating effects of tidal volume stretch (Young et al., 2002) 
(figure 1.3).  
In addition, upper airway function is often impaired in obesity. The risk of 
developing obstructive sleep apnoea (OSA) increases markedly at higher BMIs. This 
correlation is in part explained by disturbances in the neuromuscular control of the 
pharyngeal dilatory muscles resulting in a failure to protect the upper airway against 
high extra-luminal pressures (Horner, 2007) and greater adipose tissue deposition 
around the soft tissues of the neck and tongue resulting in increased extraluminal 

















Figure 1.3. Schematic representation showing how changes in lung function in 
the obese state may lead to asthma symptoms (Shore, 2008). Increasing BMI 
results in a reduction in functional residual capacity (FRC) and tidal volumes (VT). 
This leads to decreased airway calibre and increased airway hyper-responsiveness 
(AHR). Obesity is additionally associated with increased adipose tissue hypoxia 
(discussed in greater detail in figure 1.4) which contributes to systemic inflammation 
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↓ Airway calibre, ↑ AHR 
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In addition, the combination of obesity with sleep disordered breathing and 
hypercapnia is well recognised – otherwise known as the obesity-hypoventilation 
syndrome. There are also links with obstructive sleep apnoea and pulmonary 
hypertension (with a prevalence of 5 % in people with a body mass index of above 
30 kg / m2) (McQuillan et al., 2001, Mokhlesi and Tulaimat, 2007).  
1.3.5 Bariatric Surgery 
Studying the effects of bariatric surgery on lung function, markers of lung 
inflammation, bronchial hyper-responsiveness and medication use can provide an 
insight into the role of obesity in asthma. Bariatric surgery in obese mild to moderate 
asthma is associated with a significant reduction in the use of ICS and exhaled nitric 
oxide as a marker of lung inflammation (Lombardi et al., 2011). In addition weight 
loss post bariatric surgery has been associated with improvements in asthma 
control, asthma quality of life and AHR in obese asthmatics (Dixon et al., 2011, 
Boulet et al., 2012). 
1.4 Animal models of obesity and asthma 
Murine obesity has been correlated with AHR and inflammation. Different 
models of obese mice (table 1.1) have been characterised and evaluated; with 
different phenotypes of obesity exhibiting similar trends with increased AHR and 
airway inflammation (Shore, 2007). 
 Ob/Ob mice 
The Ob/Ob mouse is the result of a spontaneous mutation in the leptin gene, 
which was first noticed in a colony of mice at Jackson Laboratories. Leptin is a 
satiety hormone (Bluher and Mantzoros, 2015) and these mice eat excessively; 
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classified as obese after four weeks and by eight weeks they are twice the weight of 
their wild type controls. The higher body weight is due to high fat and these mice 
exhibit a low resting metabolic rate, hypothermia, hypoactivity, hyperinsulinaemia, 
hypertryglyceridaemia, increased serum cortisone, increased cholesterol and 
triglycerides, and infertility. The repletion of leptin reverses this phenoytype (Shore, 
2007).  
 Db/Db mice 
Db/Db mice are the result of a mutation in the cytoplasmic domain of the long 
form of the leptin receptor, Ob-Rb (Shore, 2007). This leads to a loss of expression 
of this isoform and of activation of signal transducer and activator of transcription 3 
(STAT-3), an important mediator of the signalling pathway by which leptin manifests 
its effects on satiety and metabolism. Db/Db mice are similar to Ob/Ob mice and also 
weigh twice as much as their wild type controls by eight weeks (Shore, 2007).  
 Cpefat mice  
Carboxypeptidase E (Cpe) is necessary for the processing of insulin, 
enkephalins, neurotensin and other neuropeptides (Shore, 2007). Cpefat mice result 
from a missense mutation in the enzyme which leads to an inactive protein (due to 
the replacement of Ser202 by Pro202) that is no longer able to cleave and process 
neuropeptides which mediate eating behaviour and energy expenditure. These mice 
develop obesity more slowly and weigh 50 % more than wild type controls by 10 





 Diet induced obesity (DIO) 
Mice fed a lard rich diet where 60 % of their calories are comprised of fat, will 
become obese. By 20 weeks, their body weight is approximately 25 % greater than 
their wild type controls and by 32 weeks it is about 45 % greater (Shore, 2007).  
 
Table 1.1. Phenotypes of obese mouse (Shore, 2007). 
 
        
          
  Ob/Ob Db/Db Cpefat DIO 
          
     Obesity Massive Massive Moderate Milder 
↑ insulin, 
cholesterol, sugar Yes Yes Yes Yes 
Small lungs Yes Yes Yes No 
03 induced AHR > Wild type > Wild type > Wild type > Wild type 
03 induced 
inflammation > Wild type > Wild type > Wild type > Wild type 
          
     
1.5 Adipocytes and inflammation 
1.5.1 Adipose tissue, inflammation and the role of adipokines 
Obesity and asthma are both characterised by inflammation and a common 
inflammatory pathway has been suggested as a potential link between the two 
(Weiss, 2005). In women this link may be stronger given a higher body fat 
percentage compared to men at any given body weight (Gallagher et al., 1996).    
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It has become increasingly clear that adipose tissue is not benign and in fact 
behaves like an endocrine tissue, secreting a wide variety of bioactive cytokines 
(termed adipokines) into the circulation. These cytokines are produced by the 
adipocytes themselves and by fat infiltrated immune-inflammatory cells such as 
macrophages. Visceral obesity produces a chronic, low grade inflammatory state 
that places the individual at increased risk of the metabolic syndrome, cancer, 
hypertension, liver disease, type 2 diabetes mellitus and associated cardiovascular 
complications. 
The obese state is characterised by an excess of adipose tissue, which 
produces a number of pro-inflammatory mediators (table 1.2). Plasma 
concentrations of IL-6, TNF-α and CRP are significantly raised in the obese state 
(Festa et al., 2001). Peripheral blood mononuclear cells (PBMCs) from obese 
subjects are in a proinflammatory state, exhibiting increased nuclear factor-kappa B 
(NF-κB) binding, a decrease in IĸB-β, and an increase in the transcription of 
proinflammatory genes regulated by NF-κB (Ghanim et al., 2004). Circulating 
PBMCs in the obese state are exposed to metabolic factors such as dyslipidaemia 
and inflammatory molecules produced by other organs and tissues. This may lead to 
a phenotypic shift in macrophages to the more inflammatory classical M1 type 
(Bories et al., 2012).  
Adipose tissue is made up of many different cells. These include mature 
adipocytes, preadipocytes, mesenchymal cells, stromal cells, macrophages and 
fibroblasts (Trujillo and Scherer, 2006). The tissue acts as a buffering system for 
lipids by taking up triacylglycerol (TAG) and inhibiting the release of free fatty acids 
(FFA) (Mancuso, 2010).  In the obese state, adipocytes become saturated with TAG 
and this leads to an increased circulating level of TAG and FFA. FFAs act as ligands 
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for Toll-like receptor-4 (TLR4) (Horner, 2007) and this may contribute to increased 
systemic inflammation. 
 
Table 1.2. Mediators released by adipocytes. 
          






reactants Other factors 
          
     
TNF-α CXCL8 Adiponectin Serum amyloid  A 
Acylation 
stimulating protein 
IL-1 CCL2 Leptin CRP Angiotensinogen 
IL-6 CCL3 Resistin α1 acid glycoprotein 
Complement B, C3 
and D 
Visfatin Eotaxin  PAI-1 VEGF 
IL-10    IL-1RA 
TGFβ    
Retinal binding 
protein 4 
          
      
1.5.2 Alveolar macrophages, obesity and asthma 
Alveolar macrophages (AMs) from overweight and/or obese asthmatics 
demonstrate enhanced proinflammatory responses (Lugogo et al., 2012). However, 
the precise mechanism and nature of this inflammation remains unclear. 
Lugogo et al performed bronchoscopies and bronchoalveolar lavage (BAL) on 
42 asthmatics and 46 healthy control subjects. They found that although BALF 
differential cell counts were similar in lean and overweight/obese asthmatics (13% of 
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lean subjects with asthma and 15% of overweight/obese subjects with asthma had a 
greater than 2% eosinophil count), BALF leptin levels were significantly higher in the 
overweight/obese female individuals regardless of asthma status. Additional ex vivo 
studies found that AMs taken from overweight/obese asthmatics had an enhanced 
proinflammatory response to lipopolysaccharide (LPS) and this was enhanced with 
pre-exposure to leptin; suggesting that leptin may contribute to the pathophysiology 
of airways disease in the obese state (Lugogo et al., 2012).  
A study looking at the effect of bariatric surgery in obese women (Sideleva et 
al., 2012) found that bronchial epithelial cells taken at baseline and 12 months post-
surgery, exhibited greater adiponectin (APN) receptor expression in asthma 
compared to healthy controls. BALF leptin levels were higher and adiponectin levels 
lower in the asthmatic group suggesting that both adipokines may be important 
mediators of airway disease in the obese state.  
1.6 Obesity, inflammation and oxidative stress 
1.6.1 Obesity and corticosteroid insensitivity 
The association between corticosteroid (CS) insensitivity and obesity in 
asthma is supported by retrospective analysis of clinical trials using ICS and 
additionally by an in vitro study using alveolar macrophages. 
Retrospective analysis of four clinical trials using Fluticasone propionate 
(FP)/Salmeterol and montelukast found an association between BMI and an 
attenuated response to ICS. Subgroup analysis revealed that improvements in FEV1, 
symptom scores, and albuterol use to FP/Salmeterol were significantly greater in the 
normal and overweight BMI group compared to the obese (Camargo et al., 2010a). 
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Post hoc analysis of 3073 asthmatics from four double blind placebo 
controlled studies randomised 894 to receive beclomethasone, 1439 to montelukast 
and 740 placebo. Analyses was performed according to BMI (BMI <25.0, overweight 
BMI 25 to 29.99 and obese BMI ≥ 30). The response to ICS decreased with 
increasing BMI in contrast to montelukast where no difference was seen. In addition, 
the placebo response for all end points was lower with increasing BMI. This suggests 
that increasing BMI may influence the response to ICS and the natural history of 
asthma control (Peters-Golden et al., 2006). 
Anderson and Lipworth performed a post hoc analysis of 72 patients with mild 
to moderate persistent asthma. Patients were divided into two groups (BMI < 25 and 
≥ 25) and each group received 4 weeks’ treatment with ICS (budesonide 200 µg/day 
and then 800 µg/day with a washout period). Greater improvements in terms of FENO 
and symptom scores were seen in the normal weight group compared to the 
overweight group for both ICS doses (Anderson and Lipworth, 2012).  
An in vitro study using PBMCs and BAL cells taken from 45 adults (33 with 
asthma and 12 healthy subjects) found that dexamethasone (10-6 M)-induced MAPK 
phosphatase (MKP1) suppression was attenuated in mild asthmatics with a BMI ≥25 
compared to those <25 (Sutherland et al., 2008a). MKP1 is a signalling pathway that 
can be used as a marker of the anti-inflammatory action of corticosteroids. 
These studies suggest that overweight/obesity is associated with a reduced 





1.6.2 Obesity and oxidative stress 
Reactive oxygen species (ROS) are oxygen containing molecules that are 
highly reactive and have been shown to play an important role in the pathogenesis of 
many pulmonary diseases, as well as many regulatory physiological functions. The 
effect of ROS depends on the balance between ROS production and the defensive 
capacity of antioxidant systems (Tkaczyk and Vizek, 2007). Cross-sectional studies 
have demonstrated increased levels of oxidative stress biomarkers in obese 
individuals compared to their lean counterparts (Keaney et al., 2003). There are 
multiple potential sources of increased oxidative stress in obesity, including 
increased adiposity, co-morbidities or behavioural changes associated with being 
obese (Holguin and Fitzpatrick, 2010). The systemic inflammation and oxidative 
stress secondary to adipose tissue may be due to the leptin/adiponectin ratio and 
other adipokines such as TNF and plasminogen activator inhibitor (PAI-1) (Wu et al., 
2009).  Chronic oxidative stress in obese subjects has a cumulative effect and may 
lead to end organ damage. This has been noted in the cardiovascular system 
through atherosclerosis and in the liver as non-alcoholic hepatic steatosis (Medoff et 
al., 2009). Weight gain, diabetes and poor glycaemic control are associated with 
reduced lung function and steeper airway function decline which raises the possibility 
that obesity-mediated oxidative stress may directly affect the lungs. However, the 
precise nature of this association remains unclear (Holguin and Fitzpatrick, 2010).  
Asthmatic patients have increased systemic oxidative stress compared to 
non-asthmatics (Bruno et al., 2009).  Acute asthma attacks raise the oxidative 
burden and studies have demonstrated that patients hospitalised for acute asthma 
exacerbations have a six-fold increase in the levels of urinary metabolites of F2-
isoprostanes and total plasma antioxidant capacity is reduced during these episodes 
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(Filkova et al., 2009). In addition, higher levels of oxidative stress have been noted in 
asthmatics with greater airways obstruction (Miller et al., 2005).  
1.6.3 Adipocytes and inflammation 
Adipose tissue acts as a buffering system for lipids by taking up TAG and 
FFAs. In the obese state adipocytes hypertrophy and may become saturated with 
TAG leading to increased circulating levels of both TAG and FFAs. FFAs act as a 
ligand for TLR4 receptors and may contribute to systemic inflammation in this way 
(figure 1.4). Adipocytes additionally produce adipocytokines, the majority of which 
are pro-inflammatory. Adipose tissue in the obese state becomes infiltrated with 
macrophages which correlate with both adipocyte size and BMI. These 
macrophages aggregate in crown like structures that surround dead adipocytes and 
scavenging debris.  
With the development of obesity, adipocytes hypertrophy. These larger cells 
outstrip their blood supply and this leads to localised hypoxia and apoptosis. The 
resultant cellular debris leads to the production of cytokines such as monocyte 
chemoattractant protein-1. In turn, this results in the recruitment of macrophages and 
T cells from the peripheral circulation (Beuther et al., 2007). Recruited macrophages 
produce TNF-α, IL-6 and other cytokines which inhibit the differentiation of 
preadipocytes and preventing the further uptake of TAG.  Existing adipocytes 
continue to hypertrophy and eventually undergo apoptosis, thereby creating a cycle 
resulting in increasing macrophage recruitment and cytokine production. These 
cytokines then spill out into the peripheral circulation thereby contributing to the 
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1.7 Adipokines: Leptin, adiponectin and resistin 
 Adipokines are cytokines produced by adipocytes (table 1.2). Many 
adipokines correlate to the development of asthma and play a role in its severity.  
Leptin, adiponectin and resistin are adipokines are of particular interest (Sood and 
Shore, 2013).  
1.7.1 Leptin 
Leptin is a 16 kDa adipokine that was first identified in 1994 and noted to play 
a vital role in the regulation of food intake (satiety) and body weight (Zhang et al., 
1994). It is pro-inflammatory and serum levels are positively correlated with obesity 
(Considine et al., 1996). In healthy humans circulating levels are usually below 10 
ng/ml, rising to between 10 to 60 ng/ml in obese individuals (Licinio et al., 1997). 
Obese individuals seem to lose the inhibitory activity that leptin has on food intake 
and satiety (Iikuni et al., 2008).   
Leptin is also a regulator of energy homeostasis, insulin secretion, 
angiogenesis, bone formation and reproduction (Morton et al., 2006, Emilsson et al., 
1997, Sierra-Honigmann et al., 1998, Ducy et al., 2000, Chehab et al., 1996). 
Decreased plasma leptin levels are linked to impaired immune function (La and 
Matarese, 2004). The administration of inflammatory stimuli such as LPS, or 
experimental acute inflammation, results in increased levels of leptin expression in 
both serum and adipose tissue (Faggioni et al., 1998, Iikuni et al., 2008).  
The structure of leptin is similar to that of the IL-6 cytokine family. In mice, six 
different receptor isoforms (OB-Ra, OB-Rb, Ob-Rc, OB-Rd, OB-Re and Ob-Rf), 
derived from alternative splicing of RNA transcripts of the db gene, have been 
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identified (Wang et al., 1996). In humans, only OB-Ra, OB-Rb and OB-Rc have been 
reported (Chua et al., 1997). OB-Rb appears to be the most important and is 
involved with the satiety effects of leptin and is expressed in high levels in the 
hypothalamus and at lower levels in many peripheral tissues (De et al., 2007b, Kielar 
et al., 1998). OB-Rb can also be found on immune cells including sub-populations of 
T cells, B cells, dendritic cells, monocytes, neutrophils, macrophages, and natural 
killer (NK) cells (Iikuni et al., 2008).  
Once bound to its receptor, leptin activates Janus kinase 2 (JAK2), which 
becomes autophosphorylated. Subsequent phosphorylation of tyrosine residues on 
the intracellular domain of the receptor upregulates the binding and activation of 
signal transducers and activators of transcription (STAT) – including STAT1, STAT3, 
STAT5, and STAT6. Phosphorylated JAK2 activates other pathways such as 
mitogen-activated-protein kinase (MAPK), extracellular signal-regulated kinase 
(ERK) and phosphatidylinositol 3-kinase (PI3K) and Akt (Martin-Romero and 
Sanchez-Margalet, 2001) (figure 1.5).  
PBMCs incubated in the presence of leptin have been shown to 
phosphorylate both ERK-1 and ERK-2 in a concentration dependent fashion (Martin-
Romero and Sanchez-Margalet, 2001). Leptin additionally leads to sustained 









Figure 1.5: The pathways influenced by leptin.  Leptin binds to the leptin receptor 
(OB-Rb), activating Jak2 and resulting in the autophosphorylation of tyrosine 
residues and phosphorylation of tyrosines. Autophosphorylated Jak2 can 
phosphorylate insulin receptor substrate 1/2 (IRS1/2) resulting in activation of 
phosphatidylinositol 3-kinase (PI3K)/Akt pathway. NF-κB activation can occur via Akt 
activation. Leptin binding to OB-Rb can also activate phospholipase C (PLC) 
resulting in stimulation of c-jun N-terminal protein kinase (JNK) via protein kinase C 
(PKC). Tyr1077 and Tyr1138 bind to STAT5. Tyr1138 additionally recruits STAT1 and 
STAT3. Tyr985 binds to the SH2 domain-containing phosphatase 2 (SHP2) resulting 
in activation of mitogen-activated protein kinase (MAPK) pathways including ERK 





1.7.2 Leptin and asthma 
Shore and colleagues used mini-Alzet pumps to increase blood leptin levels 
during allergen challenge of sensitised mice (Shore et al., 2005). Leptin augmented 
the AHR but did not appear to alter eosinophil influx or TH2 cytokine expression. This 
suggests that leptin is able to augment AHR through mechanisms that are 
independent of TH2 mediated inflammation. The authors also reported that 
exogenous administration of leptin to lean mice increased their acute ozone-induced 
inflammatory response (Shore et al., 2003).  
 An in vitro study using bronchial epithelial cells from asthmatic subjects found 
that TGF-β expression of leptin and leptin receptors were significantly lower in mild 
uncontrolled untreated asthmatics and in severe uncontrolled asthmatics than in 
healthy controls. These lower levels suggest a dysregulation in the leptin/leptin 
receptor pathway linked to asthma control and bronchial inflammation. In addition, 
TGF-β expression was inversely correlated with leptin and leptin receptor expression 
and positively correlated with reticular basement membrane (RBM) thickness but 
only when severe uncontrolled asthmatics on ICS and oral steroids were excluded 
(Bruno et al., 2009).  
 Serum leptin concentrations are higher in asthmatics compared to healthy 
controls even after adjusting for BMI (Gurkan et al., 2004). This association appears 
to be stronger in atopic boys (Guler N. Leptin- does it have any role in childhood 
asthma? JACI 2004). A raised serum leptin concentration has also been correlated 
with an increased risk of developing asthma. In women, a serum leptin concentration 
of >21.9 ng/ml was associated with an increased risk of developing asthma (Sood et 
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al., 2006). However, other studies have failed to confirm this finding (Jartti et al., 
2009, Sutherland et al., 2009). 
 Sputum leptin concentrations appear to be higher in asthmatics than healthy 
controls but BMI may be a significant confounding factor (Lessard et al., 2011). 
However, other studies have not found a correlation between leptin concentrations in 
asthma in BAL or serum, even after adjusting for obesity (Holguin F, 2011, Sideleva 
et al., 2012, Jang et al., 2009). There may be an association between serum leptin 
concentrations and asthma severity. A small case-controlled study found high serum 
levels were present in women with severe asthma compared to mild/moderate 
disease. However, BMI values were significantly different between the groups 
(Tsaroucha et al., 2013). In contrast, another study found no association between 
serum or BAL leptin concentrations and lung inflammatory biomarkers (Holguin F, 
2011). 
 Overall, there appears to be a stronger correlation between leptin (serum, 
sputum and BAL) and asthma in children than there does in adults. This may reflect 
a number of factors such as specific childhood asthma phenotypes, atopic status 
and the fact that leptin concentrations in children are more reflective of BMI than in 








Adiponectin, also known as Acrp30, AdipoQ, APM1, and GBP28, was initially 
described as an abundant serum protein produced by adipocytes (Scherer et al., 
1995, Hu et al., 1996, Nakano et al., 1996). It is a 247-amino acid, 30 kDa adipokine 
that is produced predominantly by adipocytes and is the most abundant adipokine, 
accounting for 0.01% of total plasma protein (Hu et al., 1996), circulating in the 
plasma at concentrations of between 3 and 30 µg/ml (Folco et al., 2009). There are 
three major oligomeric complexes (including trimeric, hexameric, and high molecular 
mass form) with distinct biological functions (Okamoto et al., 2006).  
In humans, adiponectin is negatively correlated with increasing obesity and 
levels increase following weight loss (Kern et al., 2003). Furthermore, lower serum 
adiponectin levels are found in patients with Type 2 Diabetes, the metabolic 
syndrome and cardiovascular disease compared to healthy controls, matched by 
BMI (Lara-Castro et al., 2007). Although white adipose tissue is the main site of 
adiponectin secretion, other cell types are able to produce small quantities. These 
include brown adipocytes, colonic mucosal cells, fetal tissue (Corbetta et al., 2005), 
salivary gland epithelial cells (Katsiougiannis et al., 2006), osteoblasts (Berner et al., 
2004), myocytes (Pineiro et al., 2005) and myofibroblasts (Matsunaga et al., 2008).  
1.7.4 Adiponectin isoforms 
Adiponectin contains four different domains based on its primary sequence: 
an N-terminal signal peptide, a short-hyper variable region, a collagen domain, and a 
C-terminal globular domain (Sun et al., 2009). There are six isoforms: globular 
adiponectin (gAPN), full length adiponectin (fAPN), low molecular weight adiponectin 
(LMW), medium molecular weight adiponectin (MMW), high molecular weight 
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adiponectin (HMW), and the serum albumin bound LMW form (Alb-LMW). In plasma, 
adiponectin circulates in LMW and HMW isoforms (Bozza et al., 1997).  
fAPN is also known as monomeric adiponectin. Three monomers, via 
hydrophobic interactions within globular domains, can form a 
homotrimer/trimeric/LMW form with a molecular weight of about 75-90 kDa (Sun et 
al., 2009). MMW or hexameric adiponectin is made up from two LMW trimmers by a 
disulphide bond and the HMW isoform (400 to 600 kDa) is composed of eight or 
more monomers or two/three hexamers by noncovalent bonds (Giannessi et al., 
2007). fAPN may be proteolytically cleaved to a smaller form, globular adiponectin, 
by leukocyte elastase (Waki et al., 2005). In comparison to other adiponectin 
isoforms, gAPN is present in small amounts in plasma (Fruebis et al., 2001) and 
appears to be more extensively biologically active (Nishida et al., 2007). 
Furthermore, the HMW isoforms have been shown to be more active than LMW 
isoforms (Song et al., 2009, Pajvani et al., 2003).  
1.7.5 Adiponectin receptors  
Three adiponectin receptors have been identified: AdipoR1, AdipoR2 and T-
Cadherin. (Takemura et al., 2007, Hug et al., 2004, Yamauchi et al., 2007). These 
receptors are expressed in multiple cell types, including bronchial epithelial cells but 
their functional role in respiratory disease remains poorly understood (Hug et al., 
2004). More recently, calreticulin has been identified as a fourth adiponectin binding 
protein. Calreticulin is a ubiquitous calcium binding protein of the endoplasmic 
reticulum (ER) that may provide protection from systemic inflammation through 
binding adiponectin by promoting the clearance of early apoptotic cells by 
macrophages (Takemura et al., 2007).  
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AdipoR1 is present on approximately 1% of T cells, 93% of monocytes, 47% 
of B cells and 21% of NK cells (Pang and Narendran, 2008).  AdipoR2 distribution is 
similar to AdipoR1 with 2%, 87%, 36% and 19% respectively. AdipoR1 is more 
prevalent on monocytes but expression decreases following differentiation into 
mature macrophages whilst AdipoR2 expression remains constant and becomes the 
predominant adiponectin receptor (Chinetti et al., 2004). 
Globular adiponectin primarily binds to AdipoR1 whilst multimeric adiponectin 
binds to AdipoR2 (Arima and Fukuda, 2011). The expression of AdipoR2 and T-
cadherin mRNA is greater in bronchial epithelial cells taken from obese asthmatics in 
comparison to obese healthy controls (Sideleva et al., 2012).  
1.7.6 Adiponectin: cellular action 
Adiponectin stimulates AMP-activated protein kinase (AMPK) and this is 
implicated in its insulin-sensitising properties in liver and muscle (Nawrocki et al., 
2006, Yamauchi et al., 2002, Kadowaki and Yamauchi, 2011). The receptors 
AdipoR1 and R2 regulate glucose and fatty acid metabolism partly through the 
activation of AMPK, Ca2+ and peroxisome proliferator-activated receptor alpha 
(PPARα) signalling pathways (table 1.6). However, this does not explain the 
pleiotropic effects of adiponectin. More recently, adiponectin has been shown to 
decrease cellular ceramide levels through activation of AdipoR1 and R2 and 
independently of AMPK. Ceramide is a sphingolipid and increased levels have been 








Figure 1.6: Schematic diagram of the pathways influenced by adiponectin. 
Adiponectin interacts with AdipoR1 and AdipoR2 resulting in the stimulation of 
peroxisome-proliferator-activated receptor-α (PPARα), AMP-activated protein kinase 
(AMPK) and p38 mitogen-activated protein kinase (p38 MAPK). Adiponectin’s anti-
inflammatory actions relate to suppression of the synthesis of tumour-necrosis factor 
(TNF) and interferon-γ (IFN-γ) and via increased production of interleukin-10 (IL-10) 
and IL-1 receptor antagonist (IL-1RA). PPARγ activation results in an anti-
inflammatory action via inhibition of the transcriptional activation of pro-inflammatory 
response genes.  
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1.7.7 Adiponectin and asthma 
In a mouse model of acute asthma, adiponectin infusion attenuated airway 
inflammation and airway hyperresponsiveness (Shore et al., 2006). APN-deficient 
mice develop spontaneous emphysema and their lung macrophages express higher 
levels of inflammatory mediators compared to their wild type control group (Summer 
et al., 2008). Male apolipoprotein E deficient mice fed a high fat diet developed 
pulmonary hypertension associated with lower APN levels compared to wild type 
mice. Subsequent treatment with rosiglitazone, a proliferator-activated receptor-γ 
activator, resulted in raised APN level and complete regression of pulmonary 
hypertension and pulmonary artery remodelling (Hansmann et al., 2007).   
Mice acutely challenged with ovalbumin demonstrate decreased serum levels 
of APN (Shore et al., 2006) and APN (-/-) mice display more eosinophilic airway 
inflammation in a chronic model of asthma (Medoff et al., 2009).  These findings 
suggest that adiponectin plays a role in the development and severity of asthma.  
T-cadherin (-/-) mice are protected from OVA-induced AHR, increases in BAL 
inflammatory cells, and induction of IL-13, IL-17 and eotaxin expression. Serum 
adiponectin levels were higher in the T-cad (-/-) mice, possibly due to a lack of 
sequestering of adiponectin by endothelial T-cad, and the reduction in AHR may be 
due to adiponectin acting on alternative signalling pathways (Williams et al., 2012).  
 In humans, a low total serum adiponectin concentration has been correlated 
with a greater risk of developing asthma. One study found that a low serum 
adiponectin predicted asthma in women more strongly than BMI (Sood et al., 2012). 
Conversely, the same study noted that prevalent asthma did not predict a low future 
adiponectin concentration. Other studies have noted that low serum adiponectin was 
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associated with a greater risk of developing asthma in premenopausal women and 
prepubertal girls (Sood et al., 2008, Nagel et al., 2009). In contrast, other studies 
have failed to identify a correlation (Kim et al., 2008, Jartti et al., 2009, Sutherland et 
al., 2009).  
 Sputum adiponectin concentrations are lower in asthmatics compared to 
healthy controls (Sood, 2012) and appear to predict the presence of asthma better 
than serum adiponectin. Other studies have failed to find a difference between BAL 
adiponectin concentrations between asthmatic patients and healthy controls despite 
matching or adjusting for BMI (Holguin F, 2011, Jang et al., 2009). A proposed 
explanation for this difference is that sputum adiponectin concentrations are 
approximately 40 times more concentrated than that in BAL (Sood and Shore, 2013). 
With regard to asthma severity, high serum adiponectin concentrations have been 
correlated with more frequent asthma medication use and higher symptoms in men. 











1.7.8 Adiponectin: inflammatory action 
The cellular actions and in vivo studies discussed above support the view that 
adiponectin is an anti-inflammatory cytokine. However, there are some disease 
states which are associated with raised adiponectin levels. These include 
rheumatoid arthritis, systemic lupus erythematosis (SLE), type 1 diabetes and 
inflammatory bowel disease. In these disease states there is a paradox of high levels 
of adiponectin in the presence of systemic inflammation (Fantuzzi, 2008).  Potential 
explanations for this include the observations that adiponectin isoforms may exert 
different inflammatory effects and the suggestion that the ratio of different isoforms, 
such as HMW to total adiponectin, may determine cellular effects (Pajvani et al., 
2004). 
1.7.8.1 The anti-inflammatory role of adiponectin  
In humans, pre-treatment of monocyte-derived macrophages (MDMs) with 30 
µg/ml (the upper range of circulating plasma concentrations) adiponectin for 48 
hours has been shown to increase tissue inhibitor of metalloproteinase (TIMP) -1 
mRNA levels. In addition, the MDMs exhibited increased IL-10 mRNA expression 
within six hours with a significant increase in IL-10 protein secretion within 24 hours. 
Pre-treatment of the MDMs with an anti-IL-10 monoclonal antibody indicated that the 
effect on TIMP-1 appeared to be due to the upregulation of IL-10 (Kumada et al., 
2004). Globular adiponectin suppresses TLR4-mediated signalling via IL-10 
expression in RAW 264.7 macrophages via a cAMP-dependent pathway and 
transcriptional and posttranscriptional control of TNF-α expression (Park et al., 2007, 
Wolf et al., 2004).  
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The pre-treatment of human macrophages with 10 µg/ml of adiponectin 
suppressed the LPS induced IĸB, JNK and p38 MAPK phosphorylation. In addition, 
adiponectin inhibited the TNF-α induced IĸB, JNK, and p38 MAPK phosphorylation 
as well as IL-6 induced STAT-3 phosphorylation. These anti-inflammatory effects 
appear to be independent of IL-10 (Folco et al., 2009).  
It has been suggested that macrophages from adipose tissue in lean 
individuals express markers of M2 macrophages whilst obesity leads to a reduction 
in these markers and an increase of genes associated with the pro-inflammatory M1 
macrophages (Lumeng et al., 2007). Peritoneal macrophages from adiponectin 
knock-out mice display increased M1 markers and decreased M2 markers. 
Adiponectin appears to stimulate the expression of M2 markers in human monocyte 
derived macrophages and regulate macrophage polarisation towards an anti-
inflammatory phenotype (Ohashi et al., 2010).  
Adiponectin inhibits LPS-induced NF-κB activation and IL-6 production and 
increases PPARγ2 expression in adipocytes (Ajuwon and Spurlock, 2005). 
Furthermore, adiponectin attenuates TNF-α and IL-6 production by activated porcine 
macrophages via suppression of NFκB and ERK1/2 activity (Wulster-Radcliffe et al., 
2004). In human aortic endothelial cells (HAEC) adiponectin inhibits TNF-α induced 
CXCL8 synthesis via PKA dependent NFκB signalling (Kobashi et al., 2005).  
1.7.8.2 The pro-inflammatory role of adiponectin 
Adiponectin is a potent pro-inflammatory agent for a number of different cell 
types. Human placenta and adipose tissue release IL-1β, IL-6, TNF-α, and 
prostaglandin E2 (PGE2) in the presence of adiponectin (Lappas et al., 2005). 
Globular APN induces the release of TNF-α and IL-6 from primary human peripheral 
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macrophages, in THP-1 human macrophage cell line, and in primary mouse 
peritoneal macrophages. However, pre-treatment with low dose adiponectin (1 
µg/ml) for 24 hours prior to re-stimulation led to tolerance and suppression of TNF-α 
and IL-6 release. This suggests that globular APN may induce macrophage 
tolerance although this effect was not seen with higher concentrations of adiponectin 
(10 µg/ml) (Tsatsanis et al., 2005). Microarray analysis of cDNA from the RNA 
prepared from human umbilical vein endothelial cells (HUVECs) treated with globular 
adiponectin (10 µg/ml) using gene expression analysis has revealed that adiponectin 
increased the expression of 187 genes, including intercellular adhesion molecule-1, 
E-selectin, vascular cell adhesion molecule-1, and monocyte chemoattractant 
protein-1. This gene expression is dependent on NF-κB activation which is induced 
by globular adiponectin (Hattori et al., 2006). 
Stromal preadipocytes exposed to adiponectin released PGE2 and expressed 
cyclooxygenase-2 (COX-2) (Yokota et al., 2002). Adiponectin induces CXCL8 
secretion from human chondrocytes (Gomez et al., 2011). 
Adiponectin has been shown to exert a pro-inflammatory effect on human 
placenta and adipose tissue through the release of proinflammatory cytokines 
(Lappas et al., 2005). Treatment with the anti-inflammatory ERK1/2 MAPK inhibitor, 
U0126, BAY 11-7082, and troglitazone (a PPARγ ligand), all suppressed adiponectin 
(and leptin) induced IL-1, IL-6 and TNFα release from human placenta cells. This 
suggests that NF-κB, PPARγ, ERK 1/2 and MAPK all appear to be key transcription 
factors involved in the adiponectin induced pro-inflammatory response. 
There are disease states in which adiponectin levels are raised. In SLE, 
patients with acute lupus nephritis, urine HMW adiponectin levels are raised (Song et 
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al., 2009) suggesting that HMW adiponectin contributes to the renal inflammation of 
SLE. In rheumatoid arthritis, serum adiponectin levels are raised and may even 
correlate to disease severity (Tan et al., 2009, Chen et al., 2012). Adiponectin levels 
are significantly higher in synovial fluid of patients with osteoarthritis and rheumatoid 
arthritis and increases the secretion of MMP-3, which may contribute to the 
breakdown of articular cartilage, in cultured human chondrocytes. These actions 
were inhibited by the pre-treatment with AMPK inhibitor (compound C), p38 MAPK 
inhibitor (SB203580), and NF-κB inhibitor (PDTC and TPCK) (Tong et al., 2011). 
Adiponectin induces phosphorylation of AMPK (Kang et al., 2010), JNK, ERK1/2 
(Kang et al., 2010, Koskinen et al., 2011), and p38 MAPK (Koskinen et al., 2011) in 
primary chondrocytes isolated from osteoarthritis cartilage.  
A study in patients with rheumatoid arthritis found that globular adiponectin 
enhanced ROS production via the phagocytic NADPH oxidase (Chedid et al., 2012). 
In contrast, production was inhibited by adiponectin. Selective inhibitors of p38 
MAPK and ERK1/2 abrogated p47(phox) phosphorylation by adiponectin. This 
suggests different roles for adiponectin and globular adiponectin on phagocyte ROS 
production and an imbalance between these isoforms may contribute to chronic 
inflammation (Chedid et al., 2012). 
Adiponectin treatment of CD4+ T cells increased phosphorylation of p38 
MAPK and STAT4, and augmented T-box transcription factor (T-bet) expression. 
Inhibition of p38 with SB203580 abrogated adiponectin induced IFN-γ production. 
This indicates that adiponectin enhances TH1 differentiation through the activation of 




1.7.9 Adiponectin: tolerance 
Short term treatment of macrophages with adiponectin initially induces pro-
inflammatory signalling (Cheng et al., 2012, Folco et al., 2009, Park et al., 2007), 
whereas, prolonged exposure is associated with tolerance. The mechanisms 
involved may include increased IL-10 expression, suppression of TNF-α mRNA 
stability and translation, and increased expression of IRAK-M (Zacharioudaki et al., 
2009). The pre-treatment of HUVECs with globular adiponectin for 16 hours followed 
by stimulation with TNFα to induce NF-κB activation produces suppression in a 
concentration-dependent manner (Hattori et al., 2006). 
1.7.10 Prokaryotic or eukaryotic derived adiponectin 
There are two main sources of commercially available adiponectin: those 
produced from either prokaryote or eukaryote cells. Adiponectin expressed in 
eukaryotic cells appears able to form HMW complexes whilst prokaryotic derived 
adiponectin forms trimers and hexamers due to inadequate folding of the collagen-
like domain (Richards et al., 2006). This difference may have important implications 
for in vitro work given the differences in the inflammatory actions of the various forms 
of adiponectin. 
1.7.11 Resistin 
 Resistin is part of the resistin-like molecule (RELM) gene family; also 
known as found in inflammatory zone (FIZZ); (figure 1.7) and four members have 
been identified to date; RELM-α, RELM-β, RELM-γ and resistin. These cytokines 
appear to induce inflammation, angiogenesis, and smooth muscle proliferation (Fang 
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et al., 2012, Sood and Shore, 2013); responses which have led to an interest in 
asthma. 
Resistin (also known as found in inflammatory zone, FIZZ3, and adipocyte 
secreted factor, ADSF) is a 12.5 kDa adipocytokine originally described in obese 
mice in 2001 as an exciting link to diabetes (“resistance to insulin”). Resistin is 
positively correlated with increasing BMI, adipose mass and is viewed as 
proinflammatory (Al-Suhaimi and Shehzad, 2013). However, whilst resistin levels are 
raised in obese patients who have had a previous myocardial infarction 
(Piestrzeniewicz et al., 2008), they are not raised in obese subjects following weight 
loss (Iqbal et al., 2005). Furthermore, a more recent study failed to identify a 
correlation between indices of adiposity and serum resistin levels, indicating that 
adipose tissue does not appear to be responsible for resistin production (Cabrera de 
Leon et al., 2014). Therefore, the precise relationship between serum resistin and 
adiposity remains unclear.  
Resistin is predominantly expressed in macrophages in humans and to a 
lesser degree by white adipocytes (Fukuhara et al., 2005). Normal physiological 
serum levels range from 7 to 22 ng/ml and are raised in inflammatory states 
including acute coronary syndrome, inflammatory bowel disease, rheumatoid arthritis 
and sepsis (Fadda et al., 2013). It is produced by PBMCs, macrophages and 
adipocytes. Resistin expression is increased by TNF-α, IL-1β, IL-6 and LPS. It 
induces the synthesis and secretion of TNF-α and IL-12 from macrophages through 
NFκB and MAPK via TLR4. Little is known about its receptors, and the exact 
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asthmatics (Larochelle et al., 2007). High serum resistin levels in non-obese women 
with newly-diagnosed steroid naive asthma predicted a good anti-inflammatory 
response to ICS; suggesting that high resistin levels were a marker of a steroid-
sensitive phenotype (Leivo-Korpela et al., 2011). 
1.8 Leptin, adiponectin and resistin: summary of in vivo data 
  The data for leptin, adiponectin and resistin in vivo have mainly focused on 
serum concentrations and association studies with asthma. There appears to be a 
positive correlation between serum leptin concentration and asthma; an association 
that is stronger in childhood. In contrast, low serum adiponectin concentrations 
appear to predispose to a greater risk of developing asthma and improved asthma 
symptoms and lower asthma medication use in women. There is a paucity of data 
regarding serum resistin concentrations and asthma and the correlation remains 
unclear.  
 The lacks of clear correlations are likely to reflect a number of factors. 
Previous studies have not looked at specific asthma phenotypes and have relied on 
subgroup analysis. Furthermore, adipokines are probably just a component of the 
correlation between obesity and asthma. Other important factors include genetics, in 
utero conditions, oxidative stress, comorbidities, lung mechanics, sleep disordered 
breathing and hormonal effects (figure 1.2).  
1.9 Adipokines: diurnal variation 
A study taking blood samples at 15-minute intervals from six healthy normal 
weight men, receiving an isocaloric diet, found that circulating adiponectin and the 
soluble cleaved extracellular part of the leptin receptor (sOB-R) levels, which is the 
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main binding protein in the serum, exhibited ultradian pulsatility and diurnal variation 
with a significant nocturnal decline and morning nadir (Lammert et al., 2001, Gavrila 
et al., 2003). 
1.10 Adipokines in the lung 
Obese leptin receptor deficient mice (db-/db-) exhibit higher concentrations of 
BAL leptin and reduced adiponectin compared to lean wild type mice (Holguin et al., 
2007). BALF taken from obese women prior to undergoing bariatric surgery found 
higher leptin and lower adiponectin levels in asthmatics compared to healthy controls 
(Sideleva et al., 2012). Another study in lean and obese asthmatics found that 
increasing BMI was associated with increased BAL leptin and a small reduction in 
adiponectin (F et al., 2011).  
Epithelial cells isolated from brushings of patients with asthma exhibit higher 
expression of Adipo R2 and T-cadherin mRNA. Leptin expression, but not leptin 
receptor, has been shown to decrease following bariatric surgery. BALF adiponectin 
levels are lower and leptin levels higher in asthmatics compared to healthy controls 
(Sideleva et al., 2012).  
Studies using induced sputum have noted increased adiponectin levels 
following inhalational challenge (Biagioni et al., 2014) whilst leptin levels are 
positively correlated with BMI and serum leptin (Lessard et al., 2011).  
1.11 White and brown adipose tissue 
 Mammals have two distinct types of adipose tissue: white adipose tissue 
(WAT) and brown adipose tissue (BAT). In mice and rats the subcutaneous deposit 
amount to 60-70% of total adipose tissue. The remaining 30-40% is composed of 
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visceral deposits in the thorax, abdomen and limbs (Cinti, 2009). The coexistence of 
white and brown adipocytes within the same depots has led to the concept of the 
adipose organ (Cinti, 2009). In humans, there is greater extension of subcutaneous 
depots and in females they are more developed in the mammary glands and gluteo-
femoral areas.  In addition, adipocytes form normal constituents of bone marrow, 
parotid glands, parathyroid glands, pancreas and synovial membranes.  
WAT is composed of white adipocytes (figure 1.8B). These are large spherical 
cells, 60 to 80µm in diameter with a compressed nucleus, poorly developed 
organelles, few mitochondria and characterised by a single lipid droplet which 
accounts for 90% of the cell volume.  
 
 
Figure 1.8: Brown (A) and white (B) adipose tissue. Brown adipose tissue 
contains multiple small lipid droplets, numerous mitochondria which are able to store 
iron and create the brown appearance. White adipose tissue contain a single large 





WAT stores and releases chemical energy in the form of fatty acids which 
allow animals to have intervals between meals. In addition they play an important 
role, via the secretion of leptin, in satiety (DiSpirito and Mathis, 2015). 
BAT is composed of brown adipocytes (figure 1.8A). In contrast to WAT they 
are polygonal cells with a diameter of 30 to 50 µm, a central round nucleus and 
abundant cytoplasm containing numerous characteristic mitochondria and multiple 
lipid droplets. BAT plays an important role in thermogenesis and weight loss. 
Although white and brown adipocytes differ with regard to cell morphology 
and physiology, they both are able to store and release lipid and express β3-
adrenoreceptors on their cell surface (DiSpirito and Mathis, 2015). 
1.12 Lipid-laden macrophages (LLMs) 
 Preliminary Oil red O staining of BAL, endobronchial biopsies and lung 
biopsies (figure 1.9) show the presence of lipid in the form of lipid laden 
macrophages.  These cells may form following phagocytosis of lipid material by AMs 
or from lipid laden blood monocytes that migrate to the airways (Shibuya et al., 
1991); and the precise derivation of lipid laden macrophages remains unclear. 
Lipid laden macrophages are associated with impaired phagocytosis 
(Schrijvers et al., 2005), increased predisposition to apoptosis, raised lipid 
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spontaneously reprogramme their genes to develop different characteristics 
according to the requirements of their local environment.  
In vivo murine experiments suggest that white adipocytes are able to undergo 
reversible transdifferentiation under particular physiological conditions.  In mice 
treated with a β3-adrenoreceptor agonist, a subpopulation of unilocular adipocytes 
were converted to multilocular mitochondria-rich adipocytes; a process consistent 
with white to brown adipocyte transdifferentiation (Himms-Hagen et al., 2000, 
Granneman et al., 2005, Barbatelli et al., 2010). Mice subjected to 6◦C for 10 days 
revealed that 80% of adipocytes in dissected adipose tissue were brown adipocytes 
(Murano et al., 2009). This increase in brown adipocytes corresponds to a decrease 
in white adipocytes in the absence of cell degeneration or apoptosis (Vitali et al., 
2012). This process is attenuated in β3-adrenoreceptor knockout mice exposed to 
cold (Jimenez et al., 2003). 
Another example of reversible transdifferentiation of adipocytes is the tissue 
plasticity of mammary glands during pregnancy, lactation and post-lactation stages 
(Morroni et al., 2004). In virgin females the majority of the mammary gland consists 
of adipocytes. During pregnancy and lactation the organ is replaced by 
approximately 90% secretory epithelial cells. This process is reversed following rapid 
and massive adipogenesis after lactation (Hennighausen and Robinson, 2001, 
Silberstein, 2001). The transdifferentiation process in this case is supported by the 
findings that electron microscopy has excluded the presence of dormant adipocytes 
during lactation and BrdU injections have demonstrated the absence of dormant 
adipocytes in mammary tissue during post lactation adipogenesis and a low rate of 
epithelial proliferation during pregnancy (Morroni et al., 2004). 
66 
 
1.14 Hypothesis and aims 
The link between obesity and asthma is a relatively recent association and 
there is an increasing body of research suggesting the link is both bidirectional and 
multifactorial.  I have chosen specific areas that form important components of this 
relationship and currently remain poorly understood.  
1) Obesity-associated severe asthma is a distinct phenotype because obesity-
related inflammation contributes to the severity of asthmatic inflammation, 
remodelling and to the associated corticosteroid insensitivity. 
To address this, I aim to analyse a large database of severe asthmatics with 
regard to multiple variables (including demographic data, medical history, allergen 
testing, healthcare utilisation and medication, lung function, blood testing and bone 
density) and look for correlations between obesity and severe asthma. This will 
enable me to define the phenotypic characteristics of patients with obesity-related 
compared to non-obese severe asthma in terms of demographics, clinical features, 
markers of inflammation, healthcare utilisation and lung physiology. This is 
discussed in Chapter 3. 
 
2) Obesity related severe asthma is associated with increased lipid laden 
macrophages and intracellular lipid droplets.  
 Lipid laden macrophages in bronchoalveolar lavage cells will be analysed 
using Oil Red O staining (Chapter 4) and lipid droplets in endobronchial biopsies will 
be assessed using perilipin staining (Chapter 5). Their relationship with asthma 




 3) Raised BMI is associated with corticosteroid insensitivity in patients with 
asthma. 
 Suppression of LPS-induced cytokine release by dexamethasone from 
PBMCs taken from asthmatics and healthy controls will be examined and assessed 
according to BMI (Chapter 6). 
  
 4) Adipokines modulate inflammatory cytokine release and corticosteroid 
insensitivity in severe asthma.  
 The role of adipokines in obesity related severe asthma through in vitro 
experiments involving peripheral blood mononuclear cell taken from asthmatics and 
healthy controls is examined in Chapters 6 and 7. The aims are to study the effect of 
adiponectin, resistin and leptin on PBMCs in terms of inflammatory response, 



































Chapter 2: Materials and Methods 
2.1 Patient cohorts and characterisation 
Chapter 3: Obesity-associated asthma: a distinct phenotype 
Subjects were included if they fulfilled the ATS definition of refractory asthma 
(ATS, 2000)  and had a recorded body mass index (BMI).  Subjects had at least one 
major and two of the minor criteria listed below. 
Major criteria (must show at least one from):  
1) Treatment with continuous or near continuous (>50 % of year) oral 
corticosteroids (OCS) 
Or  
2) Requirement for treatment with high dose ICS  
 
Minor criteria (at least 2 out of the following):  
1) Requirement for daily treatment with a controller medication in addition to 
ICS e.g. long acting β2-agonists (LABA), theophylline or leukotriene 
antagonists  
2) Asthma symptoms requiring short acting β2-agonists (SABA) on a daily or 
near daily basis  
3) Persistent airways obstruction (FEV1 <80 % predicted, diurnal peak 
expiratory flow (PEF) variation >20 %)  
4) One or more emergency care visits for asthma per year  
5) 3 or more steroid “bursts” per year  
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6) Prompt deterioration with ≤ 25 % reduction in oral CS or ICS  
7) Near fatal asthma event in the past  
Chapter 4: The relationship between lipid-laden macrophages, asthma and BMI 
and chapter 5: Asthma, BMI and lipid droplets 
All patients underwent a screening visit. Healthy subjects had no smoking 
history and no history of respiratory or cardiac disease. Asthma was based on a 
physician diagnosis and patients either had a PC20 methacholine concentration 
causing a 20% fall in FEV1 of <8mg/ml and/or an FEV1 reversibility of ≥ 12% of 
baseline. Severe asthma was defined according to the ATS definition of refractory 
asthma (ATS, 2000). Patients who did not fulfil the criteria for severe asthma were 
classified as non-severe asthmatics and they were taking ≤1000mcg of inhaled 
beclomethasone dipropionate (BDP) or equivalent per day. Patients with chronic 
cough reported a dry persistent cough for at least 8 weeks duration. All subjects had 
been investigated with a standard protocol to exclude a diagnosis of asthma or other 
respiratory disease. 
Healthy subjects had no smoking history and no history of respiratory or 
cardiac disease.  
Chapter 6: The impact of leptin, resistin and adiponectin on PBMCs in severe 
and non-severe asthma and chapter 7: The effect of adiponectin on PBMCs: 
inflammatory response and corticosteroid insensitivity in severe asthma 
Subjects underwent spirometry with reversibility testing, a methacholine 
challenge test (to assess the degree of bronchial hyper-responsiveness), skin prick 
tests and IgE levels (to assess atopic status), and measurement of exhaled nitric 
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oxide (as a non-invasive marker of inflammation). All subjects had blood taken to 
obtain PBMCs. In addition, asthmatic subjects completed an Asthma Control 
Questionnaire.  
Non-severe asthmatic subjects: mild to moderately severe asthma. The groups 
were defined as follows, according to their need for treatments (as established in the 
Asthma Management GINA or BTS guidelines): (i) Mild: intermittent symptoms and 
need for reliever bronchodilator less than once a day; (ii) moderate asthma: well-
controlled asthma with minimal symptoms while on ICS therapy not exceeding 2,000 
μg beclomethasone equivalent . 
Severe asthmatic subjects: fulfilled the ATS, 2000 criteria for refractory asthma as 
previously described. (ATS, 2000). 
Obese subjects: obesity is defined as a body mass index (BMI) over ≥ 30 
Overweight subjects: 25 to 29.99 
Normal weight subjects: BMI ≤ 24.99 
Exclusion criteria (for all chapters): 
 Current smokers, or < 3 years since quitting smoking (< 5 pack/years) 
 Less than 4 weeks from an asthma exacerbation 
 On steroid-sparing agent or immunosuppressant (e.g. azathioprine, 
methotrexate and ciclosporin) 
 Concomitant anti-IgE therapy 
 On anti-platelet or anti-coagulant drugs 
 Low platelet count 
 Pregnancy or breast-feeding 
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2.2 Clinical Methods 
2.2.1 Ethics 
All studies were approved by the Office for Research Ethics Committees 
Northern Ireland (ORECNI) (10/NIR02/37), the West London 3 and the Brompton, 
Harefield and NHLI Research Ethics Committees (11/H0706/4 and 08/H0708/29). 
Subjects provided written informed consent. Clinical investigations were performed in 
accordance with ‘Good Clinical Practice’ guidelines.  
 Healthy subjects, patients with chronic cough, mild/moderate asthmatics and 
severe asthmatics were recruited at the National Heart and Lung Institute (NHLI) and 
the Royal Brompton Hospital.  
2.2.2 Skin prick testing 
Skin prick testing was performed on the anterior forearm of one arm. A lancet 
was used to breach the surface of the epidermis through a drop of allergen extract 
on the skin at a 90 degree angle and surplus fluid was blotted with a tissue. After 15 
minutes, the sites were examined and the reaction to individual allergens measured 
using a transparent ruler. Measurements were taken from the wheal produced and 
not the erythematous reaction. Measurements were recorded in the patient notes. 
The following allergens were tested: Dermatophagoides pteronyssimus, mixed grass 
pollen, cat dander and Aspergillus fumigatus. Histamine (10 mg/ml) and normal 
saline served as positive and negative controls respectively. A positive reaction 
occurs when a wheal measures 3 mm in maximum diameter with a negative control 





Baseline spirometry was measured in all subjects using a calibrated, dry 
wedge spirometer (Vitalograph, Buckingham, UK). Assessments were performed 
according to a standardised protocol. Subjects rested for 15 minutes prior to three 
measurements of FEV1 and FVC. The procedure was performed with the subject 
sitting and they were asked to take a full inspiration, seal his/her lips around the 
mouthpiece and perform an expiratory manoeuvre as rapidly and forcefully as 
possible. Expiration was encouraged until a two second plateau phase had been 
achieved or 6 seconds overall. This was repeated a further two times with a one 
minute rest between and the best value recorded.  
2.2.4 Methacholine provocation test (PC20) 
Bronchial challenge testing with methacholine was conducted according to the 
departmental protocol. This incorporated a wash out period of 8 hours for short-
acting β2-adrenergic agonists. Following arrival to the laboratory, subjects were 
required to rest for 15 minutes prior to an assessment of lung function. Three 
measurements of FEV1 at 1 minute intervals were taken and the highest value used 
for the baseline. Subjects then inhaled five breaths of 0.9% saline nebulised from a 
breath activated dosimeter by inspiring slowly from functional residual capacity 
(FRC) to total lung capacity (TLC) over 3 seconds and then breath holding for 6 
seconds. Subsequent FEV1 measurements were then taken at 30 seconds, 90 
seconds and 180 seconds post nebulisation. At each time point, three 
measurements were taken and the highest was used. The concentration of 
methacholine inspired was doubled until a ≥ 20% fall in FEV1 from the post saline 
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value was achieved. The starting concentration of methacholine is 0.03 mg/ml. 
Patients were given an inhaled β2-agonist if required.  
Patients with severe asthma who had an FEV1 <1.5 litres or <60% and 
patients in whom it was felt clinically inappropriate did not undergo a PC20. 
2.2.5 Exhaled nitric oxide (NO) measurement 
Exhaled NO measurements were taken using the hand-held device NObreath 
(Bedfont Scientific Ltd, UK). This is a non-invasive test that is easy to perform, 
requires a warm up time of approximately 60 seconds followed by a baseline 
measurement of ambient air NO and the breath time, at an exhalation flow rate of 
50mls per second, is approximately 12 seconds. The machine concentration range is 
from 5 to 300 ppb NO with an accuracy and repeatability of ±5 ppb for values ≤50 
ppb and ± 10% of measured value >50 ppb. Three successive measurements were 
performed on each occasion and the highest reading recorded. Ambient air NO was 
recorded for a second time after each subject was studied. 
2.2.6 Measuring obesity 
There are a number of different ways to measure body fat percentage and the 
definition of ‘overweight’ and ‘obesity’ is dependent on which method is used. Each 
way has particular advantages and disadvantages (see table 2.1) with cost 
implications meaning that anthropometric measurements are the most used 





Table 2.1. Different methods to measure obesity. 
Method Pros Cons 
Body Mass Index (BMI) 
 
Chapters 3, 4, 5, 6, 7 
 Simple  
 Inexpensive  
 Easy to perform 
 Standardised cut off points 
 Well validated 
 Inaccurate in specific groups (e.g. 
body builders, the elderly) 
 Sex and racial variance (women 
generally have more fat than men 
and that Asians have more fat than 
whites) 
Waist hip ratio 
 
Chapters 6 and 7 
 Easy to perform 
 Measure of abdominal obesity 
 Inexpensive 
 Not standardised 
 Difficult to measure 
 Less accurate in the obese 
Hydrostatic weighing  Accurate 
 Time consuming 
 Not practical - subjects need to be 




Chapters 6 and 7 
 Easy to perform 
 Quick results 
 Requires calibration 
 Ratio of water to fat is variable (e.g. 
dehydration, weight loss, illness) 




 Good for very high BMI, 
elderly and children 
 Expensive 
Dilution method (hydrometry)  Accurate 
 Applicable to all subjects 
 Variability of body water to fat-free 
mass ratio e.g. during illness, 
dehydration, weight loss 
Skin fold thickness 
 
Chapters 6 and 7 
 Inexpensive 
 Quick to perform, portable 
 User dependent 
 Requires training 
 Not always reproducible 
 Difficult to measure in those with a 
high BMI (e.g. >35) 
Dual energy X-ray 
absorptiometry (DEXA)  Accurate 
 Expensive 
 Not portable 
 Time consuming  
 Cannot distinguish types of fat 
(visceral vs. subcutaneous) 
 Most machines cannot handle 
subjects with a high BMI (>35) 
CT or MRI  Accurate 
 Expensive 
 Non-portable 
 Not possible in all cases  
 Radiation risk 
 Unable to accommodate those with 




 Quick to perform 
 Expensive 
 User dependent – requires 
experience and skill 
 Not standardised 
 Inherent artefacts (e.g. fascia) 
In vivo neutron activation 
analysis 






The body mass index (BMI) is the most basic and widely used method. It is a 
simple index of weight-for-height and a popular method in classifying overweight and 
obese individuals and populations. BMI is calculated by the dividing the weight in kg 
by the square of the height in metres (kg/m2). A BMI of ≥ 25 is considered to be 
overweight whilst those ≥ 30 are classified as obese (table 2.2).  
BMI is particularly useful because it is standardised, the same for both sexes 
and for adults of all ages. However, there are some important considerations when 
using BMI. These include the fact that it does not take body composition, fat 
distribution and racial variance into account. BMI does not differentiate between 
adipose tissue and lean mass and therefore results in specific populations (e.g. body 
builders) may be misleading. 
Although BMI does not appear to be a particularly good way to quantify body 
fat composition, it is widely used as a risk factor for disease and as a marker for 
mortality. BMI tends to underestimate higher body fat percentages and there is some 
age dependent variability with overestimation in older subjects and underestimation 








Table 2.2. The International Classification of adult underweight, overweight 
and obesity according to BMI (Organisation, 2011). 
Classification 
BMI (kg/m2) 
Principal cut-off points Additional cut-off points 
   
Underweight <18.5 <18.5 
Severe thinness <16.0 <16.0 
Moderate thinness 16.0 – 16.99 16.0 – 16.99 
Mild thinness 17.0 – 18.49 17.0 – 18.49 
Normal range 18.5 – 24.99 18.5 – 22.99 23.0 – 24.99 
Overweight ≥25.0 ≥25.0 
Pre-obese 25.0 – 29.99 25.00 – 27.49 27.5 – 29.99 
Obese ≥30.0 ≥30.0 
Obese class I 30.0 – 34.99 30.0 – 32.49 32.5 – 34.99 
Obese class II 35.0 – 34.99 35.0 – 37.49 37.5 – 39, 
Obese class III ≥40.0 ≥40.0 
 
 
Waist-hip ratio (WHR) 
WHR is the ratio of the circumference of the waist compared to that of the 
hips and focuses on central adiposity. A longitudinal study of 1462 middle aged 
women found subjects with a high WHR were associated with a significantly raised 
12 year incidence of myocardial infarction, angina, stroke, and death (Lapidus et al., 
1984) (table 2.3). This relationship was stronger than other anthropometric variables 
(including skin fold measurements and BMI).  A 13 year follow up study of 79,254 
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men aged 54 found that WHR, but not BMI or skin fold measurements, was 
significantly correlated with stroke, ischaemic heart disease or death from all causes 
(Larsson et al., 1984). 
 
Table 2.3. Correlating waist hip ratio (WHR) with myocardial infarction, stroke 
and death – 12 year follow up of 1462 women aged 38 to 60 (Lapidus et al, 
1984). 
Centiles of waist to hip ratio 
End points 




    
0 – 10 0 0 2.9 
11 – 20 0.4 0.4 3.2 
21 – 40 0.4 0.7 5.4 
41 -60 2.4 0.4 3.9 
61 - 80 2.4 1.1 6.5 
81 - 90 2.2 0 3.6 
91 - 95 2.9 1.5 2.9 
96 - 100 5.9 4.4 15.5 
 
 
The WHO advises that waist circumference should be measured at the 
approximate midpoint between the lower margin of the last palpable rib and the top 
of the iliac crest whilst hip circumference should be taken around the widest portion 





Skinfold measurements can be used as an indirect measurement of body 
composition. It is simple to perform, inexpensive and repeatable. Two of the most 
common methods are the Durnin and Wormersley equation (Durnin and Womersley, 
1974) and the Jackson and Pollock equation (Jackson and Pollock, 1978). These 
methods use regression equations to estimate body density using skinfold 
measurements and age. A further equation is then used to convert body density to 
body fat percentage. The Durnin and Wormersley method uses skinfold thickness 
measurements taken at four sites (biceps, triceps, subscapular and supra-iliac 
areas) on the right side of the body with the subject standing (figure 2.1). Jackson 
and Pollock equations calculate body density using either the quadratic or log form of 
the sum of skinfolds, in combination with age, waist and forearm circumference 
(Jackson and Pollock, 1978).  
Measurements are taken to the nearest mm, except for values below 5 mm 
where the nearest 0.5 mm is used.  The Womersley and Durnin (Durnin and 
Womersley, 1974) method was used. Four skinfold sites were measures (triceps, 
biceps, subscapular and suprailiac). Body density was then calculated using the log 
of their sum in one of the equations shown in table 2.4. The density value was then 

















Figure 2.1: Durnin and Womersley Method 1974. Skin fold measurements are 
taken at four sites (bicep, tricep, subscapular and suprailiac). Body fat percentage 














Table 2.4. Body density equations: Durnin and Womersley (Durnin and 
Womersley, 1974). 






< 17 D = 1.1533 - (0.0643 X L) D = 1.1369 - (0.0598 X L) 
17-19 D = 1.1620 - (0.0630 X L) D = 1.1549 - (0.0678 X L) 
20-29 D = 1.1631 - (0.0632 X L) D = 1.1599 - (0.0717 X L) 
30-39 D = 1.1422 - (0.0544 X L) D = 1.1423 - (0.0632 X L) 
40 -49 D = 1.1620 - (0.0700 X L) D = 1.1333 - (0.0612 X L) 
> 50 D = 1.1715 - (0.0779 X L) D = 1.1339 - (0.0645 X L 
      
 
D = predicted density of the body (g/ml), L = log of the total of the 4 skin fold sites 
(mm). The density can then be converted to body fat percentage using the Siri 
Equation (% Body Fat = 495/Body Density) – 450) (Patil et al., 2007).  
 
Bioelectrical impedance analysis (BIA) 
BIA was introduced in the 1980’s as a new method to calculate body 
composition (Baumgartner et al., 1989). Body fat percentage can be calculated using 
one or more frequencies introduced via electrodes across the body (usually via the 
hands or feet). The body resistance, or impedance (voltage drop), of the electrical 
flow is detected and is determined by the amount of fluid present. This method is 
non-invasive, portable and convenient. However, it relies on correlation and multiple 
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regression analysis, with an assumption that body geometry and fat-free mass is 
constant. Therefore there are concerns regarding repeatability and accuracy in 
specific situations. These include changes in weight, fluid volumes (for example in 
diseases such as renal failure and heart failure) and hydration status. In addition, 
BIA may underestimate body fat percentage in obese individuals (body fat > 30%) 
(Bohm and Heitmann, 2013). 
BIA was measured using a Tanita TBF-300MA composition analyser. 
Subjects stood on the BIA after taking their shoes and socks off. Feet were free of 
excess dirt and heels were placed directly on the top of the posterior electrodes, 
while the front part of the foot was in contact with the anterior electrodes. In the 
event of calluses, 0.5cc of normal saline or water was placed in the centre of each 
electrode to ensure that current could freely pass through. A print out provided data 
on impedance, body fat percentage, fat mass and fat free mass. 
Hydrostatic weighing 
Hydrostatic weighing is considered the gold standard for measuring body 
density. It utilises the Archimedes principle to calculate body volume by measuring 
the difference between a subject’s weight submersed in water and that in air. Whole-
body density can subsequently be calculated. The subject must be at maximal 
exhalation whilst submerged in water to minimise the effect of buoyancy from air in 
the lungs and result in an accurate measurement (Behnke et al., 1995). This is a 
well-established method with excellent reliability. However, it is time-consuming, 
often uncomfortable for the subject and not accessible for many different groups 




Air displacement plethysmography 
Air displacement plethysmography (AP) uses a chamber with a fixed volume 
of air and determines body volume by measuring the reduction in volume after a 
subject is introduced. Whole-body density and body composition can subsequently 
be calculated using validated prediction equations (Biaggi et al., 1999).  
Dilution Method (hydrometry) 
 The dilution method (hydrometry) utilises isotope-labelled liquid for ingestion 
or injection and then subjects provide body fluid samples which are subsequently 
analysed for isotope levels. Total body water, fat free mass and body fat mass can 
then be calculated utilising the dilution of the isotope. This is based on the premise 
that more of the isotope will be mixed (diluted) when there is a greater amount of 
lean tissue and lower body fat. 
Computerised tomography (CT) and magnetic resonance imaging (MRI) 
CT, utilising x-rays, and MRI, using magnetic fields, scans can be used to 
visualise the fat and lean tissues and measure the amount of visceral fat.  
Neutron Activation Analysis (NAA) 
NAA is a sensitive analytical technique based on the interaction of a neutron 
with an atomic nucleus. This results in the transformation of the target nucleus to an 
unstable isotope or nuclear state and subsequently decays. The amount of energy 
produced in this process can be measured in the form of gamma rays (Kehayias and 
Valtuena, 1999). This process can be used to calculate the rate of bone loss, using 
49Ca gamma ray measurement with DEXA absorptiometry, and body composition, 
using  40K gamma ray measurement. 40K is present in equal proportions to total body 
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potassium which allows it to be used as a surrogate marker and as a measurement 
of total body cell mass, synonymous with fat free mass. 
Dual energy X-ray absorptiometry (DEXA) 
DEXA uses x-rays of two different energies to scan the body. One ray is 
absorbed more readily by fat compared to the other. This allows calculation of body 
composition and body fat using a computer program to subtract one image from the 
other. 
Techniques used in this study 
This study incorporates BMI, bioelectrical impedance, waist-hip ratio and skin 
fold measurements. These methods were chosen in view of the various pros and 
cons highlighted above. 
2.2.7 Fibreoptic bronchoscopy: 
Fibreoptic bronchoscopies were performed under sedation according to 
standard clinical practice at the Royal Brompton Hospital. All patients underwent a 
screening visit and those with significant respiratory or inflammatory comorbidities 
and those requiring treatment for a respiratory tract infection within the preceding 
four weeks were excluded. Healthy subjects had no smoking history and no history 
of respiratory or cardiac disease.  
BAL was performed from a segment of the right middle lobe (RML). The 
bronchoscope was wedged and warmed aliquots of buffered normal saline were 
installed (50 ml x 4, total 200 mls) and immediately aspirated through the 
bronchoscope by gentle suction. 
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BAL fluid was centrifuged (500 x g for 10 minutes), washed with Hanks’ 
balanced salt solution (HBSS) and the cell pellet re-suspended in culture media 
(RPMI with 0.5% fetal bovine serum, antibiotics and L-glutamine) to a density of ~ 
0.5 x 106 macrophages/ml. Cytospins were stained with REASTAIN Quick-Diff kit 
(Reagena International Oy Ltd, Finland) and a differential cell count was performed. 
Cytospins were then stained with Oil Red O prior to calculation of the lipid laden 
macrophage index (LLMI).  
Endobronchial biopsies were taken from segmental and subsegmental 
airways of the right middle and right lower lobe. Biopsies were embedded in optimal 
cutting temperature medium and then snap-frozen in pre-cooled isopentane in liquid 
nitrogen and stored at -70 °C. Cryostat sections (6 mm) were obtained from biopsies, 
placed on poly-L-lysine-coated microscope slides and stained with haematoxylin and 
eosin for measurement of subbasement membrane (SBM) thickness. Slides were 










2.3 Laboratory Methods: 
All materials, compounds, buffers and solutions used in this project are listed in the 
following tables. 
Table 2.5. Materials for cell culture. 
Material Supplier 
Acid Citrate Dextrose (ACD) 
(see table 2.7 for recipe) Sigma-Aldrich, Dorset, UK 
Ficoll PaqueTM Plus GE Healthcare, Buckinghamshire 
Hank’s Buffered Saline Solution (HBSS) Sigma-Aldrich, Dorset, UK 
Heat-inactivated foetal bovine serum 
(FBS) PAA Laboratories Ltd, UK 
Kimura Stain 
(see table 2.7 for recipe) Reagents from Sigma-Aldrich, Dorset, UK 
L-Glutamine Sigma-Aldrich, Dorset, UK 
Penicillin-Streptomycin solution Sigma-Aldrich, Dorset, UK 
PercollTM GE Healthcare, Buckinghamshire, UK 
Phosphate-buffered saline (PBS) Sigma-Aldrich, Dorset, UK 
Roswell Park Memorial Institute (RPMI) 
1640 medium Sigma-Aldrich, Dorset, UK 
Sodium chloride 0.9% (w/v) IV Baxter Healthcare, Berkshire, UK 





Table 2.6. Corticosteroids, cytokines and inhibitors. 
Treatment Source Stock solution 
Dexamethasone (Dex) Sigma-Aldrich, Dorset, UK 10
-3  M in sterile water 
Lipopolysaccharide (LPS; from 
Escherichia coli) 
Sigma-Aldrich, 
Dorset, UK 1 mg/ml in PBS 
Adiponectin (APN) Insight Biotechnology Ltd, Wembley, UK 1 mg/ml in DMSO 
Leptin R & D Systems, Abington, UK 1 mg/ml in DMSO 
Resistin Peprotech, London, UK 100 µg/ml in water 
Dexamethasone Sigma-Aldrich, Dorset, UK 10
-3 in water 
GW856553 GlaxoSmithKline, Stevenage, UK 10
-2 in water 
U10126 Sigma-Aldrich, Dorset, UK 10
-2 in DMSO 
SP600125 Sigma-Aldrich, Dorset, UK 10
-2 in DMSO 
PI3K wortmannin Sigma-Aldrich, Dorset, UK 10
-3 in DMSO 
Perilipin antibody New England Biolabs, Hitchin, UK  1:100 dilution 
Oil Red 0 Sigma-Aldrich, Dorset, UK  Ready to use 
Anti CD45 monocolonal mouse anti-
human antibody 
Dako Ltd, Cambridge, 
UK 1:100 dilution 
Polyclonal rabbit anti-human perilipin 
protein 
New England Biolabs, 
Hitchin, UK 1:50 dilution 
EnVision-alkaline phosphatase (EV-
AP)  
Dako Ltd, Cambridge, 
UK  Ready to use 
Labelled polymer, AP (prediluted 
secondary antibodies, rabbit anti-
mouse/rabbit) (K4018 
Dako Ltd, Cambridge 
UK  Ready to use 
Polyclonal goat anti-mouse rabbit 
horseradish peroxidase (HRP)-
conjugated secondary antibody 
(P0448) 
Dako Ltd, Cambridge 
UK  Ready to use 
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Table 2.7. Buffer, solution or stain recipe. 
Material Supplier 
Acid citrate dextrose solution (ACD) 
5 g glucose; 4.2 g di-sodium hydrogen 
citrate; made up to 100 ml with deionised 
water; filtered and sterilised prior to use. 
Kimura stain 
11 ml Toluidine Blue; 0.5 ml Saponin 
saturated in 50% (v/v) ethanol; 0.8ml Light 
Green; 5 ml PBS; filtered and sterilised prior 
to use. 
Stop solution (used for ELISAs) 11ml Sulphuric Acid; made up to 100 mls with deionised water 
Wash buffer (for ELISA) 5 PBS tablets diluted in 1000mls of deionised water; 500 µl Tween®20. 
Oil Red O Sigma-Aldrich, Dorset, UK.  0.7% in propylene glycol (Sigma-Aldrich, Dorset) 













Table 2.8. Kits and assays. 
Material Supplier 
Duoset ELISA Kits (for detection of IL-6 
and CXCL8) R & D Systems, Abingdon, UK 
Milliplex® MAP Human Magnetic 
Cytokine/Chemokine kit Millipore, Watford, UK 
 
 
Table 2.9. Equipment and devices used. 
Equipment or device Supplier 
96-well MicroWell NUNC plates Fisher Scientific UK Ltd,  Loughborough, UK 
Inverted light microscope Microsystems, Buckinghamshire, UK Leica 












2.3.1 Blood processing and isolation of PBMCs 
80 millilitres of peripheral venous blood was collected into a syringe 
containing acid citrate dextrose (ACD), an anticoagulant. The blood was then divided 
into four aliquots of 20 ml and diluted with an equal volume of Hanks’ Buffered Saline 
Solution, HBSS (Sigma, Dorset, UK). 25 mls were then carefully layered onto 20 ml 
of Ficoll-PaqueTM PLUS (Amersham plc, Dorset, UK) in a 50 ml Falcon tube. 
Following centrifugation (30 minutes at 400 x g at 21°C), PBMCs were collected from 
the interface between Ficoll and plasma. They were then washed with HBSS and 
centrifuged (10 minutes at 400 x g). The cell pellet was then resuspended with 1 ml 
of HBSS and red cell lysis was induced by the addition of 5 ml of cold water added 
whilst agitating the mixture. This was subsequently diluted with HBSS and a further 
centrifugation was carried out (10 minutes at 400 x g). PBMCs were then 
resuspended in 1 ml of RPMI culture media (Sigma; 0.5% v/v Foetal bovine serum, 2 
mM L-glutamine, 100U penicillin-streptomycin) and counted using a haemocytometer 
and Kimura staining. 
2.3.2 Cell viability assay 
 PBMCs were seeded in 96 well plates and stimulated as described later in 
this section. Following stimulation, the supernatant was removed and cells 
subsequently incubated with 200 µl of 1 mg/ml MTT solution in serum-free DMEM at 
37°C in 5% C02/95% air (vol/vol) for 20 minutes. Staining of the cells  
(green/purple tinge) was confirmed by observation under a light microscope, the 
MTT solution was removed, and 100 µL of DMSO was then added to each well. The 
resting solution was then transferred into 96-well microtitre plates and the 
absorbance at 550 nm was measured with the absorbance microplate reader. The 
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effect of a treatment on cell viability was determined as a fold change in absorbance 
compared to the unstimulated control. 
2.3.3 PBMC plating and stimulation for steroid/inhibitor combination study 
experiments 
PBMCs were then diluted to a stock solution of 0.5 million per ml using RPMI. 
200 µL (100, 000 cells) were placed in each well of a 96 well plate and allowed to 
settle in an incubator (37oC, 5% C02, 90% humidity) for 2 hours. Cells were then pre-
treated with/without dexamethasone (Dex) for one hour prior to the addition of leptin, 
resistin or adiponectin (APN) for a further hour prior to the addition of LPS. PBMCs 
were then incubated overnight (37ºC, 5% C02, 90% humidity) and supernatants 
harvested after 20 hours and stored at -20ºC until ready for cytokine analysis. 
2.3.4 Cytokine analysis using ELISA 
IL-6 and CXCL8 cytokine release levels in supernatant were measured by 
enzyme-linked immunosorbent assay (ELISA) using DuoSet ELISA kits (R & D 
Systems, Abingdon, UK) according to the manufacturer’s protocol.  
ELISA uses an immunodetection method which utilises biotinylated detection 
antibodies to identify specific antigens in a complex of proteins. This is a sensitive 
method that allows accurate measurement of the concentration of a specific cytokine 
in a sample. The technique has been termed a sandwich assay because an 
antibody-antigen-antibody complex is formed. A 96 well microtitre plate is coated 
with a ‘capture antibody’ against the target protein. The antigen in the sample is then 
immobilised by the capture antibody in the well. A biotin-labelled ‘detection antibody’ 
is then added which is also directed against the protein being tested. This antibody 
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binds to exposed sites on the protein and the biotin tag allows conjugation to 
streptavidin horseradish peroxidise (HRP) enzyme. Following the addition of a 
substrate, e.g. tetramethylbenzidine, an enzymatic reaction produces a visible colour 
change which is detected. The reaction is halted with ‘stop solution’ (2N H2SO4) and 
the colour intensity, which is proportional to the concentration of the protein tested, 
can be measured on a microplate reader. 
 Briefly, 100 μl of capture antibody solution at the working concentration in 
PBS were added to a 96-well microtitre plate and incubated for 24 hours at room 
temperature. The capture antibody solution was then removed; wells were washed 
three times with 300 μl of wash buffer and then dried by blotting the plate several 
times against a pad of paper towels. 300 μl of Blocking Buffer (1% BSA and 0.05% 
NaN3 in PBS) per well were used to block and the plate was incubated for 1 hr at 
room temperature prior to a second wash step (as described above). A seven-point 
protein standard with 2-fold serial dilutions was prepared from the stock protein 
standard in Reagent Diluent buffer (0.1% BSA and 0.05% Tween 20 in PBS). 100 μl 
of the standards and diluted supernatants were then aliquotted into the wells of the 
plate. Following an incubation period of 2 hours at room temperature, the wash step 
was repeated. 100 μl of detection antibody, diluted to the working concentration in 
Reagent Diluent buffer, was added to each well and the plate incubated for 2 hours 
at room temperature. Following another wash step, 100 μl of streptavidin-HRP 
solution, diluted 1/200 in Reagent Diluent buffer, was placed into each well and the 
plate was incubated and covered, to protect from sunlight, for 20 min at room 
temperature. Following a final wash step, 100 μl of the substrate solution, prepared 
by mixing equal volumes of Colour Reagents A (H2O2) and B (tetramethylbenzidine), 
was added to each well and incubated until a blue colour developed. 50 μl of stop 
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solution (2N H2SO4) was added to each well to terminate the substrate reaction. The 
absorbance of each well was then measured at 450 nm with a 540 nm correction 
using a microplate reader and a four-parameter logistic standard curve was 
automatically generated using the microplate reader software. The cytokine 
concentration of each sample was determined from the standard curve and 
corrected for the dilution by multiplying by the dilution factor.  
2.3.5 Multiplex Assay 
Concentrations of six different human cytokines in culture medium were 
assayed using the Milliplex® MAP kit (table 2.10). Human cytokine/chemokine 
magnetic bead panels were purchased from Millipore (Watford, Hertfordshire, UK).  
Black 96-well plates were coated with 200 μl wash buffer and left for 10 min at 
room temperature. Wash buffer was decanted and all residual amount of buffer was 
removed. 25 μl of each standard or quality control were added to the appropriate 
wells. 25 μl of assay buffer was used for the background (0 pg/ml) standard. 
Dilutions for a standard curve were prepared (as shown in table 2.11) and pipetted 
onto the plate in duplicate. 25 μl of assay buffer was added to the sample wells. 25 
μl of matrix solution were added to the background, standard and quality control 
wells. 25 μl were added to the sample well (neat). Finally, 25 μl of mixed magnetic 
beads were added to all wells. Plates were incubated overnight at 4 oC with gentle 
shaking. Plates were washed twice with 200 μl wash buffer per well, using a hand-
held magnet. Briefly, the plates were placed on the magnet for a minute to allow 
complete settling of the magnetic beads. All contents were removed by decanting the 
plates. Plates were washed twice by removing them from magnet and adding the 
wash buffer and allow shaking for 30 seconds. Once again the plate was placed on 
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the magnet for a minute to allow the settling for the magnetic beads before removing 
all contents of wells. 25 μl of detection antibodies were added to each well and the 
plate was incubated at room temperature for 1 hour, followed by the addition of 25 μl 
of Streptavidin-Phycoerythrin to each well for further 30 minutes incubation. Plates 
were washed as explained before and 150 μl of drive fluid were added to all wells. 
Beads were re-suspended on a plate shaker for 5 min. The plate was run on a 
MAGPIX® instrument with a xPONENT software (Austin, TX, USA). The mean 



















Table 2.10.  H-CYTOMAG-60K – 6-Plex Panel. 
Bead/Analyte Name Luminex Magnetic Bead Region Catalog # 
Anti-Human IFNγ Bead 25 HCYIFNG-MAG 
Anti-Human IL-10 27 HCYIL10-MAG 
Anti-Human IL-1RA 42 H1RA-MAG 
Anti-Human CCL2 67 HCYMCP1-MAG 
Anti-Human CCL3 72 HMIP1A-MAG 
Anti-Human TNFα 75 HCYTNFA-MAG 
 
 
Concentrations of six different human cytokines in culture medium were 
assayed using the Milliplex® MAP kit. Human cytokine/chemokine magnetic bead 













Add 60 μl of each antibody bead vial to the mixing 











10,000 – 3.2 pg/ml 
Reconstitute human cytokine standard with 250 μl 
of deionised H2O for a 10,000 pg/ml concentration 
for all analytes. Prepare a 6-point standard curve 
by making a 1:5 serial dilution with assay buffer 
 











RPMI-1640 medium supplemented with 0.5 % (v/v) 







2.3.6 Slide staining 
 The methods for oil red O, perilipin and CD45 staining for BAL cytospins and 
endobronchial biopsies are discussed in this section. A more detailed description of 
the immunohistochemistry stain protocols and methods for scoring slides or biopsies 
can be seen in the methods section of each chapter.  
Oil red O staining and lipid laden macrophage index (LLMI) score calculation 
A lipid laden macrophage index (LLMI) was used to quantify lipid 
accumulation in AMs. BAL cytospins were stained with Oil-Red-O (Sigma-Aldrich 
Ltd, UK) to enable scoring and LLMI calculated by grading the amount of intracellular 
Oil-Red-O positive particles per 100 AMs. Intracellular lipid was evaluated using a 
modified version of that proposed by Corwin and Irwin (RW and RS, 1985, Colombo 
and Hallberg, 1987). Cells were scored from 0 to 4 whereby 0 = no opacification, 1 = 
up to ¼ opacified, 2 = ¼ to ½ opacified, 3 = ½ to ¾ opacified, and 4 = totally 
opacified (figure 4.2). The LLMI was calculated by the sum of the scores of 100 cells 
giving a potential range from 0 to 400.  The person who measured the LLMI was not 
aware of clinical findings.  
Perilipin 
Endobronchial biopsies were stained for CD45+ cells and for perilipin. 
Monoclonal mouse anti-human antibodies anti-CD45 (Dako, cat no: M0701), at 
1:100 dilution, and polyclonal rabbit anti-human perilipin protein (Cell Signaling 
Technology, cat no: 3470), at 1:50 dilution, were applied to bronchial biopsy sections 
for 1 hour.  
EnVision-alkaline phosphatase (EV-AP) technique (Dako Ltd, Cambridge, UK) 
was used to label CD45+ pan leukocyte/inflammatory cells. A modified EnVision 
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peroxidase staining method (Dako) was used to identify perilipin+ cells as previously 
described (O'Shaughnessy et al., 1997) for 2 hours.  
Irrelevant mouse IgG1 kappa antibody (MOPC21) and rabbit serum were used 
to substitute for the primary layer as negative control for staining specificity of CD45 
and Perilipin antibodies, respectively.  
Histological slides were coded to avoid observer bias. The immunostaining 
intensity for perilipin expression in the airway epithelium, where it was mostly 
observed, was semi quantitatively given a score ranging from 0 to 2 (0: negative, 0.5: 
weak staining, 1: moderate staining and 2: strong staining). An example of the 
perilipin immunohistochemistry staining in bronchial epithelial cells and scoring can 
be seen in figure 5.1. 
2.2.7 Statistical methods 
Chapter 3 
Between group comparisons for continuous variables were made using 
Kruskal-Wallis and for categorical variables using Chi-squared exact testing. 
Chapter 4 
 Categorical variables were reported as percentages and comparisons done 
using the chi–square or Fisher’s exact test.  Numerical variables were reported as 
mean (SD) or median (IQR) and comparisons done using Mann-Whitney test or 
Kruskal Wallis test. Statistical significance was defined as p<0.05. Logistic 






Statistical analysis was performed using StatView (SAS Institute. Inc. and 
GraphPad Prism 4 (GraphPad Software, Inc.). One way ANOVA followed by the 
unpaired Student’s t-test was used for the analyses of age, serum IgE, lung function and 
histamine PC20 data between groups. In respect of cell counts, these data were non-
normally distributed and differences between groups were assessed first using the Kruskal-
Wallis test, which, if significant, was followed by Mann-Whitney U-test between groups at 
baseline and infection. The coefficient of variation (CV = SD/mean  100) was used to 
express the error of repeat counts. A p value of < 0.05 was accepted as indicating a 
significant difference. 
Chapter 6 and 7 
GraphPad Prism Version 5.03 was the software for statistical analysis. 
Repeated measures analysis of variance (ANOVA) with Dunnet multiple comparison 
test was used for intra-group analysis of i) the effect of cytokine compared to 
unstimulation and ii) the effect of leptin, resistin, adiponectin, dexamethasone, LPS 
or in combination compared to control. Kruskal-Wallis test with Dunn’s multiple 
comparison was used to compare results between groups. p<0.05 was taken as 
significant. 
Power calculations: studies were exploratory in nature and no data existed for 
assessing power. For chapters 6 and 7 numbers required were estimated using data 
from previous studies from the research group. Chapters 4 and 5 were retrospective 
studies and therefore numbers were dependent on available samples and data. 
Primary and secondary comparisons were pre-determined to avoid the need for 
correction given the multiple tests performed.  
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Chapter 3: Obesity-associated asthma:             

























Chapter 3: Obesity-associated asthma: a distinct clinical phenotype 
Hypothesis and aim 
Obesity-associated severe asthma is a distinct phenotype because obesity-
related inflammation contributes to the severity of asthmatic inflammation, 
remodelling and to the associated corticosteroid insensitivity. 
To address this, I aim to analyse a large database of severe asthmatics with 
regard to multiple variables (including demographic data, medical history, allergen 
testing, healthcare utilisation and medication, lung function, blood testing and bone 
density) and look for correlations between obesity and severe asthma. This will 
enable me to define the phenotypic characteristics of patients with obesity-related 
compared to non-obese severe asthma in terms of demographics, clinical features, 
markers of inflammation, healthcare utilisation and lung physiology.  
 
3.1 Introduction 
Obesity has been identified as a major risk factor for the development of 
asthma (Dixon et al., 2010). This is supported by large prospective epidemiological 
studies, almost all of which have noted that obesity antedates a diagnosis of asthma 
(SA., 2006, Beuther and Sutherland, 2007, Ford, 2005). As BMI increases, the 
relative risk of developing asthma concurrently increases (Hjellvik et al., 2010). In 
addition, increasing BMI is associated with a reduced asthma related quality of life, 
more frequent exacerbations and a greater severity and frequency of respiratory 
symptoms (Akerman et al., 2004, Shore, 2007, Taylor et al., 2008).  
The link between the two appears to be multifactorial and is likely to involve a 
combination of in-utero conditions, genetic factors, comorbidities and inflammation 
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secondary to excess adipose tissue (Shore, 2008). Obesity-associated asthma may 
represent a distinct clinical phenotype (Dixon et al., 2010), characterised by later 
onset, female preponderance and greater symptoms than classic atopic asthma. 
Cluster analysis of a large cohort of patients noted an obese subgroup in both mild to 
moderate and refractory asthma. This subgroup was more likely to be female, 
display greater symptoms and had an absence of eosinophilic airway inflammation. 
(Haldar et al., 2008).  
There is evidence to support the presence of steroid resistance in overweight 
and obese asthmatics. This stems from post-hoc analyses of clinical trial data, which 
have associated  increasing BMI with a reduced response to ICS (Peters-Golden et 
al., 2006, Sutherland et al., 2010, Boulet and Franssen, 2007), and by an in vitro 
study on PBMCs, which found that overweight and obese asthmatics exhibited a 
reduced response to corticosteroids (Sutherland et al., 2008a).  
BMI is a simple index of weight-for-height and is calculated by dividing the 
weight in kg by the square of the height in metres (kg/m2). A BMI of ≥25 is 
considered overweight, whilst those ≥30 are classified as obese. It is particularly 
useful because it is standardised, calculated in the same way for both sexes and for 
adults of all ages (table 2.2).  
The exact role of obesity in the pathophysiology of asthma and the 
relationship to severe asthma remains unclear.  The aim of my study was to explore 
this relationship in a large well-characterised UK refractory asthma population, 
derived from the National Difficult Asthma Registry, by comparing the demographics, 
clinical features, markers of inflammation and healthcare utilisation in patients that 
were categorised by their BMI. 
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The British Thoracic Society (BTS) Research Committee, alongside 
physicians with a special interest in severe asthma, developed a National Registry 
for dedicated UK Difficult Asthma Services in 2006. This project aimed to 
standardise specialist clinical services, to further define and to facilitate research into 
the assessment and management of difficult asthma. Pilot data from 382 well 
characterised patients, who fulfilled the ATS definition for refractory asthma, 
collected from four specialist UK centres, were used to compare patient 
demographics, disease characteristics and healthcare utilisation (Heaney et al., 
2010). At present, there are seven UK dedicated Specialist Difficult Asthma Services 
submitting data to the registry; two centres in Glasgow and single centres in Belfast, 
Manchester, Leicester, Birmingham and London. The Registry is hosted online by 
Dendrite Clinical Systems Ltd and admits password protected anonymised data, 
after fully informed written consent has been obtained.  
Ethical approval for the Registry was obtained from the Office for Research 
Ethics Committees Northern Ireland (ORECNI) (10/NIR02/37). 
Patients at all centres underwent a multi-disciplinary systematic assessment 
of their asthma. At present there is no standardised method of assessing severe 
asthmatics in the UK. However, all patients underwent multiple investigations 
including a thorough medical history and examination, pulmonary function tests, 
allergy assessment (skin prick testing and/or RAST), blood tests (incorporating 
serum eosinophil count and IgE), and bone densitometry. Investigations were 
performed according to protocols at individual centres and lung function % predicted 
values were centrally calculated. Skin prick testing results were included for 
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aeroallergens tested at all centres. Although asthma quality of life questionnaires 
were completed, data was not available at the time of analysis. 
Subjects were entered into the Registry in a non-selected manner and  were 
included if they fulfilled the ATS definition of refractory asthma (ATS, 2000)  and had 
a recorded BMI.  Patients were then divided into three groups according to their BMI 
(normal weight 18.5 to 24.99, overweight 25 to 29.99, obese ≥30). The obese group 
were then subdivided into obese class I (BMI ≥30.0 to 34.99), obese class II (≥35 to 
39.99) and obese class III (≥40) for subgroup analysis. These groups are taken from 
the WHO international classification of underweight, overweight and obesity 















The study population consisted of 666 patients with severe asthma. The 
median BMI was 29.8 (IQR, 22.5 – 34.0); 48.3% were obese, 29.3% were 
overweight and 22.4% were of normal weight.  
Group data and between BMI comparisons are shown in tables 3.1 to 3.5.  
Values are presented in the following manner (% of obese compared to % 
overweight and % normal weight). 
3.3.1 Demographics 
There was a predominance of females (65%) and Caucasians (91.1%) in all 
BMI groups (table 3.1). The median age of asthma diagnosis in the overall cohort 
was 18 years (IQR 3 – 35) and 43.2% required maintenance oral prednisolone to 
control or partially control their symptoms. 89.4% had required short burst oral 
corticosteroid therapy in the preceding year and the median number of courses for 
those who required short burst therapy was 4 (IQR 2 – 7). There were high 
medication requirements in terms of leukotriene receptor antagonists (46%), 
theophylline (39.7%) and nebuliser use (47.9%). 
Obese severe asthmatics were less likely to be in full-time employment than 
overweight or normal weight individuals (34.9% compared to 39.3% and 44.2%, 
p<0.005) and this was more likely to be related to asthma ill health (33.3% compared 
to 23.6% and 19.6%). The obese group were more likely to have a basic level of 
education (31.1% compared to 20.7% and 17.0%) and appeared less likely to have 
achieved an advanced (19.7% compared to 17.0% and 35.8%) or graduate level 
(9.6% compared to 17.0% and 10.4%). Obese severe asthmatics appeared more 
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likely to be current smokers or ex-smokers (10.5% and 31.3%, respectively) than 
their overweight (6.3% and 30.5%) or normal weight (9% and 27.1%) counterparts, 
although this did not reach statistical significance. 
3.3.2 Medical history and atopy 
Obese severe asthmatics were more likely to report a history of eczema 
(31.9% compared to 23.9% and 22.6%), GORD (53.9% compared to 48.1% and 
39.7%) and have a documented abnormal pH profile study (pH profile results were 
available in 57 cases). Nasal polyposis (10.7% compared to 17.4% and 18.4%) and 
previous nasal surgery were both reported less frequently with increasing BMI (table 
3.2).  
Increasing BMI was associated with a lower aspergillus sensitisation (either a 
positive RAST or skin prick test) and a trend towards lower HDM, cat and mixed 
grass sensitisation (table 3.2). Serum IgE levels were lower in the overweight 
(median 144 [IQR, 46 – 384]) and obese group (119 [46 – 418]) compared to the 
normal BMI group (266 [83 – 480]) (table 3.5).  
3.3.3 Medications and healthcare utilisation  
The use of maintenance oral steroids (48.9% compared to 40.4% and 34.5%, 
p<0.01) increased alongside BMI. The overweight (92%) and obese (91.1%) groups 
were more likely than the normal (82.4%, p<0.01) BMI group to have required a short 
burst of OCS during the preceding year. Of those requiring OCS courses, the 
number of courses required was greater in the obese (5 [2-8]) than the overweight (4 
[2-6]) and normal (4 [1.3-6]) groups. Nebuliser use, SABA use per day and PPI use 
(45.4% compared to 30.7% and 29.3%) were all greater with increasing BMI. 
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Insufficient numbers of patients were on steroid sparing agents or anti-IgE treatment 
at the time of referral to specialist services for meaningful results to be generated 
(table 3.3). 
No significant difference was noted in the number of previous ICU 
admissions, emergency admissions or unscheduled visits over the preceding 12 
months between BMI groups.  
3.3.4 Lung function and radiology 
The obese group had a reduced prebronchodilator FVC (80.1% [95% CI, 78.0 
– 82.3]) compared to both the overweight (86.7% [83.7 – 89.8]) and normal weight 
groups (86.2.0% [82.8 – 89.6]). In those subjects where pre/post bronchodilator 
study data was available, the obese group had a reduced pre- and post- 
bronchodilator FVC compared to the overweight group. In contrast, the FEV1/FVC 
ratio was higher in the obese group (63.5% [61.5 – 65.4]) compared to the 
overweight group (59.3% [56.6 – 61.9]). The transfer coefficient (Kco) was greater in 
the obese group (104.5% [95% CI, 102.1 – 106.9]) compared to the normal weight 
group (97.0% [93.5 – 100.7]). The proportion of CT scans reported as normal by 
radiologists appeared to increase with BMI (20.9% compared to 15.1% and 13.1%). 
Central bronchiectasis was reported less often in the obese group (6.7% compared 
to 12.6% and 17.6%) although this did not achieve statistical significance (Table 4).  
3.3.5 Inflammatory markers and bone densitometry 
No difference was seen in baseline peripheral blood eosinophil or sputum 
eosinophil counts between groups. No significant difference in the level of exhaled 
nitric oxide (FENO) was seen between groups.   
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Bone densitometry revealed a trend towards greater T scores at the lumbar spine 
with increasing BMI. The normal weight group exhibited a lower T score at the 
femoral neck (T score -1.02 ± 1.21) compared to the overweight or obese group (-



















Table 3.1. Patient demographic data. 
    BMI   
  Overall 18.50 to 24.99 25.00 to 29.99 ≥ 30.00 p value 
 
666 (149, 22.4%) (195, 29.3%) (322, 48.3%)   
BMI 29.8 (22.5-34.0) 22.8 (18.9-24.9) 27.4 (26.3-28.5) 34.2 (31.8-38.9) 
 
 
        
 
Female (%) 435 (65) 107 (72) 111 (57) 217 (67) 0.009 
Race, n (%) 
         Caucasian 607 (91.2) 133 (89.3) 173 (89.6) 301 (94.4) 0.31 
    Asian 36 (5.5) 12 (8.1) 13 (6.7) 11 (3.4) 
     African 8 (1.2) 1 (0.7) 3 (1.6) 4 (1.3) 
     Other 10 (1.5) 3 (2.0) 4 (2.1) 3 (0.9) 
 Age at assessment  45.0 (37.0-54.0) 44.0 (34.0-54.0) 46.0 (38.0-57.0) 45.0 (38.0-54.0) 0.3 
Age at diagnosis 18.0 (3.0 - 35.0) 15.0 (3.0 - 35.0) 18.0 (3.0 - 36.0) 18.0 (4.0 - 34.0) 0.94 
Smoking status n (%) 
        Never 394 (60.9) 92 (63.9) 120 (63.2) 182 (58.1) 0.45 
   Ex-smoker 195 (30.1) 39 (27.1) 58 (30.5) 98 (31.3) 
    Current smoker 58 (9.0) 13 (9.0) 12 (6.3) 33 (10.5) 
    Ex or current smoker 253 (39.1) 52 (36.1) 70 (36.8) 131 (41.7) 0.38 
Smoking (pack years) 18.6 ± 19.8 14.8 ± 14.0 16.2  ± 19.6 21.2 ± 21.4 0.08 
Working status, n (%) 
        Full time 246 (38.2) 61 (44.2) 75 (39.3) 110 (34.9) 0.005 
   Asthma related not working 177 (27.5) 27 (19.6) 45 (23.6) 105 (33.3) 
    Other cause for not working 176 (27.3) 38 (27.5) 62 (32.5) 76 (24.1) 
    Part time due to asthma 21 (3.3) 4 (2.9) 8 (4.2) 9 (2.9) 
    Part time - other cause 24 (3.7) 8 (5.8) 1 (0.5) 15 (4.8) 
 Educational achievement, n (%) 
      Basic 117 (24.9) 18 (17.0) 28 (20.7) 71 (31.1) 0.0016 
   Intermediate 165 (35.2) 32 (30.2) 52 (38.5) 81 (35.5) 
    Advanced 106 (22.6) 38 (35.8) 23 (17.0) 45 (19.7) 
    Graduate 56 (11.9) 11 (10.4) 23 (17.0) 22 (9.6) 
    Post-graduate  25 (5.3) 7 (6.6) 9 (6.7) 9 (3.9) 
 Family history of asthma (%) 358 (55.2) 80 (54.4) 102 (54.5) 176 (55.9) 0.91 
Evidence of poor adherence (%) 86 (13.3) 21 (14.9) 19 (10.1) 46 (14.6) 0.3 
 
Group data (median (IQR)) for all subjects are presented in column 2 followed by data for individual BMI groups. Between 
group comparisons for continuous variables were made using Kruskal-Wallis and for categorical variables using Chi-squared 
exact testing. 
Educational achievement: Basic: Level 1 NVQ, GCSE D-G, Foundation GNVQ, Intermediate: Level 2 NVQ, 5 GCSE A*-C, 
Intermediate GNVQ, Advanced: Level 3 NVQ, AS & A level, Advanced GNVQ, Graduate: Level 4 NVQ, Graduate studies, Post 





Table 3.2. Medical history and allergen testing. 
  BMI  
 Overall 18.50 to 24.99 25.00 to 29.99 ≥ 30.00 p value 
 666 (149, 22.4%) (195, 29.3%) (322, 48.3%)  
BMI 29.8 (22.5 - 34.0) 22.8 (18.9 - 24.9) 27.4 (26.3 - 28.5) 34.2 (31.8 - 38.9)  
 
Medical History, n (%)      
Prior history of atopy 410 (62.6) 93 (63.7) 116 (61.4) 201 (62.8) 0.9 
Perennial rhinitis 225 (34.2) 51 (34.7) 68 (35.6) 106 (33.2) 0.85 
Seasonal rhinitis 263 (40.4) 57 (38.5) 75 (39.7) 131 (41.7) 0.78 
Eczema 178 (27.3) 33 (22.6) 45 (23.9) 100 (31.9) 0.049 
Nasal polyps 94 (14.4) 27 (18.4) 33 (17.4) 34 (10.7) 0.03 
Prior nasal surgery 100 (16.3) 26 (17.7) 37 (19.8) 37 (11.7) 0.036 
GORD 321 (49.1) 59 (39.7) 91 (48.1) 171 (53.9) 0.018 
Prior OGD  27 (4.2) 5 (3.5) 8 (4.3) 14 (4.5) 0.88 
Prior pH profile (abnormal profile) 57 (30) 11 (2) 17 (11) 29 (17) 0.036 
Aspirin sensitivity 74 (11.7) 20 (14.1) 22 (11.6) 32 (10.7) 0.59 
Significant catamenial asthma 33 (8.8) 10 (10.0) 8 (8.7) 15 (7.9) 0.76 
      
Allergen testing, n (%)      
Domestic exposures pets 219 (34.2) 50 (34.7) 59 (31.4) 110 (35.7) 0.61 
Aspergillus* 234 (47.3) 65 (58.6) 68 (46.3) 101 (42.6) 0.02 
House dust mite* 300 (67.1) 68 (70.8) 90 (69.8) 142 (64.0) 0.37 
Cat* 256 (57.4) 59 (62.8) 75 (57.7) 122 (55.5) 0.48 
Dog* 237 (53.5) 50 (55.6) 71 (52.6) 116 (53.2) 0.9 
Mixed grasses* 238 (54.8) 59 (63.4) 66 (54.1) 113 (51.6) 0.15 
 
Group data (%) for all subjects are presented in column 2 followed by data for individual BMI groups. Between group 
comparisons were made using Chi-squared exact analysis. 
*The data presented are for subjects with either a positive RAST or skin prick test 







Table 3.3. Medications and healthcare utilisation. 
   BMI  
  Overall 18.50 to 24.99 25.00 to 29.99 ≥ 30.00 p value 
 666 (149, 22.4%) (195, 29.3%) (322, 48.3%)  
BMI 29.8 (22.5-34.0) 22.8 (18.9-24.9) 27.4 (26.3-28.5) 34.2 (31.8-38.9)  
Medications      
PPI use 244 (37.3) 43 (29.3) 58 (30.7) 143 (45.4) 0.0002 
Maintenance oral steroids 286 (43.2) 51 (34.5) 78 (40.4) 157 (48.9) 0.009 
Oral steroid dose 15 (10 - 20) 10 (10 - 20) 10 (10 - 20) 15 (10 - 22.5) 0.19 
Oral corticosteroids (OCS) past year 
Patients requiring rescue steroids  538 (89.4) 112 (82.4) 160 (92.0) 266 (91.1) 0.01 
No. rescue courses steroids 4 (2.0 - 7.0) 4 (1.30- 6.0) 4 (2.0 - 6.0) 5 (2.0 - 8.0) 0.01 
SABA use per day 8 (4.0 - 10.0) 6 (3.0 - 10.0) 8 (4.0 - 10.0) 8 (4.0 - 10.0) 0.008 
Nebuliser use 314 (47.9) 58 (39.7) 89 (46.4) 167 (52.5) 0.03 
BDP equivalent dose (µg) 2000 (1600-2000) 2000 (1500-2000) 2000 (1000-2000) 2000 (1600-2000) 0.015 
Leukotriene receptor antagonists 303 (46.0) 61 (41.5) 82 (42.7) 160 (50.2) 0.12 
Antihistamines 193 (29.4) 45 (30.4) 54 (28.4) 94 (29.6) 0.92 
Nasal steroids 184 (27.9) 39 (26.4) 57 (29.7) 88 (27.5) 0.78 
Theophylline 262 (39.7) 56 (38.1) 73 (37.8) 133 (41.6) 0.64 
Steroid sparing meds 24 of 664 4 6 14  
  None 628 142 181 305  
  Methotrexate 12 1 2 9  
  Ciclosporin 5 3 1 1  
  Azathrioprine 5 0 1 4  
  Mycophenolate mofetil 1  1   
  Other 1  1   
Anti-IgE treatment 15 of 652 4 3 8 0.72 
Healthcare utilisation (past year) 
Unscheduled GP/A&E visits  558 (88.4) 132 (90.4) 163 (89.1) 263 (87.1) 0.56 
No. unscheduled visits  5 (3 – 8) 4 (2 – 7) 5 (3 – 8) 5 (3 – 8) 0.1 
Admissions 319 (48.6) 64 (43.5) 101 (52.1) 154 (48.7) 0.3 
No of admissions  2 (1 – 3) 2 (1 – 3) 2 (1 -3) 2 (1 – 3) 0.93 
ICU admissions to date 137 (20.9) 28 (19.2) 41 (21.6) 68 (21.4) 0.84 
No of ICU admissions to date 1 (1 – 2) 2 (1 – 3) 1 (1 – 2) 1 (1 – 2) 0.51 
 
Group data (median (IQR)) or % are presented in column 2 followed by data for individual BMI groups. Between group comparisons for 
continuous variables were made using Kruskal-Wallis and for categorical variables using Chi-squared exact analysis. 
 
PPI, proton pump inhibitor  SABA, short-acting β2-agonist  BDP, beclomethasone dipropionate  GP, general practitioner   A&E, accident and emergency   ICU, 
intensive care unit. 
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Table 3.4. Lung function and FENO. 
   BMI   
  
Overall 18.50 to 24.99 25.00 to 29.99 ≥ 30.00 P value 
  666 (149, 22.4%) (195, 29.3%) (322, 48.3%)   
BMI 29.8 (22.5 - 34.0) 22.8 (18.9 - 24.9) 27.4 (26.3 - 28.5) 34.2 (31.8 - 38.9)   
FENO ppb  33.0 (15 - 61) 34 (21 - 62.5) 35.5 (15.2 - 85.4) 31 (13.5 - 57.3) 0.11 
PreBD FEV1 (litres) 1.97 (1.9 - 2.0) 2.04 (1.9 - 2.2) 2.00 (1.9 - 2.1) 1.91 (1.8 - 2.0) 0.43 
(% predicted) 67.7 (65.8 - 69.7) 69.6 (65.1 - 74.1) 67.8 (64.3 - 71.3) 66.9 (64.2 - 69.5) 0.67 
PreBD FVC (litres) 3.10 (3.0 - 3.2) 3.20 (3.0 - 3.4) 3.29 (3.1 - 3.5) 2.94 (2.8 - 3.1) 0.0009 
(% predicted) 84.0 (81.9 - 85.0) 86.2 (82.8 - 89.6) 86.7 (83.7 - 89.8) 80.1 (78.0 - 82.3) 0.0004 
Subjects with baseline bronchodilator study  
   
PreBD FEV1 (litres) 1.90 (1.8 - 2.0) 1.95 (1.8 - 2.1) 1.92 (1.8 - 2.1) 1.86 (1.8 - 2.0) 0.94 
(% predicted) 65.5 (63.2 - 67.7) 67.0 (61.9 - 72.1) 65.3 (61.1 - 69.6) 64.8 (61.8 - 67.8) 0.85 
PreBD FVC (litres) 3.07 (3.0 - 3.2) 3.12 (2.9 - 3.3) 3.30 (3.1 - 3.5) 2.90 (2.8 - 3.0) 0.01 
(% predicted) 82.6 (80.7 - 84.5) 84.5 (80.1 - 88.4) 87.1 (84.0 - 90.8) 78.8 (76.2 - 81.4) 0.002 
PostBD FEV1 (litres)  2.20 (2.1 - 2.3) 2.21 (2.0- 2.4) 2.25 (2.1 - 2.4) 2.16 (2.1 - 2.3) 0.67 
(% predicted) 76.0 (73.7 - 78.2) 76.4 (71.4 - 81.3) 76.5 (72.1 - 81.0) 75.4 (72.3 - 78.6) 0.89 
BDR (% ∆ FEV1) 19.6 (17.4 - 21.7) 17.3 (13.3 - 21.2) 19.9 (15.8 - 24.0) 20.4 (17.1 - 23.7) 0.34 
PostBD FVC (litres)  3.33 (3.2 - 3.4) 3.35 (3.1 - 3.6) 3.53 (3.3 - 3.7) 3.19 (3.1 - 3.3) 0.02 
(% predicted) 89.9 (88.2 - 91.7) 91.4 (87.7 - 95.1) 93.5 (89.9 - 97.0) 87.0 (84.7 - 89.3) 0.003 
PreBD FEV1/FVC %  61.8 (60.4 - 63.2) 61.6 (58.4 - 64.8) 59.3 (56.6 - 61.9) 63.5 (61.5 - 65.4) 0.04 
PostBD FEV1/FVC %  65.7 (64.3 - 67.2) 65.1 (61.8 - 68.4) 63.4 (60.8 - 65.9) 67.5 (65.4 - 69.5) 0.052 
TLC % pred 103.0 (101.1-104.2) 106.4 (103.1-109.6) 103.6 (100.8-106.3) 100.3 (98.2-102.5) 0.003 
RV % pred (n) 124.0 (123.6-131.3) 129.3 (121.2-137.3) 124.2 (117-131.5) 128.7 (123.1-134.3) 0.45 
KCO % pred (n) 101.0 (100.3-103.7) 97.0 (93.5-100.7) 101.6 (98.6-104.6) 104.5 (102.1-106.9) 0.002 
    
 
      
 
Group data (mean (95% CI)) for lung function, otherwise (mean ± SD or median (IQR)) for all subjects are presented in column 2 followed by data 
for individual BMI groups. Between group comparisons for continuous variables were made using Kruskal-Wallis (for posthoc analysis, see text).  
FEV1, forced expiratory volume in 1 second  FENO, exhaled nitric oxide  FVC, forced vital capacity   KCO, carbon monoxide transfer coefficient   





Table 3.5. Blood testing and radiology. 
   BMI   
 Overall 18.50 to 24.99 25.00 to 29.99 ≥ 30.00 P value 
 666 (149, 22.4%) (195, 29.3%) (322, 48.3%)  
BMI 29.8 (22.5 - 34.0) 22.8 (18.9 - 24.9) 27.4 (26.3 - 28.5) 34.2 (31.8 - 38.9)  
Blood eos count x 109/l (n) 0.28 (0.11 - 0.53) (629) 
0.30 (0.1 - 0.67) 
(141) 
0.31 (0.11 - 0.60) 
(184) 
0.26 (0.11 - 0.49) 
(304) 0.21 
Sputum eos count (n) 2.9 (0.5 - 9.9) (174) 
4.0 (0.38 - 14.0) 
(41) 2.8 (0 - 12.1) (49) 2.8 (1.0 - 9.7) (84) 0.92 
IgE kU/l (n) 158 (51 - 421) (610) 
266 (83 - 480) 
(133) 
144 (46 - 384) 
(181) 
119 (46 - 418) 
(296) 0.005 
Bone density (T-scores) (n)     
L1 to L4 -0.71 ± 1.48 (239) -1.08  ± 1.25 (50) -0.73  ± 1.68 (70) -0.55  ± 1.42 (119) 0.051 
Femoral neck -0.27 ± 1.24 (233) -1.02  ± 1.21 (48) -0.32  ± 1.13 (72) +0.074  ± 1.19 (113) <0.0001 
HRCT (n)      
Reported normal 68, 17.3% (392) 11, 13.1% (84) 19, 15.1% (126) 38, 20.9% (182) 0.21 
Abnormal HRCT 344, 81.9% (420) 75, 83.3% (90) 114, 86.4% (132) 155, 78.3% (198) 0.16 
Central bronchiectasis 34, 11.1% (306) 12, 17.6% (68) 13, 12.6% (103) 9, 6.7% (135) 0.053 
Other bronchiectasis 77, 24.3% (317) 19, 27.9% (68) 28, 26.7% (105) 30, 20.8% (144) 0.42 
Bronchial wall thickening 214, 65.4% (327) 44, 62.0% (71) 67, 63.2% (106) 103, 68.7% (150) 0.52 
Bronchial dilatation 58, 18.2% (318) 12, 17.9% (67) 21, 20.2% (104) 25, 17.0% (147) 0.81 
Ground glass 35, 11.0% (317) 9, 13.0% (69) 11, 10.5% (105) 15, 10.5% (143) 0.84 
Air trapping 63,19.7% (319) 12, 17.4% (69) 19, 17.9% (106) 32, 22.2% (144) 0.6 
Mucus plugging 31, 9.8% (316) 9, 13.0% (69) 7, 6.8% (103) 15, 10.4% (144) 0.38 
Emphysema 15, 4.5% (333) 4, 5.5% (73) 4, 3.7% (109) 7, 4.6% (151) 0.84 
      
 
Group data (mean (95% CI)) for lung function, otherwise (mean ± SD or median (IQR)) for all subjects are presented in column 2 followed by data for 
individual BMI groups. Between group comparisons for continuous variables were made using Kruskal-Wallis (for posthoc analysis, see text).  
IgE, immunoglobulin E   L1, first lumbar vertebra   L5, fifth lumbar vertebra   HRCT, high resolution computerised tomography. 







3.3.6 Subdivisions of obesity 
The obese group were then subdivided into three groups according to WHO 
subclasses, used to facilitate international comparisons (Organisation, 2011):  class I 
(BMI 30 to 34.99), class II (35 to 39.99) and class III (≥40). 56.2% of the cohort fell 
into class I, 23.9% into class II and 19.9% in class III.  
Group data and between BMI comparisons are shown in tables 3.6 to 4.1. 
Values are presented in the following manner (% of class III compared to % 
class II and % class I). 
Class III were more likely to be female than class II and class I (82.8% 
compared to 67.5% and 61.9%, p<0.01); (table 3.6). In addition, class III were more 
likely to be current smokers (16.9% compared to 13% and 5.8%, p=0.013). No 
significant differences were seen in terms of medical history or allergen testing. 
Although no difference was seen regarding maintenance OCS use or the proportion 
of each group requiring short burst therapy in the preceding year, there was a 
difference in terms of the number of short burst courses required (6 [4-9] versus 5 [3-
7] and 4 [2-7], p=0.046). Class III were more likely to be on steroid sparing agents 
(11.3% versus 3.9% and 2.2%, p=0.01) or anti IgE therapy (7.9% versus 1.4% and 
1.1%, p=0.01). In addition, this group had a greater number of unscheduled GP or A 
& E visits in the preceding year (6 [4-9.3] versus 5 [4-8] and 4 [4-9.3], p=0.02). No 
significant differences were noted in terms of lung function or inflammatory markers 
(blood and sputum eosinophilia). Intriguingly, class III had a higher T score for the 
neck of femur compared to the other two groups (+0.7 ± 1.3 versus +0.5 ± 1.1 and -
0.2 ± 1.1, p=0.005). 
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Table 3.6. Patient demographic data (obese cohort). 
    BMI   
 Overall Class I Class II Class III P value 
   30 to 34.99 35 to 39.99 ≥40  
 322 181 (56.2) 77 (23.9) 64 (19.9)  
BMI 34.2 (31.8 - 38.9) 32 (31 - 33.1) 37.3 (36.1 - 38.9) 43.6 (41.1 - 45.3)  
      
Female (%) 217 (67) 112 (61.9) 52 (67.5) 53 (82.8) 0.009 
Race, n (%)      
    Caucasian 301 (94.4) 168 (93.9) 72 (94.7) 61 (95.3) 0.41 
    Asian 11 (3.4) 7 (3.9) 3 (3.9) 1 (1.6)  
    African 4 (1.3) 3 (1.7) 1 (1.3) 0  
    Other 3 (0.9) 1 (0.6) 0 2 (3.1)  
Age at assessment  45.0 (38.0 - 54.0) 46 (38.5 - 55) 46 (40 – 52) 42 (34.4 – 48.8) 0.02 
Age at diagnosis 18.0 (4.0 - 34.0) 18 (3 – 37.8) 18 (6.3 – 33) 15 (4 – 27.3) 0.39 
Smoking status n (%)      
   Never 182 (58.1) 104 (60.5) 41 (53.2) 37 (57.8) 0.013 
   Ex-smoker 98 (31.3) 58 (33.7) 26 (33.8) 14 (21.9)  
   Current smoker 33 (10.5) 10 (5.8) 10 (13) 13 (16.9)  
   Ex or current smoker 131 (41.7) 68 (39.5) 36 (46.8) 27 (42.2)  
Smoking (pack years) 21.2 ± 21.4 17.4 ± 22.0 25.5  ± 18.5 24.8  ± 4.5 0.013 
Working status, n (%)      
   Full time 110 (34.9) 77 (43.3) 19 (25) 14 (23) 0.07 
   Asthma related not working 105 (33.3) 51 (28.7) 29 (38.2) 26 (42.6)  
   Other cause for not working 76 (24.1) 40 (22.5) 21 (27.6) 15 (24.6)  
   Part time due to asthma 9 (2.9) 3 (1.7) 2 (2.6) 3 (4.9)  
   Part time due to other cause 15 (4.8) 7 (3.9) 5 (6.6) 3 (4.9)  
Educational achievement, n (%)     
Basic 71 (31.1) 39 (31.0) 18 (26.5) 14 (31.8) 0.7 
Intermediate 81 (35.5) 42 (33.3) 22 (32.4) 17 (38.6)  
Advanced 45 (19.7) 25 (19.8) 11 (16.2) 9 (20.5)  
Graduate 22 (9.6) 15 (11.9) 3 (4.4) 4 (9.1)  
Post-graduate 9 (3.9) 5 (4.0) 4 (5.9) 0  
Family history of asthma (%) 176 (55.9) 94 (53.1) 47 (61.8) 35 (56.5) 0.44 
Evidence of poor adherence (%) 46 (14.6) 24 (13.6) 12 (15.8) 10 (16.1) 0.84 
 
Group data (median (IQR)) for all subjects are presented in column 2 followed by data for individual BMI groups. Between 
group comparisons for continuous variables were made using Kruskal-Wallis and for categorical variables using Chi-squared 
exact testing. 
 
Educational achievement: Basic: Level 1 NVQ, GCSE D-G, Foundation GNVQ, Intermediate: Level 2 NVQ, 5 GCSE A*-C, 
Intermediate GNVQ, Advanced: Level 3 NVQ, AS & A level, Advanced GNVQ, Graduate: Level 4 NVQ, Graduate studies, Post 
Graduate: Level 5 NVQ, Post graduate studies. 
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Table 3.7. Medical history and allergen testing (obese cohort). 
   BMI  
  Overall Class I 30 to 34.99 
Class II 
35 to 39.99 
Class III 
≥40 P value 
 (322, 48.3%) 181 (56.2) 77 (23.9) 64 (19.9)  
BMI 34.2 (31.8 - 38.9) 32 (31 - 33.1) 37.3 (36.1 - 38.9) 43.6 (41.1 - 45.3)  
Medical History, n (%) 
     
Prior history of atopy 201 (62.8) 112 (62.2) 48 (63.2) 41 (64.1) 0.96 
Perennial rhinitis 106 (33.2) 59 (33.0) 23 (29.9) 24 (38.1) 0.59 
Seasonal rhinitis 131 (41.7) 80 (44.9) 25 (33.8) 26 (41.9) 0.26 
Eczema 100 (31.9) 59 (33.7) 25 (33.3) 16 (25.4) 0.46 
Nasal polyps 34 (10.7) 20 (11.2) 7 (10) 7 (12.3) 0.89 
Prior nasal surgery 37 (11.7) 24 (13.6) 6 (7.9) 7 (11.1) 0.43 
GORD 171 (53.9) 94 (53.1) 41 (53.2) 36 (57.1) 
0.85 
Prior OGD  14 (4.5) 9 (5.1) 5 (6.7) 0 (0) 0.14 
Prior pH profile (abnormal profile) 29 (17) 12 (60) 2 (40) 3 (75) 0.56 
Aspirin sensitivity 32 (10.7) 19 (11.2) 6 (8.4) 7 (12.1) 0.77 
Significant catamenial asthma 18 (8.1) 11 (9.7) 1 (2.6) 3 (7.7) 0.37 
      
Allergen testing, n (%)      
Domestic exposures pets 110 (35.7) 64 (36.6) 25 (34.7) 21 (34.4) 0.94 
Aspergillus* 101 (42.6) 60 (44.4) 24 (42.9) 17 (37.0) 0.67 
House dust mite* 142 (64.0) 83 (64.8) 33 (63.5) 26 (61.9) 0.94 
Cat* 122 (55.5) 71 (54.6) 30 (58.8) 21 (53.8) 0.86 
Dog* 116 (53.2) 68 (54.0) 26 (50.0) 22 (42.3) 0.86 
Mixed grasses* 113 (51.6) 73 (56.2) 23 (46.9) 17 (42.5) 0.24 
 
Group data (%) for all subjects are presented in column 2 followed by data for individual BMI groups. Between group 
comparisons were made using χ2 exact analysis. 
*The data presented are for subjects with either a positive RAST or skin prick test. 











Class I Class II Class III 
P value 
30 to 34.99 35 to 39.99 ≥40 
 
(322, 48.3%) 181 (56.2) 77 (23.9) 64 (19.9) 
 
BMI 34.2 (31.8 - 38.9) 32 (31 - 33.1) 37.3 (36.1 - 38.9) 43.6 (41.1 - 45.3) 
 
Medications 
     
PPI use 143 of 315 (45.4) 72 (40.7) 37 (49.3) 34 (54.0) 0.14 
Maintenance oral steroids 157 of 321 (48.9) 81 (44.8) 42 (55.3) 34 (53.1) 0.23 
Oral steroid dose 15 (10 - 22.5) 15 (10 -20) 15 (10 – 20) 15 (10 – 30) 0.68 
Oral corticosteroids past year: 
     
Patients requiring rescue steroids  266 of 292 (91.1) 152 (91) 60 (89.6) 54 (93.1) 0.78 
No. rescue courses steroids 5 (2.0 - 8.0) 4 (2 – 7) 5 (3 – 7) 6 (4 – 9) 0.046 
SABA use per day 8 (4.0 - 10.0) 6 (4 – 8) 8 (7.5 – 12) 8 (8 – 10.5) <0.0001 
Nebuliser use 167 (52.5) 81 (45.3) 42 (55.3) 44 (69.8) 0.003 
BDP equivalent dose (µg) 2000 (1600- 2000) 2000 (1600–2000) 2000 (1600–2400) 2000 (1600–3000) 0.23 
Leukotriene receptor antagonists 160 (50.2) 88 (49.4) 35 (45.5) 37 (57.8) 0.33 
Antihistamines 94 (29.6) 51 (28.3) 21 (27.6) 22 (35.5) 0.52 
Nasal steroids 88 (27.5) 52 (28.9) 21 (27.3) 15 (23.8) 0.74 
Theophylline 133 (41.6) 70 (39.1) 31 (40.3) 32 (50) 0.31 
Steroid sparing meds 13 4 (2.2) 3 (3.9) 7 (11.3) 0.01 
  None 305 
      Methotrexate 9 3 2 4 
 
  Ciclosporin 1 
 
1 




  Mycophenolate mofetil 
     
Anti-IgE treatment 8 (2.6) 2 (1.1) 1 (1.4) 5 (7.9) 0.01 
Healthcare utilisation (past year) 
    
Unscheduled GP/A&E visits 263 (87.1) 148 (86.5) 65 (91.5) 50 (83.3) 0.36 
No. of unscheduled visits 4 (2 - 7) 4 (4 -9.25) 5 (4 – 8) 6 (4 – 9.25) 0.02 
Admissions 154 (48.7) 86 (48.0) 38 (51.4) 30 (47.6) 0.87 
No. of admissions  2 (1 – 3) 2 (1 – 3) 2 (1 – 3.25) 2.5 (1 – 4.25) 0.13 
ICU admissions to date 68 (21.4) 39 (21.8) 14 (18.7) 15 (23.4) 0.78 
No. of ICU admissions 1 Range (1 - 2) 1 (1 – 2) 1 (1 – 2.3) 1 (1 – 1) 0.73 
 
Group data (mean (95% CI)) for lung function, otherwise (mean ± SD or median (IQR)) for all subjects are presented in column 2 followed by data for 
individual BMI groups. Between group comparisons for continuous variables were made using Kruskal-Wallis (for posthoc analysis, see text).  
 
PPI, proton pump inhibitor  SABA, short-acting β2-agonist  BDP, beclomethasone dipropionate  GP, general practitioner   A&E, accident and emergency   




Table 3.9. Lung function and FENO (obese cohort). 
    BMI   
 Overall Class I Class II Class III 
P 
value 
   30 to 34.99 35 to 39.99 ≥40  
  (322, 48.3%) 181 (56.2) 77 (23.9) 64 (19.9)  
BMI 34.2 (31.8 - 38.9) 32 (31 - 33.1) 37.3 (36.1 - 38.9) 43.6 (41.1 - 45.3)  
Lung function and FENO      
FENO ppb  31 (13.5 - 57.3) 29 (13 – 48) 26 (13 – 50.3) 32.5 (15 – 62) 0.41 
PreBD FEV1 (litres) 1.91 (1.8 - 2.0) 1.82 (1.3 – 2.4) 1.8 (1.4 – 2.5) 2.1 (1.7 – 2.5) 0.1 
(% predicted) 66.9 (64.2 - 69.5) 64 (46 – 83.5) 67.5 (46.5 – 86.8) 70 (55.3 – 81) 0.73 
PreBD FVC (litres) 2.94 (2.8 - 3.1) 2.1 (1.5 – 2.74) 2.1 (1.48 – 2.4) 2.1 (1.7 – 2.5) 0.76 
(% predicted) 80.1 (78.0 - 82.3) 80 (68 – 94) 80 (68.3 – 93) 78.5 (69.3 – 88) 0.82 
Subjects with baseline bronchodilator (BD) study   
PreBD FEV1 (litres) 1.86 (1.8 - 2.0) 1.82 (1.3 – 2.4) 1.67 (1.28 – 2.1) 1.83 (1.42 – 2.3) 0.6 
(% predicted) 64.8 (61.8 - 67.8) 65.5 (46 – 81.5) 59 (43 – 83) 71 (57 – 85.5) 0.42 
PreBD FVC (litres) 2.90 (2.8 - 3.0) 2.96 (2.4 – 3.64) 2.74 (2.2 – 3.25) 2.71 (2.3 – 3.38) 0.2 
(% predicted) 78.8 (76.2 - 81.4) 80 (67 – 93) 78 (68 – 90) 84 (71.5 – 96.8) 0.5 
PostBD FEV1 (litres)  2.16 (2.1 - 2.3) 2.13 (1.5 – 2.74) 2.1 (1.5 – 2.42) 2.1 (1.7 – 2.55) 0.73 
(% predicted) 75.4 (72.3 - 78.6) 74 (44.8- 91.3) 76 (53 – 94) 85 (67 – 95) 0.31 
BDR (% ∆ FEV1) 20.4 (17.1 - 23.7) 18.7 (14.8-22.7) 24.4 (15.7-33.1) 20.0 (14.3-25.8) 0.6 
PostBD FVC (litres)  3.19 (3.1 - 3.3) 3.27 (2.64 – 3.85) 2.97 (2.42 – 3.76) 2.97 (2.74 – 3.47) 0.35 
(% predicted) 87.0 (84.7 - 89.3) 87 (75.5 – 96) 90 (75.3 – 96) 91 (78 – 103) 0.35 
PreBD FEV1/FVC ratio %  63.5 (61.5 - 65.4) 65 (57 – 76.8) 68 (52 – 72) 68.5 (57 – 76.8) 0.26 
PostBD FEV1/FVC ratio %  67.5 (65.4 - 69.5) 67 (57 – 76) 70.5 (60 – 78) 72.5 (60.3 – 81) 0.39 
TLC % predicted (n) 100.3 (98.2-102.5) 102 (91 – 111) 99 (88.8 – 109) 98 (83.8 – 108.3) 0.19 
RV % predicted (n) 128.7 (123.1-134.3) 127 (99 – 155.5) 122 (103 – 151) 123.5 (88.5–141.8) 0.37 
KCO % predicted (n) 104.5 (102.1-106.9) 103 (90.8 – 117.8) 104 (91.8 – 118.3) 105.5 (98.3–117.5) 0.49 
       
 
Between group comparisons for continuous variables were made using Kruskal-Wallis (for posthoc analysis, see text). Group 
data (mean (95% CI)) for lung function, otherwise (mean ± SD or median (IQR)) for all subjects are presented in column 2. 
 
FEV1, forced expiratory volume in 1 second  FENO, exhaled nitric oxide  FVC, forced vital capacity   KCO, carbon monoxide transfer coefficient   






Table 3.10. Blood testing and radiology (obese cohort). 
    BMI   
 Overall Class I Class II Class III 
P 
value 
   30 to 34.99 35 to 39.99 ≥40  
  (322, 48.3%) 181 (56.2) 77 (23.9) 64 (19.9)  
BMI 34.2 (31.8 - 38.9) 32 (31 - 33.1) 37.3 (36.1 - 38.9) 43.6 (41.1 - 45.3)  
Blood testing and radiology      
Blood eos count x 109/l (n) 0.26 (0.11 - 0.49) 0.27 (0.1 – 0.58) 0.22 (0.1 – 0.37) 0.26 (0.13 – 0.4) 0.33 
Sputum eos count (n) 2.8 (1.0 - 9.7) (84) 4 (1 – 10.3) 1.3 (0.2 – 4.3) 1.5 (0 – 11.3) 0.069 
IgE kU/l (n) 119 (46–418) (296) 157.5 (55.1–457.5) 115.5 (58.8–270.5) 70.5 (32.5–349.5) 0.18 
Bone density (T scores) (n)      
   L1 to L4 -0.55  ± 1.4 (119) -0.68 ± 1.5 (76) -0.42 ± 1.1 (24) -0.22 ± 1.4 (19) 0.43 
   Femoral neck +0.074  ± 1.2 (113) -0.2 ± 1.1 (73) 0.5 ± 1.1 (23) 0.7 ± 1.3 (17) 0.005 
HRCT      
   Reported normal (n) 38, 20.9% (182) 20 (17.1) 7 (17.5) 11 (37.9) 0.039 
   Abnormal HRCT (n) 155 , 78.3% (198) 99 (84.6) 35 (71.4) 21 (65.6) 0.028 
   Central bronchiectasis (n) 9, 6.7% (135) 7 (8.4) 1 (3.4) 1 (5) 0.62 
   Other bronchiectasis (n) 30, 20.8% (144) 20 (22.0) 8 (24.2) 2 (10) 0.42 
   Bronchial wall thickening (n) 103, 68.7% (150) 68 (70.8) 23 (65.7) 12 (63.2) 0.73 
   Bronchial dilatation (n) 25, 17.0% (147) 20 (21.3) 3 (8.8) 2 (10.5) 0.18 
   Ground glass (n) 15, 10.5% (143) 11 (12.0) 3 (9.1) 1 (5.6) 0.69 
   Air trapping (n) 32, 22.2% (144) 19 (20.9) 7 (20.6) 6 (31.6) 0.57 
   Mucus plugging (n) 15, 10.4% (144) 9 (9.8) 5 (15.2) 1 (5.3) 0.5 
   Emphysema (n) 7, 4.6% (151) 6 (6.2) 1 (2.9) 0 0.42 
 
Between group comparisons for continuous variables were made using Kruskal-Wallis (for posthoc analysis, see text). 
FEV1, forced expiratory volume in 1 second, Group data (mean (95% CI)) for lung function, otherwise (mean ± SD or median (IQR)) 
for all subjects are presented in column 2 followed by FVC, forced vital capacity, KCO, carbon monoxide transfer coefficient. 








This study has found that overweight and obesity are common findings in 
severe asthma (77.6% of the study population) and these patients display particular 
characteristics according to BMI. These include greater medication use in terms of 
SABA use per day, nebulisers and oral steroid requirements (both maintenance and 
short burst therapy). Additionally, severe asthmatics that are obese reported greater 
GORD and PPI use but were less likely to have a history of nasal polyposis. Lung 
function testing revealed reduced FVC, TLC and elevated carbon monoxide transfer 
coefficient. This group were also less likely to be in full time work due to their asthma 
symptoms. These factors support the hypothesis that that obesity-associated severe 
asthma represents a distinct clinical phenotype.  
Obesity is frequently encountered in severe asthma and was observed in just 
under half of this cohort of severe asthmatics taken from the National Registry for 
dedicated UK Difficult Asthma Services. This is greater than that seen in the general 
population, almost a quarter of the UK population aged ≥16 (care, 2011). 
Determining whether obesity is a co-morbidity, affecting pathophysiology and 
response to therapy, or secondary to disease driven inactivity and/or systemic 
steroid therapy is often unclear and requires further study.  
The severe asthmatics analysed in this cohort were predominantly female and 
the median BMI was just below the obese range. This compares with other cohorts 
of severe asthmatics such as TENOR (adult mean 30.4) (Dolan et al., 2004) and is 
higher than in the ENFUMOSA cohort (male mean 26.5, female mean 27.2) (Group, 
2003). The majority (77.6%) of patients in this cohort had a BMI of ≥25 and just 
under half had a BMI of ≥30.  
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The overall figure for the cohort of 9% for current smokers is lower than the 
rates in asthmatics of all severity in the UK (just under 25%) (report, 2005) and in the 
general population where the proportion of obese adults who smoke is approximately 
20% (Healton et al., 2006). Just over 30% of the cohort were ex-smokers which is 
higher than the figure of 18% (Cerveri et al., 2012) seen in subjects with asthma of 
all severity in a large cohort and 21% seen in the general population (glance, 2013). 
The overall difference may reflect the impact of disease severity on patients and 
greater clinical input from primary and secondary care with regard to smoking 
cessation. The differences between BMI groups is harder to explain, but may be 
related to health beliefs and perceptions, or potential concerns regarding further 
weight gain following smoking cessation. 
Severe obese asthmatics were less likely to be in full-time employment and 
asthma was volunteered as the reason for not working in a third of this group. This is 
in contrast to the overweight and normal weight groups where 23.6% and 19.6%, 
respectively, felt their asthma prevented them from working. This observation may 
be related to increased inactivity and reduced mobility, potentially secondary to 
greater disease severity. However, the lower levels of educational achievement 
(33.3% achieving an advanced, graduate or post-graduate level compared to 40.7% 
and 52.8% respectively) seen in the obese group are also likely to play an important 
role. The relationship between employment and educational achievement is complex 
and a lack of information regarding the development of obesity and asthma 
diagnosis makes it difficult to infer causality. 
The view that increasing BMI in severe asthma is associated with CS 
insensitivity is supported by the findings from this cohort. CS burden was greatest in 
the obese group, where just fewer than half the patients were on maintenance oral 
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prednisolone and short burst steroid use was increased. Previous studies have 
noted that obese asthmatics appear to be less responsive to ICS. A post hoc 
analysis, pooling data from four double-blind, placebo controlled studies, 
randomising 3073 moderate adult asthmatics to montelukast (1439), 
beclomethasone (894) or placebo (740) noted that the response to ICS decreased 
with increasing BMI. Interestingly, the response to placebo was also lower with 
increasing BMI whilst that to montelukast remained stable. Taken together, this 
implies that BMI influences placebo and drug response in asthma (Peters-Golden et 
al., 2006). Another study looked at five clinical trials incorporating 1242 asthmatic 
patients who were not taking ICS prior to enrolment. Obese patients, particularly 
those with a BMI ≥40 had a lower probability of achieving well-controlled asthma with 
FP or FP/salmeterol therapy (Boulet and Franssen, 2007). Other retrospective 
studies have noted similar findings (Camargo et al., 2010a, Camargo et al., 2010b). 
There is a paucity of molecular data supporting the link between obesity and 
corticosteroid insensitivity. One in vitro study using PBMCs and BAL cells taken from 
45 non-smoking adults (33 with asthma, 12 healthy subjects) found that asthmatics 
with a higher BMI showed relative corticosteroid insensitivity in terms of attenuated 
dex (10-6M) induced MKP-1 suppression (Sutherland et al., 2008a). 
Although the obese group were more likely to be using maintenance oral 
steroids, there was no significant difference in the dose between groups. This 
difference may in fact reflect that raised BMI is a consequence of long term steroid 
use.  
In addition to differences in steroid use, SABA use per day was greater in the 
overweight and obese group and nebulised bronchodilator use increased alongside 
BMI, suggesting that asthma symptoms increase with increasing BMI. A study of 366 
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adults with well characterised asthma taking part in the Epidemiological Study on the 
Genetics and Environments of Asthma, looking at the relationship between BMI and 
asthma severity by sex, found that asthma severity was significantly correlated with 
increasing BMI in women but not in men (Varraso et al., 2005). This difference 
persisted despite adjusting for confounders and the association appeared strongest 
in women with early menarche. Higher BMI has also been associated with lower 
Asthma Quality of Life Questionnaire (AQLQ) scores and greater Asthma Control 
Questionnaire (ACQ) scores (Lavoie et al., 2006). 
Although no significant difference was noted between BMI groups in terms of 
health care utilisation, other studies have noted hospitalisation rates (Rodrigo and 
Plaza, 2007) and unscheduled doctor visits (Taylor et al., 2008) are greater in obese 
patients with asthma compared to under/normal weight subjects with asthma.  
GORD and PPI use were reported more in the obese group as was an 
abnormal 24 hour oesophageal pH study. The link between GORD and obesity in the 
general population remains unclear and a recent meta-analysis of 30 studies found a 
weak to moderate association. However, sub-analysis of subjects with a BMI greater 
than 35 revealed that they were six times more likely to suffer with GORD than their 
normal weight counterparts (Eslick, 2012). GORD was reported by 49.1% of this 
cohort, which is slightly higher than the 41% reported in severe asthmatics in the 
SARP cohort (Moore et al., 2007) and in contrast to 12.5% to 30% seen in 
unselected adult cohorts with a BMI of ≥30 (Nilsson et al., 2003, Locke et al., 1999). 
GORD in severe asthma is a common finding and is compounded by systemic 
corticosteroid use. This is particularly relevant given that steroid use in our cohort 
increased with BMI.  
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Asthma is classically described as being characterised by type 2 T helper cell 
(TH2) mediated allergic inflammation. There appears to be no correlation between 
obesity and atopy (Loerbroks et al., 2008, von Mutius et al., 2001) or eosinophilia 
(Lugogo et al., 2010). Obesity has been associated with a lack of both eosinophilic 
and neutrophilic inflammation in the airways (Todd et al., 2007, Dixon et al., 2010). 
The lack of eosinophilic inflammation is supported by the similar sputum eosinophil 
counts and FENO levels between groups in this cohort, a finding that has been noted 
in previous studies (Sutherland et al., 2008b). IgE levels and aspergillus sensitisation 
decreased with BMI despite a lack of difference in a prior history of atopy. These 
findings fit well with the reduced atopy and lower IgE levels in conjunction with raised 
BMI that were factors in 2 of 5 clusters in the SARP cohort (Moore et al., 2010). A 
recent study looking at 131 severe asthmatics, categorised into lean, overweight and 
obese groups according to BMI found that sputum IL-5 and submucosal eosinophils, 
but not sputum eosinophils, were greater in the obese group (Desai et al., 2013). 
This study suggests that eosinophilic inflammation may play an important role in 
severe obese asthmatics who have until now been labelled as non-eosinophilic 
and/or paucigranulocytic.  
In this cohort, the obese group were more likely to report a history of eczema 
(31.4%) than the overweight (23.9%) or normal weight (22.6%) group. This is similar 
to the 33.9% of obese adults in a recent study looking at patients presenting to an 
allergy clinic who were found to have atopic dermatitis (Silverberg et al., 2012). 
However, both cohorts relied on self-reporting and this may be a bias in the obese 
population. These collective findings, in addition to a non-significant difference in 
FENO and lower IgE levels noted in the obese group, are discordant, and potentially 
other skin complaints may have been misreported as eczema. Obesity has been 
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associated with a reduction in FEV1 and FVC (Schachter et al., 2001), findings that 
were also seen in this cohort. In healthy obese adults, the reductions in FEV1 and 
FVC are usually small with preservation of FEV1/FVC ratio (Schachter et al., 2001, 
Gurkan et al., 2004, Sood et al., 2006). These findings are essentially seen in this 
cohort of severe asthmatics where the reductions in FEV1 and FVC and the degree 
of airflow obstruction were not markedly different between BMI groups. 
Obesity is associated with increased intra-abdominal pressure on the 
diaphragm and the chest wall, leading to lower tidal volumes (TV), functional residual 
capacity (FRC) and expiratory reserve volume (ERV). The FEV1/FVC ratio may be 
normal or elevated if gas trapping and airway closure reduce FVC (Dixon et al., 
2010). The small but significant decrease in total lung capacity (TLC) seen in this 
cohort with increasing BMI has been well documented in previous studies (Jartti et 
al., 2009, Jang et al., 2009). Despite the small reduction in TLC, absolute levels 
remained within normal limits and residual volumes (RV) were maintained. These 
findings have also been shown previously (Tsaroucha et al., 2013, Sood et al., 
2006). The mechanism for the reduction in TLC is not completely understood but 
may reflect the mechanical effects of adipose tissue. This includes limiting the 
volume for lung expansion, preventing the downward movement of the diaphragm 
and a reduced chest cavity volume due to adipose deposition in the subpleural 
space (Jartti et al., 2009). This is supported by an increase in TLC seen in obese 
subjects following weight loss (Sood, 2012, Sood et al., 2012). 
Obesity appears to be associated with greater bone density, particularly at the 
femoral neck and this was greatest in the most obese subgroup (class III). Previous 
studies have reported that obesity exerts a protective effect on bone density and that 
a decrease in body weight correlates with associated bone loss. This correlation has 
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been noted in men and women, all adult age ranges and at all assessed sites in the 
skeleton (Zhao et al., 2008, Ravn et al., 1999). This is felt to be secondary to several 
mechanisms, including greater mechanical stress placed on bone secondary to the 
greater fat mass, increased levels of oestrogens and adipokine imbalance (Greco et 
al., 2010). Additionally, adipocytes and osteoblasts originate from the same 
progenitor, pluripotential mesenchymal stem cells (Akune et al., 2004). Conversely, 
other studies have suggested that adiposity is not associated with protection against 
osteoporosis (Janicka et al., 2007). One study found that fat mass negatively 
correlates with bone mass when the mechanical effect of total body weight is 
statistically removed (Zhao et al., 2007). Furthermore, even though obesity appears 
to be associated with increased bone density, the quality of the bone may be 
reduced and the fracture risk increased (Blum et al., 2003).  
Analysis of the subdivisions of the obese cohort revealed that the super-
obese (class III) are more likely to be female, current smokers, had greater use of 
their short-acting β2-agonist per day and was more likely to be taking steroid sparing 
medications or anti-IgE therapy. These findings are similar to the initial analysis 
according to normal weight, overweight and obese groups but suggest that the 
differences are magnified in the super-obese.  
There are several limitations to this study, which should be considered when 
interpreting these results. BMI is a crude population measurement and does not take 
account of body composition, fat distribution and racial variance, although these 
factors are not routinely measured in clinical practice. Increasing BMI is associated 
with comorbidities that may influence respiratory symptoms such as impaired 
ventilatory function (reduced FEV1, FVC, TLC, FRC and ERV), sleep disordered 
breathing, reduced exercise tolerance and GORD. This may result in a diagnostic 
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bias in severe asthma. A study looking at 540 individuals with physician diagnosed 
asthma found that just under a third of those assessed did not have objective 
evidence of asthma. There were no differences between the obese and normal 
weight groups in terms of asthma diagnosis suggesting an over diagnosis of asthma 
was not more likely to occur in obese individuals (Aaron et al., 2008). However, 
patients in this cohort were subject to a detailed systematic assessment and 
multidisciplinary decision regarding their asthma diagnosis prior to inclusion, which 
makes over diagnosis less likely to be a significant factor. This is supported by a 
mean bronchodilator reversibility for the entire cohort of 19.6% (95% CI, 17.4% to 
21.7%), with no significant difference between BMI groups. In addition, whilst our 
previous study identified differences in severe asthma characteristics between 
different centres, BMI figures remained similar.  
Although the use of BMI is convenient and widely accepted as a measure of 
adiposity, it may not be the best measure of the effect of adiposity on the lung (Dixon 
et al., 2010). Central body fat distribution may be a better associated factor with the 
mechanical effects of obesity on lung function (Collins et al., 1995). The National 
Registry does not include data regarding exercise habits or levels of physical activity, 
which prevents any inferences regarding their role on BMI in severe asthma. In 
addition, the cohort of patients in this study did not have temporal information 
regarding the development of obesity. This would provide insight into the direction of 
causality for many of the factors discussed. It has been suggested that early onset 
asthmatics become obese following a diagnosis of severe asthma, whilst those with 
late onset disease are more likely to have severe disease resulting from obesity 
(Holguin et al., 2011). Obesity-associated severe asthma is likely to comprise a 
spectrum of patients with two distinct ends:  severe asthmatics who gain weight 
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secondary to disease related inactivity and corticosteroid use, and those where 
obesity predated the diagnosis of asthma, contributing to symptoms and relative 
corticosteroid insensitivity. 
Analysis of this large cohort of severe asthmatics provides evidence that 
obese severe asthmatics may represent a distinct clinical phenotype within the 
severe asthma population. Further studies looking at the mechanisms by which 
obesity affects asthma as well as longitudinal studies designed to explore the 
temporal role of obesity in asthma will improve our understanding of this group of 
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Chapter 4. The relationship between lipid-laden bronchoalveolar macrophages, 
asthma and BMI 
Hypothesis and aim 
Obesity related severe asthma is associated with increased lipid laden 
macrophages. Lipid laden macrophages in bronchoalveolar lavage cells will be 
analysed using Oil Red O staining and their relationship with asthma severity and 
BMI will be examined. 
4.1 Introduction 
Macrophages were the first immune cell type to be identified in adipose tissue 
(Sood et al., 2011, Govindaraju et al., 2006) and increasing adiposity is associated 
with macrophage recruitment and inflammation. Adipose tissue macrophages are 
thought to clear dead, hypertrophied adipocytes and have been postulated to result 
in LLMs (Sood et al., 2011). Alveolar macrophages are responsible for the 
phagocytosis and endocytosis of dying cells and pathogens. They are derived from 
circulating bone marrow-derived monocytes which then become tissue 
macrophages. These links suggest that AMs may correlate with obesity and in 
particular there may be higher numbers of LLMs in the obese state.  
AMs were thought to develop from circulating bone marrow-derived 
monocytes. They have recently been shown to develop from primitive precursors 
before birth (Geissmann et al., 2010) and the overall pool of AMs is only minimally 
made up of bone marrow-derived monocytes with two groups of researchers 
suggesting that there may be a self-maintaining, proliferating pool of macrophages in 
the lung (Gibson et al., 2001, Chanez et al., 1996). 
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AMs that become laden with lipid (predominantly cholesterol) are termed 
pulmonary foam cells (PFCs) or lipid-laden alveolar macrophages (LLAMs). Their 
formation may be due to endogenous sources, such as with endogenous lipoid 
pneumonia, or an exogenous source, for example following aspiration (Hadda and 
Khilnani, 2010). These macrophages are more likely to undergo apoptosis and 
exhibit impaired phagocytosis (Schrijvers et al., 2005), which may play an important 
pathogenic role in asthma. Furthermore, markers of lipid peroxidation measured in 
plasma are increased in asthma subjects (Rahman et al., 1996) whilst erythrocytes 
and platelets exhibit alterations in membrane fatty acid composition (De et al., 
2007a). These factors may lead to increased PFC formation in asthma. 
A high fat content diet and the administration of a lipid emulsion in rats has 
been associated with the formation of LLAMs, leading to the view that the lungs may 
be a potential route for lipid excretion. However, it remains unclear whether such 
cells are derived from AMs ingesting lipids in the alveoli or from lipid-laden blood 
monocytes that migrate to the alveoli (Shibuya et al., 1991). In addition, 
macrophages have been shown to internalise and degrade surfactant lipids and 
surfactant protein A (SP-A) in vitro, suggesting a role for AMs in surfactant clearance 
(Wright and Youmans, 1995). Other factors such as obesity and cholesterol may 
also influence lipid-laden macrophage formation, but their role has not yet been 
established. 
Lipid accumulation in AMs appears to occur primarily through the 
phagocytosis of external lipoproteins. This process may be  secondary to 
endogenous sources, such as lipoid pneumonia, where the presence of bronchial 
obstruction, chronic lung infection or a lipid storage disorder results in the 
accumulation of LLAMs; or an exogenous source, for example following aspiration or 
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gentamicin          
(Nacca et al., 2012) 
Hypoxia induces CD36 
expression and subsequent 
LLM formation  
(Gileles-Hillel et al., 2014) 
Increasing adiposity and 
cholesterol levels are 
associated with LLMI 







The lipid laden macrophage index (LLMI) was first introduced in 1985 by 
Corwin and Irwin as a marker of aspiration in parenchymal lung disease (Corwin and 
Irwin, 1985). It is calculated using Oil-Red-O staining in BALF and grading the 
amount of intracellular Oil-Red-O per 100 AMs (figure 4.2). 
LLMI has been identified as a marker of recurrent aspiration in children 
(Colombo and Hallberg, 1987) and correlates with increased airway neutrophils, 
suggesting a link with parenchymal inflammation (Sacco et al., 2006). However, 
other studies have failed to show a correlation (Knauer-Fischer and Ratjen, 1999, 
Chang et al., 2005) and the use of LLMI as a marker of aspiration and lung 
inflammation remains unclear.  
The utility of the LLMI in adults as a marker of aspiration, inflammation or lung 
disease has not been investigated. LLMI could provide a novel way of identifying 
chronic aspiration and assessing the response to reflux treatment. Furthermore, 
increasing BMI and airway inflammation may result in LLM formation. These factors 
suggest that LLMI could potentially be a marker of asthma severity and correlated to 
obesity related severe asthma in particular.  
In this chapter, the presence of LLAMs in asthma and their relationship with 
BMI are examined. The aim of this study was to explore the relationship between the 
presence of LLAMs and asthma severity in a cohort of patients with mild/moderate 
and severe asthma. In addition, the influence of obesity, GORD, lung inflammation 
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Patients were recruited from our Asthma Clinic and through advertisement, 
and underwent a screening visit. Those with significant respiratory or inflammatory 
comorbidities and those requiring treatment for a respiratory tract infection within the 
preceding four weeks were excluded. All subjects underwent a bronchoscopic 
procedure with BAL. 
Asthma was based on a physician diagnosis and patients either had a PC20 
methacholine concentration causing a 20% fall in FEV1 of <8mg/ml and/or an FEV1 
reversibility of ≥ 12% of baseline. Severe asthma was defined according to the ATS 
definition of refractory asthma (ATS, 2000). Patients who did not fulfil the criteria for 
severe asthma were classified as non-severe asthmatics and they were taking 
≤1000mcg of inhaled beclomethasone dipropionate (BDP) or equivalent per day.   
Two control groups were investigated. Healthy subjects had no smoking 
history and no history of respiratory or cardiac disease. Patients with chronic cough 
were recruited from a specialist cough clinic at our hospital and all subjects reported 
a dry persistent cough for at least 8 weeks duration. All subjects had been 
investigated with a standard protocol to exclude a diagnosis of asthma or other 
respiratory disease. 
Ethical approval was obtained from the West London 3 and the Brompton, 





4.2.2 Fibreoptic bronchoscopy and bronchoalveolar lavage 
Sixty-seven patients (21 severe asthma, 19 mild/moderate asthma, 16 
patients with chronic cough, and 11 healthy subjects) underwent fibreoptic 
bronchoscopy with BAL. The methods for this have been discussed in section 2.2.7. 
4.2.3 Measurement of lipids in macrophages  
We used the LLMI to quantify lipid accumulation in AMs. Slides were stained 
with Oil-Red-O (Sigma-Aldrich Ltd, UK) to enable scoring and LLMI calculated by 
grading the amount of intracellular Oil-Red-O positive particles per 100 AMs. 
Intracellular lipid was evaluated using a modified version of that proposed by Corwin 
and Irwin (RW and RS, 1985, Colombo and Hallberg, 1987). Cells were scored from 
0 to 4 whereby 0 = no opacification, 1 = up to ¼ opacified, 2 = ¼ to ½ opacified, 3 = 
½ to ¾ opacified, and 4 = totally opacified (figure 4.2). The LLMI was calculated by 
the sum of the scores of 100 cells giving a potential range from 0 to 400.  The person 
who measured the LLMI was not aware of clinical findings.  
4.2.4 Statistical analysis 
Categorical variables were reported as percentages and comparisons done 
using the chi–square or Fisher’s exact test.  Numerical variables were reported as 
mean (SD) or median (IQR) and comparisons done using Mann-Whitney test or 
Kruskal Wallis test. Statistical significance was defined as p<0.05. Logistic 





    Score 
 
    0: no opacification 
 
    1:  up to ¼ opacified 
 
    2:  ¼ to ½ 
 
    3:  ½ to ¾ 
 
    4:  totally opacified 
 
Figure 4.2. LLMI calculation. 
Determination of lipid-laden macrophage index (LLMI). BAL cytospins were stained with Oil-
Red-O. AMs were graded by the amount of lipid in the cytoplasm staining red. Cells were 
scored from 0 to 4: 0 = no opacification, 1 = up to ¼ opacified, 2 = ¼ to ½ opacified, 3 = ½ to 
¾ opacified, and 4 = totally opacified. The panels show examples of each score. LLMI was 
reported as the sum of the scores of 100 cells giving a potential score range of 0 to 400. 
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4.2.5 Determination of lipid-laden macrophage index (LLMI)  
BAL cytospins were stained with Oil-Red-O. AMs were graded by the amount 
of lipid in the cytoplasm staining red. Cells were scored from 0 to 4: 0 = no 
opacification, 1 = up to ¼ opacified, 2 = ¼ to ½ opacified, 3 = ½ to ¾ opacified, and 
4 = totally opacified. The panels show examples of each score. LLMI was reported 



















67 patients (21 severe asthma, 19 mild/moderate asthma, 16 patients with 
chronic cough, 11 healthy subjects) with BAL specimens were included in the study. 
Two patients (1 severe and 1 mild/moderate asthma) were excluded from 
subsequent analysis due to poor quality of the staining and five patients had missing 
BAL differential cell count data.  
Significant differences were seen between groups in terms of inhaled and oral 
corticosteroid use, FEV1 % predicted and FEV1/FVC ratio (table 4.1). 14 out of 21 
(66.7%) patients with severe asthma were taking maintenance OCS with a median 
dose of 10mg a day. This group were also taking high dose ICS (median 1600 µg, 
IQR [1600 – 4000]) compared to the mild/moderate group (median 200 µg, IQR [0 – 
600]). The severe asthma group exhibited greater bronchodilator reversibility and 
lower PC20. Both asthmatic groups were more likely to be atopic than the chronic 
cough and healthy control group (81% and 87.5% compared to 33.3%, 27.3% 
respectively; p<0.0005). Sixteen patients (28.6 %) reported a history of GORD of 
which 14 were taking medication with proton pump inhibitors. A greater history of 
GORD and PPI use was noted in the severe asthma (40% and 42.1% respectively) 
and chronic cough (41.7% and 44.4%) groups compared to the mild/moderate 
asthma (21.4% and 13.3%) and healthy control (none reported) groups.  
BAL differential cell counts were similar between all the groups with an 
increase in eosinophils noted in the mild/moderate group (p<0.05). A higher 
neutrophil percentage in BALF was noted in the severe group (median 3.4%, [IQR 
0.9 - 7.3]), but this did not reach statistical significance (table 4.3).  
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Table 4.1. Demographics. 
 
Healthy subjects Chronic cough Mild/moderate asthma Severe asthma P value 
N 11 16 17 21  
      
Age (years) 35.6 ± 13.9 43.1 ± 12.8 43.7 ± 14.6 43.8 ± 12.5 0.34 
M/F 8/3 5/11 11/6 11/10 0.13 
BDP eq  (µg) 0 0 (0 - 500) 200 (0 - 600) 1600 (1600 - 4000) <0.0001 
Oral steroid (n) 0 (0) 0 (0) 0 (0) 10 (0 - 20) 14 
 
BMI 26.9 (25.6 - 32.4) 25.5 (23.9 - 27.4) 24.9 (21.1 - 30.3) 28.4 (24.6 - 33.5) 0.33 
Smoking  
     
  Current 0 1 0 0 0.45 
  Ex 1 1 0 3 
 
  Never 10 13 17 18 
 
FEV1 % 104.8 (98.2 - 108.0) 87.7 (83.6 - 100.4) 84.9 (69.8 - 88.9) 74.9 (60.6 - 84.0) <0.0001 
FEV1/FVC % 81.6 (75.6 - 86.1) 79.0 (75.3 - 84.4) 69.9 (67.7 - 74.2) 64.7 (54.5 - 72.9) <0.0001 
BDR (n) 1.4 ± 2.3 NA 13.9 ± 8.2 (14) 22.8 ± 13.8 (17) 0.0002 
PC20 (n) >16 (11) >16 (3) 2.3 ± 2.5 (14) 0.88 ± 0.6 (5) <0.0001 
FENO (n) 20.1 ± 12.8 (5) 37.9 ± 19.4 (3) 43.5 ± 37.7 (12) 45.3 ± 39.6 (12) 0.6 
Atopic (n, %) * 3 (10, 27.3) 4 (12, 33.3) 14 (16, 87.5) 17 (21, 81.0) 0.0005 
IgE kU/l 73.5 (21 - 126.3) 58.5 (16 - 137.5) 151.0 (63 - 268.5) 184 (49.5 - 615.5) 0.06 
GORD (n, %) 0 (11, 0) 6 (12, 50) 2 (14, 14.3) 8 (19, 42.1) 0.02 
PPI (n, %) 0 (11, 0) 4 (9, 44.4) 2 (16, 12.5) 8 (19, 42.1) 0.03 
       
   
   Data are presented as mean ± SD or median (IQR). Between group comparisons for continuous variables were made using  
Kruskal-Wallis test and for categorical variables using Chi Squared exact testing. 
BDP, beclomethasone dipropionate  BMI, body mass index  BDR, bronchodilator response  PPI, proton pump inhibitor. 






4.3.2 Lipid-laden macrophage index (LLMI) in different groups 
LLMI exhibited a wide range in the severe asthma (0 to 246) and chronic 
cough (0 to 297) groups. The distribution of LLMI by diagnoses can be seen in figure 
4.3. The mild/moderate asthmatic group had the lowest LLMI (median, 7; IQR 0.5-
37) with a significant difference noted versus the severe asthma (median, 37; IQR 
11.5–61, p<0.05) and healthy groups (median, 48; IQR 10-61, p<0.05). No 
significant difference was noted between the other groups.  
No significant associations were noted between BALF cell differential and the 
LLMI for the entire cohort or for individual groups. One chronic cough patient with an 
LLMI of 297 had a BAL neutrophilia of 69% although, in two other cases where the 







Figure 4.3. LLMI by diagnosis.  LLMI scores were calculated for all cohorts. 
Mild/moderate asthmatic exhibited a significantly lower LLMI score compared to the 
severe asthmatic and healthy cohorts. Horizontal lines represent median. *p<0.05. 
 
Table 4.2. LLMI by diagnoses. 
Diagnosis No. Mean of LLMI Median (IQR) (SD) Minimum LLMI Maximum LLMI 
      
Healthy subjects 11 36.6 (26.9) 48 (10 - 61) 3 79 
Chronic cough 16 38.8 (72.5) 15.5 (5 - 41) 0 297 
Mild/moderate asthma 17 17.9 (21.7) 7 (0.5 - 37) 0 61 
Severe asthma 21 55.1 (69.5) 37 (11.5 - 61) 0 246 





4.3.3 Lipid-laden macrophage index (LLMI) and BAL differential cell count 
BALF differential cell counts were similar between all the groups with a small 
but significant increase in eosinophils noted in the mild/moderate group (p<0.05). A 
higher neutrophil percentage was noted in the severe group (median 3.4%, [IQR 0.9 
- 7.3]) although this did not reach statistical significance (table 4.3).  
 
Table 4.3. Differential cell counts in BALF. 
 Healthy subjects Chronic cough Mild/moderate asthma Severe asthma P value 
N 11 15 16 18  
      
Neutrophils % 1.5 (0 - 1.8) 1.7 (0.9 - 5.2) 1.2 (0.5 - 2.6) 3.4 (0.9 - 7.3) 0.15 
Eosinophils % 0.3 (0 - 0.8) 0.2 (0 - 1.0) 1.4 (0.3 - 6.4) 0.6 (0 - 3.8) 0.03 
Macrophages % 90.2 (55.8 - 95.8) 90.4 (64.1 - 94.3) 87.0 (73.8 - 93.2) 87.4 (75.5 - 93.3) 0.98 
Lymphocytes % 7.5 (2.0 - 39.8) 5.7 (4.0 - 24.7) 5.4 (2.1 - 12.0) 5.6 (2.0 - 12.9) 0.84 
       
 
 
4.3.4 Lipid-laden macrophage index (LLMI) and GORD 
Six of the top eight subjects with the highest LLMI scores, including the top 
four, reported a history of GORD. The median LLMI score was higher in the GORD 
group (median 41.5 [IQR, 11.3 - 138] versus 12.5 [2.3 – 35.3]) compared to those 
who did not (p<0.05) (figure 4.4). Univariate logistic analysis (Table 4.5) showed a 




Figure 4.4. LLMI and GORD. Subjects with GORD exhibited a significantly higher 
LLMI score compared to those without. Horizontal lines represent median. *p<0.05. 
 
 
Table 4.4. GORD and LLMI. 
GORD No. of patients Mean of LLMI (SD) Median (IQR) Minimum LLMI Maximum LLMI 
      
Yes 16 80.38 (95.8) 41.5 (11.3 - 138) 1 297 
No 40 22.8 (23.7) 13 (0 - 39.3) 0 81 








Figure 4.5. LLMI and BMI. No correlation was seen comparing LLMI with BMI. 
 
4.3.5 Other associations 
The severe asthma group had a significantly lower FEV1% predicted and 
FEV1/FVC ratio compared to other groups (p<0.0001). However, there was no 
association between these values and LLMI in individual groups or overall. There 







Table 4.5. Univariate logistic regression of predictive factors for GORD. 
Predicting factors Odds ratio 95% CI P value 
    
Age 1.01 0.97 – 1.05 NS 
Gender 1.07 0.34 – 3.39 NS 
FEV1 (% pred) 0.99 0.96 – 1.02 NS 
BAL eos (%) 1.31 0.28 – 6.02 NS 
BAL neut (%) 0.78 0.28 – 2.91 NS 
LLMI     
          0 – 20 1.0   
          21 – 59 2.64 0.64 – 10.91 0.18 
          ≥ 60 8.7 1.79 – 42.3 0.007 
     
 













This study found lower LLMI scores in mild/moderate asthmatics compared to 
the severe asthmatics and healthy controls. However, analysis of the groups by BMI 
revealed no significant correlation. Furthermore, analysis of the entire cohort 
correlating LLMI to BMI did not reveal any significant link. The lack of correlation with 
BMI may reflect a number of factors; there was not a significant difference in BMI 
between the groups assessed and in order to see an effect of BMI and LLMI within a 
particular group, such as severe asthma, a larger cohort with a greater BMI range 
may be needed. These findings do not support the hypothesis that obesity-related 
severe asthma is associated with an increased LLMI. This may reflect a number of 
factors. The sample size and BMI of the groups may not have been sufficiently large 
or diverse to find significant differences. In addition, GORD influences the LLMI and 
the use of OCS in the severe asthma cohort may have been a significant factor. 
The higher LLMI seen in the severe asthma compared to the mild/moderate 
cohort may reflect the fact that GORD was reported more in the severe group 
(42.1% versus 14.3%). Another potential explanation relates to increased levels of 
oxidised or glycated low-density lipoproteins (LDL) seen in asthma (Shute et al., 
1997, Neumeier et al., 2011). This has been suggested as a modulator of 
inflammation and results in LLM formation via macrophage scavenger receptor 
recognition (Brown et al., 2013). The use of OCS is another potential confounding 
factor. 14 (66.7%) of the severe cohort were on maintenance OCS therapy. 
However, subanalysis of the cohort according to OCS use did not find a significant 
difference in LLMI scores. 
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Patients with chronic cough had a lower LLMI compared to the severe asthma 
group and healthy controls, although this did not reach statistical significance. LLMI 
has been evaluated as a marker of chronic aspiration in chronic cough. A study of 30 
consecutive adults presenting to a tertiary referral centre with chronic cough found 
that there was no significant difference in LLMI score when compared to 20 
asymptomatic adults (Carney et al., 1997).  
The higher scores seen in the healthy cohort are harder to explain given that 
no GORD was reported. This supports the view that lipid accumulation is a normal 
process including the ingestion of lipids present within the alveolar space, such as 
lung surfactant (Wright and Youmans, 1995). Another explanation may be related to 
microaspiration and the fact that none of the healthy cohort were taking PPIs. LLMI 
scores were highly variable and there was considerable overlap between groups. 
Despite previous reports associating LLMI with BALF neutrophilia (Sacco et al., 
2006) and airflow obstruction (Kazachkov et al., 2001), we did not find an association 
in this cohort.  
There was a correlation between the presence of GORD and LLMI, with 
greater scores in the symptomatic group. The association between aspiration and 
LLMI has been previously evaluated in children with some studies reporting a 
positive correlation (Colombo and Hallberg, 1987, Bauer and Lyrene, 1999) and 
suggesting that particular cut-off values may be a useful diagnostic test (Furuya et 
al., 2007). However, other studies have failed to confirm that LLMI, measured in 
lavage fluid or sputum, is an indicator of GORD (Colombo and Hallberg, 1987, Kitz et 
al., 2012), highlighting a lack of specificity to detect reflux-related respiratory disease 
(Rosen et al., 2008). In adults, LLMI has been proposed as a marker for aspiration 
pneumonia (Adams et al., 1997). In cystic fibrosis patients post lung transplantation, 
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it may be a useful method of assessing response to Nissen fundoplication (Hayes et 
al., 2012) and a score of >150 was found to have a sensitivity of  82.3% and a 
specificity of 76.4% correlating with an abnormal 24-hour pH test in these lung 
transplant recipients (G et al., 2000).  
LLMI measured in macrophages obtained from sputum samples has been 
correlated to oropharyngeal reflux (Parameswaran et al., 2000). However, other 
studies have failed to confirm this (Koksal et al., 2005) and the use of LLMI in 
induced sputum is limited in smokers; where the presence of inclusions from 
cigarette smoke within the cytoplasm, resulting from the phagocytosis of cigarette 
smoke particulates, increases the LLMI score (Wilson et al., 2011). 
Although this study has identified an association between GORD and LLMI, 
there are some limitations. We relied on self-reported GORD and did not use 
objective measures such as validated questionnaires or a 24-hour pH probe. A study 
incorporating objective measures and selecting a more symptomatic cohort would be 
better placed to examine this potential association. LLMI calculation is time-
consuming and a simpler semi-quantitative method of calculating alveolar lipid 
content has been suggested (Kazachkov et al., 2001) which appear to produce 
similar results (Ding et al., 2002). In addition, the repeatability of LLMI scores in 
individuals is not known.  Further studies, incorporating repeat bronchoscopies, are 
required to establish whether this simpler method could replace the LLMI and 
provide information on individual variability. We have compared asthma and chronic 
cough patients to a cohort of healthy subjects. Furthermore, LLMI may fluctuate over 
time depending on factors such as hyperlipidaemia, BMI and micro-aspiration. LLMI 
should be correlated to the underlying disease process and co-morbidities that may 
influence the presence of LLMs.  
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The role of LLMs in asthma may become more relevant with the potential use 
of solid lipid microparticles as a controlled release delivery system for inhaled 
bronchodilators and corticosteroids (Scalia et al., 2012, Mezzena et al., 2009). This 
method of drug delivery may result in a marked increase in PFCs with impaired 
phagocytosis.  
An accurate measurement of LLMI requires a pathologist with experience in 
reporting BALF. There may be a diagnostic role for LLMI but this is likely to be in 
conjunction with other variables and the precise role of the LLMI in the clinical setting 
requires further investigation. 
This is the first study to assess LLMI in asthma. Although no correlation was 
seen with BALF neutrophils or with the degree of airways obstruction, there was a 



































Chapter 5: Asthma, BMI and lipid droplets 
Hypothesis and aim 
Obesity related severe asthma is associated with increased intracellular lipid 
droplets.  
 Lipid droplets in endobronchial biopsies will be assessed using perilipin 
staining and their relationship with asthma severity and BMI will be examined. 
5.1 Introduction 
Lipid droplets (LDs) are important cytoplasmic organelles found in almost any 
type of mammalian cell (Murphy, 2001). They are cytoplasmic structures comprised 
of an outer monolayer of phospholipids, a neutral lipid-rich core and a unique and 
variable fatty acid and protein composition depending on the type and activating 
status of cell (Moreira et al., 2009). LDs are sparse in ‘normal healthy’ cells and 
exhibit increased numbers in cells associated with inflammation (Meadows et al., 
2005). 
A variety of epithelial cell types display LDs within their cytoplasm (Beil et al., 
1995, Accioly et al., 2008) and LDs in macrophages and other leukocytes play a role 
in inflammation and phagocytosis (Melo et al., 2011). During macrophage 
phagocytosis, the LDs move position to surround phagolysosomes, suggesting that 
they have an active role. Lipid bodies in mast cells have been shown to be granule-
independent organelles with early electron microscopy work on human lung mast 
cells suggesting that lipid bodies act as a storage site of arachidonic acid. This 
suggests that LDs contribute to eicosanoid biosynthesis, metabolism and contribute 
to the release of proinflammatory lipid mediators (Dvorak et al., 1983, Dichlberger et 
al., 2011).  
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Perilipins are a class of 42 to 56 kDa polypeptides that localise exclusively to 
the surface of lipid droplets and are not found in any other subcellular compartment 
(Blanchette-Mackie et al., 1995). There are five subtypes: perilipin 1 (PLIN1, formerly 
perilipin), perilipin 2 (PLIN2, formerly adipose differentiation-relate protein), perilipin 3 
(PLIN3, formerly tail-interacting protein of 47kDa), perlipin 4 (PLIN4, formerly S3-12), 
and perilipin 5 (PLIN5, formerly lipid storage droplet protein 5) (Dichlberger et al., 
2011). Perilipin 1 is the best characterised and was first described in 1991 as an 
adipocyte protein that modulates adipocyte lipid metabolism, coating lipid storage 
droplets to protect them from being broken down by hormone-sensitive lipase 
(Greenberg et al., 1991, Brasaemle, 2007, Ducharme and Bickel, 2008, Smith and 
Ordovas, 2012). This action protects and conserves stored triacylglycerol (TAG) and 
preserves its function as a primary energy reserve (Garcia et al., 2004). 
Perilipin 1 has been associated with an increased risk of developing obesity 
and the complications of obesity (Smith and Ordovas, 2012). The overexpression of 
perilipin 1 in mice fed a high fat diet protects against adipocyte hypertrophy, the 
development of obesity, and glucose intolerance (Miyoshi et al., 2010). In contrast, 
perilipin 1 knockout mice (plin1) exhibit resistance to obesity, increased basal 
lipolysis and reduced isoproterenol-stimulated lipolysis despite similar food 
consumption when compared to wild type (Tansey et al., 2001).  
The number of perilipin positive adipose cells in mammary tissue declines 
significantly during pregnancy and lactation (Russell et al., 2007). This supports the 
theory of adipocyte transdifferentiation where, in this case, adipocytes are able to 
change to secretory epithelial cells and back again following termination of lactation. 
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In humans, there have been conflicting studies looking at perilipin expression. 
One study noted that adipose perilipin 1 mRNA and protein levels were higher in 
non-diabetic obese compared to lean subjects and positively correlated with body fat 
percentage (Kern et al., 2004).  Another study noted that perlipin 1 expression is 
reduced in severely obese (mean BMI 53), compared to non-obese (mean BMI 25) 
individuals (Wang et al., 2003). Furthermore, perilipin protein content appears to be 
reduced in the obese state and associated with higher levels of lipolysis in obese 
women (Mottagui-Tabar et al., 2003). 
The PLIN1 genotype has also been associated with obesity. Two SNPs have 
been linked with obesity phenotypes in Caucasian women (Qi et al., 2004) whilst 
other studies have shown different SNPs are linked with protection from developing 
obesity (Qi et al., 2005). However, there are likely to be ethnic differences and the 
SNPs evaluated to date may be a marker of underlying functional variants (Smith 
and Ordovas, 2012).  
The role of LDs and perilipin in asthma is currently unclear. The aims of the 
study are to investigate the relationship between intracellular LDs, asthma severity 
and BMI.  The presence of perilipin1 and CD45+ staining in endobronchial biopsies 
will be quantified; perilipin1 is used as a marker of intracellular droplets whilst CD45+ 
labels pan leukocyte/inflammatory cells. The presence and intensity of staining will 








54 patients (22 severe asthma, 18 mild/moderate asthma, and 14 healthy 
subjects) who underwent a research fibreoptic bronchoscopy with endobronchial 
biopsies between 2005 and 2012 were recruited retrospectively. All patients 
underwent a screening visit and those with significant respiratory or inflammatory 
comorbidities and those requiring treatment for a respiratory tract infection within the 
preceding four weeks were excluded. Healthy subjects had no smoking history and 
no history of respiratory or cardiac disease. Bronchoscopies were performed under 
sedation according to standard clinical practice at the Royal Brompton Hospital.  
Asthma was based on a physician diagnosis and patients either had a 
methacholine provocation test concentration of <8 mg/ml (concentration of 
methacholine causing a 20% fall in FEV1; PC20) and/or and FEV1 reversibility of 
≥12%. Severe asthma was defined according to the ATS definition of refractory 
asthma (ATS, 2000). Patients who did not fulfil the criteria for severe asthma were 
classified as mild/moderate asthma and this group were taking ≤1000 mcg of inhaled 
beclomethasone dipropionate (BDP) or equivalent per day. 
Ethical approval was obtained from the West London 3 and the Brompton, 
Harefield and NHLI Research Ethics Committees (11/H0706/4 and 08/H0708/29). 
5.2.2 Endobronchial biopsies 
Endobronchial biopsies were taken from segmental and subsegmental 
airways of the right middle and right lower lobe. Biopsies were embedded in optimal 
cutting temperature medium and then snap-frozen in pre-cooled isopentane in liquid 
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nitrogen and stored at -70ºC. Cryostat sections (6 mm) were obtained from biopsies, 
placed on poly-L-lysine-coated microscope slides and stained with haematoxylin and 
eosin. 
5.2.3 Immunohistochemistry (IHC) 
Slides were stained for CD45+ cells and for perilipin. Monoclonal mouse anti-
human antibodies anti-CD45 (Dako, cat no: M0701), at 1:100 dilution, and polyclonal 
rabbit anti-human perilipin protein (Cell Signaling Technology, cat no: 3470), at 1:50 
dilution, were applied to bronchial biopsy sections for 1 hour.  
EnVision-alkaline phosphatase (EV-AP) technique (Dako Ltd, Cambridge, UK) 
was used to label CD45+ pan leukocyte/inflammatory cells. A modified EnVision 
peroxidase staining method (Dako) was used to identify perilipin+ cells as previously 
described (O'Shaughnessy et al., 1997) for 2 hours.  
Irrelevant mouse IgG1 kappa antibody (MOPC21) and rabbit serum were used 
to substitute for the primary layer as negative control for staining specificity of CD45 
and Perilipin antibodies, respectively.  
The immunostaining procedures for detecting the CD45+ and perilipin+ cells  
Sections were dewaxed, loaded onto a Techmate ‘Horizon’ automated 
immunostainer (LJL Biosystems Inc, USA), and immunostained with anti-CD45 
antibody. Sections were then washed and incubated with labelled polymer, AP 
(prediluted secondary antibodies, rabbit anti-mouse/rabbit) (K4018, DAKO, 
Carpinteria, USA). After a further wash, bound alkaline phosphatase was detected 
as a red product following incubation with the chromogen, New Fuchsin substrate 
system. Then the slides were mounted in AquaPerm mounting medium (Thermo 
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Electron Corporation Cat No. 484990). Following incubation with anti-perilipin 
primary antibodies, sections were incubated with polyclonal goat anti-mouse rabbit 
horseradish peroxidase (HRP)-conjugated secondary antibody (cat. no. P0448; 
Dako) and subsequently incubated with diaminobenzidine (DAB) liquid and peroxide 
buffer (Dako) for 30 minutes. Stained antigen sites were detected as a brown 
product.  Slides were counterstained with haematoxylin to provide nuclear 
morphological detail and then mounted in DPX synthetic resin mountant. 
5.2.4 Quantification  
Histological slides were coded to avoid observer bias. The immunostaining 
intensity for perilipin1 expression in the airway epithelium, where it was mostly 
observed, was semi quantitatively given a score ranging from 0 to 2 (0: negative, 0.5: 
weak staining, 1: moderate staining and 2: strong staining). An example of the 
perilipin immunohistochemistry staining in bronchial epithelial cells and scoring can 
be seen in figure 5.1. 
The areas of epithelium and subepithelium, excluding muscle and gland, were 
assessed quantitatively using an Apple Macintosh computer and Image 1.5 software. 
CD45+ inflammatory cells infiltrated in both epithelium and subepithelium and 
subepithelium perilipin+ cells were counted using a Leitz Dialux 20 light microscope 
(Leitz Wetzlar, West Germany). Two to three bronchial biopsies for each subject 
were measured and counted in order to take account of within subject variability. The 
total epithelial and subepithelial areas of two or three biopsies from each 
bronchoscopy were measured and counted, respectively. Then the total counts were 
divided by total area to normalise the counts as the number of cells per unit.   The 
data for bronchial biopsy cell counts were expressed as the number of cut cell profiles 
159 
 
with a nucleus visible (i.e. positive cells) per mm2 of the subepithelium and per 0.1 mm2 
epithelium. The coefficient of variation for repeat counts of cells immunopositive for 
sub-type markers of inflammatory cells by one observer ranged between 5% and 
6%.  
5.2.5 Statistical analysis 
Statistical analysis was performed using StatView (SAS Institute. Inc. and 
GraphPad Prism 4 (GraphPad Software, Inc.). 
One way ANOVA followed by the unpaired Student’s t-test was used for the 
analyses of age, serum IgE, lung function and histamine PC20 data between groups. In 
respect of cell counts, these data were non-normally distributed and differences between 
groups were assessed first using the Kruskal-Wallis test, which, if significant, was 
followed by Mann-Whitney U-test between groups at baseline and infection. The 
coefficient of variation (CV = SD/mean  100) was used to express the error of repeat 


























Figure 5.1. Epithelial perilipin1 staining intensity score. 
Endobronchial biopsies were stained with polyclonal rabbit anti-human perilipin protein. 
Epithelial cells were graded by the intensity of epithelial cells staining brown. Cells were 
scored from 0 to 2: 0 = no opacification, 2 = complete opacification. The panels show 
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Figure 5.2. CD45 staining. 
Endobronchial biopsies were stained with anti-CD45 antibody. The total epithelial and 
subepithelial areas were measured and counted. Total counts were divided by total area to 
normalise the counts as the number of cells per unit. CD45+ inflammatory cells were 












5.3 Results  
5.3.1 Demographics 
Baseline data of patients can be seen in Table 5.1. The severe asthma group 
were slightly older than the mild/moderate and healthy groups (43.9 yrs versus 40.7 
and 35.5, respectively) although this did not reach statistical significance. All three 
groups had a mean BMI in the overweight category (25 ≤BMI< 30) and similar 
proportions had never smoked. There were a higher, but statistically non-significant, 
proportion of females in the severe asthma cohort compared to the other two groups. 
The severe asthmatic cohort exhibited greater airflow obstruction, bronchodilator 
reversibility and a lower methacholine PC20. Both asthmatic groups exhibited higher 
levels of atopy (81.8% and 83.3% in the severe and mild/moderate compared to 
28.6% in the healthy group; p=0.0009). In addition, higher serum IgE levels and 
peripheral blood eosinophil counts were seen in the asthmatic groups. The highest 
levels of GORD were noted in the severe group (57.1% compared to 18.8% in the 
mild/moderate and none in the healthy group; p=0.0017). The severe group were 
taking greater amounts of inhaled (1800µg versus 400µg; p<0.0001) and oral (63.6% 








Table 5.1. Demographics, lung function, corticosteroid use and comorbidities. 
 
        
 Healthy subjects Mild/moderate asthma Severe asthma p value 
N (%) 14 (26) 18 (33) 22 (41)  
     Age (years) 35.5 ± 15.1 40.7 ± 15.0 43.9 ± 14.2 0.2 
M/F 9/5 12/6 11/11 0.51 
BDP equivalent dose (µg)  0  400 (0 - 850) 1800 (1600 - 2550) <0.0001 
Oral corticosteroid (n) 0 0 14 (63.6) <0.0001 
Oral corticosteroid dose 
(mg) 0 0 10 (10 - 20) 
 BMI 26.8 (23.3 - 32.4) 25.1 (20.3 - 28.1) 28.0 (23.2 - 31.7) 0.31 
Never smoked (%) 11 (78.6) 14 (77.8) 20 (90.9) 0.46 
FEV1 (l) 4.0 (3.3 - 4.6) 2.8 (2.4 - 3.3) 2.5 (2.0 - 2.9) 0.0002 
FEV1 % 
104.4 (97.7 - 
107.6) 84.3 (71.1 - 88.6) 75.1 (62.4 - 85.4) <0.0001 
FEV1/FVC % 80.5 (75.9 - 85.3) 70.2 (66.6 - 75.5) 68.45 (59.6 - 75.0) 0.0008 
BDR (n) 1.1 ± 1.8 (9) 16.1 ± 6.8 (15) 22.8 ± 14.0 (20) <0.0001 
PC20 (n) >16 (14) 0.4 (0.18 - 1.9) (14) 0.89 (0.78 - 0.95) (3) <0.0001 
FENO (n) 13.5 (9.9 - 28.3) (5) 
50.25 (16.4 - 108.7) 
(10) 56.5 (21.7 - 91) (11) 0.11 
Atopic (n, %) * 4 (28.6) 15 (83.3) 18 (81.8) 0.0009 
IgE kU/l 82.5 ± 66.1 255.5 ± 302.8 426.4 ± 664.6 0.03 
Blood eos count x 109/l  0.14 ± 0.08 0.37 ± 0.26 0.34 ±  0.35 0.004 
History of GORD (n, %) 0 3 (18.8) 12 (57.1) 0.0017 
PPI (n, %) 0 2 (12.5) 12 (57.1) 0.0007 
          
 
Data are presented as mean ± SD or median (IQR). Between group comparisons for continuous variables were made using 
Kruskal-Wallis test and for categorical variables using χ2 exact testing. 
BDP, beclomethasone dipropionate   BMI, body mass index   FEV1, forced expiratory volume in 1 second   FVC, forced vital 
capacity  BDR, bronchodilator response   PC20, concentration of methacholine (mg/ml) required to produce a 20% fall in FEV1 
from baseline  FENO, exhaled nitric oxide  IgE, immunoglobulin E   GORD, gastro-oesophageal reflux disease   PPI, proton 
pump inhibitor.    
*The data presented are for subjects with either a positive RAST or skin prick test. 
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5.3.2 Expression of perilipin  
Perilipin1 was expressed weakly or moderately in the airway epithelium of 
healthy controls and the asthmatic groups. There was also expression in 
subepithelial inflammatory cells and blood vessel endothelial cells.   
26 (50%) of the overall study population had a positive score and expressed 
perilipin in the airway epithelium. This proportion was consistent with all three 
subgroups. There were higher scoring individuals in the asthmatic cohort but the 
median values were not statistically significant (figure 5.4).  
Over half the overall study population (53.8%) had a positive score and 
expressed perilipin in the subepithelial layer. A greater proportion of the asthmatic 
cohort had positive scores in comparison to the healthy cohort (60% versus 50%) 
and the subepithelial cells staining positive for perilipin were more prominent with a 
higher median value (4.2 IQR [0.1 to 83.2] compared to 0.1 [0.1 to 4.5]; p=0.03) 
(figure 5.5). When asthmatics were subdivided by severity (figure 5.6) no significant 
difference was seen between the mild/moderate and severe groups (median value 










Figure 5.3. Epithelial perilipin score. 





Figure 5.4. Epithelial perilipin score (all groups). 
Epithelial perilipin score in healthy subjects, mild to moderate and severe asthmatic patients. 




Figure 5.5. Submucosa perilipin score. 
Submucosal perilipin score (expressed on log10 scale) in healthy subjects and asthmatic 
patients. Median scores and IQR. *p<0.05. 
 
 
Figure 5.6. Submucosa perilipin score (all groups). 
Submucosal perilipin score (expressed on log10 scale) in healthy subjects, mild to moderate 





Table 5.2. Positive submucosa and epithelial scores for perilipin. 
     




Asthma p value 
  14 18 22  
     
Perilipin Epithelium n (%) 7 (50) 9 (50) 11 (50) 1.0 
Perilipin Submucosa 4 (28.6) 11 (61.1) 13 (59.1) 0.08 
          
     Presented as n (%) and between group comparisons were made using χ
2 exact testing. 
 
 
Table 5.3. Median submucosa and epithelial scores for perilipin and CD45. 
  Healthy Mild/Mod Asthma Severe Asthma p value 
  14 18 22  
     
Perilipin Ep 0.25 (0 - 0.44) 0.085 (0 - 0.63) 0.085 (0 - 0.27) 0.95 
Perilipin Subm 0 (0 - 4.5) 3.5 (0 - 103.2) 4.9 (0 - 91.0) 0.1 
CD45+ Ep 56.2 (39.4 - 99.3) 62.2 (36.0 - 110.7) 47.6 (31.1 - 105.5) 0.95 
CD45+ Subm 664.2 (445.6 - 975.6) 495.0 (202.3 - 965.3) 755.5 (256.0 - 1022) 0.41 
     
  
 





5.3.3 Expression of CD45+  
 CD45+ expression in epithelial cells (figure 5.7) was similar in the asthmatic 
(60.7 IQR [32.8 to 106.5]) and healthy group (56.2 IQR [39.4 to 99.3], p=0.9). In 
addition, no significant difference was seen when the asthmatic group was divided 
into the mild/moderate (62.2 IQR [36.0 to 110.7]) and severe (47.6 IQR [31.1 to 
105.5], p 0.9) groups (table 5.3 and figure 5.9). 
The submucosa layer exhibited similar values in the asthmatic and healthy 
group in terms of CD45+ expression (555.4 IQR [230.3 to 1015] compared to 664.2 
IQR [445 to 975.6] respectively, p 0.39). No significant difference was seen when the 
asthmatic group was divided by severity (755.5 IQR [256 to 1022]; p=0.35) (table 5.3 











Figure 5.7. Epithelial CD45 score. 




Figure 5.8. Epithelial CD45 score (all groups). 
Epithelial CD45 score in healthy subjects, mild to moderate and severe asthmatic patients. 




Figure 5.9. Submucosa CD45 score. 




Figure 5.10. Submucosa CD45 score (all groups). 
Submucosal CD45 score in healthy subjects, mild to moderate and severe asthmatic 
patients. Median scores and IQR.  
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5.3.4 Perilipin, CD45+ and BMI  
No significant relationship was noted between epithelial or submucosal 
perilipin and CD45+ expression and BMI. 
Univariate logistic analysis 
Univariate logistic analysis (table 5.4) did not demonstrate significant 
associations between a positive epithelial or subepithelial perilipin score and other 
variables. A trend was noted between subepithelial perilipin score and the presence 
of GORD with an OR of 3.73 (p=0.05). 
 
Table 5.4. Univariate Logistic Regression of predictive factors for positive 
epithelial perilipin score. 
Predicting factors Odds ratio 95% CI P value 
    
Asthma 0.71 0.19 – 2.63 0.61 
GORD 2.03 0.59 – 7.05 0.26 
FEV1 (% pred) 1.01 0.98 – 1.04 0.34 
FEV1/FVC ratio 1.05 0.99 – 1.11 0.08 
BMI 1.02 0.92 – 1.13 0.75 
Gender 1.34 0.44 – 4.1 0.61 
Atopy 0.78 0.24 – 2.54 0.68 
ICS 1.58 0.5 – 5.0 0.43 
  
   
 
GORD, gastro-oesophageal reflux disease  FEV1, forced expiratory volume in 1 second   FVC, forced vital capacity   BMI, body 
mass index   ICS, inhaled corticosteroid. 
CI = confidence interval. 
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Table 5.5. Univariate Logistic Regression of predictive factors for positive 
subepithelial perilipin score. 
Predicting factors Odds ratio 95% CI P value 
    
Asthma 2.08 0.78 – 11.65 0.11 
GORD 3.73 0.98 – 14.2 0.05 
FEV1 (% pred) 1.00 0.97 – 1.03 0.86 
FEV1/FVC ratio 1.00 0.96 – 1.06 0.81 
BMI 1.04 0.94 – 1.16 0.46 
Gender 1.52 0.5 – 4.64 0.46 
Atopy 1.25 0.38 – 4.07 0.71 
ICS  2.54 0.79 – 8.2 0.12 
  
   
 
GORD, gastro-oesophageal reflux disease  FEV1, forced expiratory volume in 1 second   FVC, forced vital capacity   BMI, body 
mass index   ICS, inhaled corticosteroid. 











This study found that perilipin expression was a common finding in epithelial 
cells and the submucosa. Although the asthmatic groups exhibited greater perilipin 
expression in the submucosa compared to the healthy cohort, no significant 
correlations were noted in terms of asthma severity or BMI. This is in contrast to the 
hypothesis and may reflect the fact the fact that the cohort was not diverse enough in 
terms of BMI to establish significant differences, that direct measures of LD 
identification and location were not used and the fact that LDs may reflect 
inflammation rather than just adiposity. 
The perilipin expression in endobronchial biopsies taken in this study is 
indicative of the presence of intracellular LDs and is a novel finding in airway 
epithelial cells. The observation that approximately half of all samples stained 
positive for perilipin in the epithelial layer, regardless of the presence of asthma, 
indicates that lipid bodies are likely to be an important and integral part of cellular 
function in the airway lining.   
LDs have been noted within the cytoplasm of a variety of epithelial cells (Beil 
et al., 1995, Accioly et al., 2008), they are a common finding in the cytoplasm of 
most eukaryotic cells and their presence in macrophages has been correlated with 
inflammation and phagocytosis (Melo et al., 2011). The exact role of LDs in epithelial 
cells remains unclear. They may function as a storage site for arachidonic acid, 
represent intracellular loci involved in eicosanoid synthesis (Plotkowski et al., 2008) 
and play a role in the release of pro-inflammatory mediators (Dichlberger et al., 
2011, Melo et al., 2013). The trend towards a correlation between a positive perilipin 
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score in the subepithelial layer and the presence of asthma or GORD on univariate 
logistic regression may reflect these points.   
Macrophage LD formation is increased with in vitro bacterial (Peyron et al., 
2008), parasitic (D'Avila et al., 2011) and viral infection (Melo and Dvorak, 2012, 
Samsa et al., 2009). LDs appear to be dynamic organelles, able to relocate in the 
cytoplasm and interact with phagosomes, presumably aiding the phagocytic process 
(Melo et al., 2006). Extrapolating this data, it would seem reasonable to hypothesise 
that LDs may aid the survival and integrity of airway epithelial cells and play an 
important role in host defence. Further studies incorporating cellular function and 
cytokine release with reference to LD content in bronchial epithelial cells would 
enable these theories to be tested in airways disease. 
 The higher perilipin expression seen in the subepithelial layer in the asthmatic 
compared to the healthy cohort may reflect underlying airway inflammation with 
greater release of eicosanoid mediators and phagocytic activity. However, whilst this 
study confirms that there is perilipin expression in the subepithelial layer, it does not 
provide information regarding which particular cell types are involved. Further work 
incorporating cell surface markers for specific cell types would allow further 
assessment in this area.  
Previous studies have noted that obesity is associated with excess lipid 
storage and LDs in adipose and non-adipose tissue (Walther and Farese, 2012). In 
turn the excess LDs correlate with a wide range of factors including obesity, fatty 
liver, coronary artery disease and infectious diseases such as tuberculosis or 
hepatitis C virus (McDonough et al., 2009).  Given the known correlation with obesity 
and other associated disease states, it was surprising that no correlation between 
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the expression of perilipin in either the epithelial or subepithelial layer and BMI was 
seen in this study. This may be explained by the use of perilipin as a marker for LDs 
rather than more direct measures such as electron microscopy or a combination to 
confirm that the perilipin is detecting LDs as intended. Alternatively, airway epithelial 
cells and subepithelial cells may behave differently and LDs may be more of a 
marker of inflammation and phagocytic function rather than obesity. 
 There are some important limitations to consider with this study. A greater 
proportion of the severe cohort (50%) were female compared to the mild/moderate 
and healthy cohorts (33% and 36% respectively). However, analysis of the overall 
data according to gender did not reveal a significant difference in epithelial or 
subepithelial perilipin scores. The severe cohort had an older median age than the 
other two cohorts and although this did not reach statistical significance, it is possible 
that increasing age may play an important role in lipid body development, number 
and perilipin expression. No significant difference was seen in CD45+ expression 
between the groups. This is in contrast to previous studies which noted increased 
subepithelial CD45+ expression in asthmatic patients compared to healthy subjects 
(Zhu et al., 2014). Although no significant relationship was noted between perilipin 
and BMI, the study population exhibited a narrow BMI range and further work 
expanding these measurements would be better placed to examine this relationship. 
This study incorporated univariate logistic regression analysis but a study 
incorporating a greater number of samples would allow multivariate analysis to be 
used which may provide a different perspective to the data. 
 The quality of the endobronchial biopsy and integrity of the epithelium may 
influence the staining and scoring of perilipin and CD45. Future work incorporating a 
quality control score or review would prevent this being a significant factor. CD45, 
176 
 
also known as leukocyte common antigen, provides an overall marker of 
inflammation but further work incorporating specific stains for eosinophils or 
neutrophils may allow greater insight into asthma specific inflammatory patterns.  
Although perilipin expression is essentially synonymous with the presence of 
LDs, the endobronchial biopsies in this study were not assessed to confirm this 
correlation. The concurrent use of electron microscopy would enable this to be 
confirmed and could be used in future studies. Furthermore, the function of the lipid 
bodies was not addressed in this study. Further work looking at how lipid bodies 
relate to cellular function in terms of cytokine release and phagocytosis would 
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Chapter 6: The impact of leptin, resistin and adiponectin on PBMCs in severe 
and non-severe asthma 
Hypothesis and aims 
Adipokines modulate inflammatory cytokine release and corticosteroid 
insensitivity in severe asthma. In this chapter, the effect of adipokines (leptin, 
adiponectin and resistin) on PMBCs are examined in terms of inflammatory 
response, corticosteroid sensitivity and their relationship with BMI through in vitro 
experiments involving peripheral blood mononuclear cell taken from asthmatics and 
healthy controls. Adiponectin is regarded as anti-inflammatory whilst leptin and 
resistin are both pro-inflammatory adipokines.  
6.1 Introduction 
Adipocytes produce a number of pro- and anti-inflammatory cytokines, termed 
adipokines, which have multiple roles and play an important part in the inflammatory 
response (table 1.2). The excess adipose tissue seen in the obese state is 
associated with greater production of pro-inflammatory adipokines: serum 
concentrations of IL-6, TNF-α and CRP are all raised in obesity (Festa et al., 2001). 
PBMCs taken from obese subjects are in a proinflammatory state, exhibiting 
increased intranuclear NF-κB binding and an increase in the transcription of NF-κB 
regulated proinflammatory genes (Ghanim et al., 2004). In addition, exposure to 
relatively high levels of dyslipidaemia and inflammatory molecules, produced by 
other organs, and tissues may result in a phenotypic shift in macrophages to the 
more inflammatory classical M1 type (Bories et al., 2012).  
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Severe asthma has been associated with relative corticosteroid insensitivity 
(Bhavsar et al., 2008). There is additionally an association between corticosteroid 
insensitivity and obesity in asthma (Gibeon et al., 2013). This is supported by 
retrospective analysis of clinical trials using ICS (Peters-Golden et al., 2006, 
Camargo et al., 2010a, Anderson and Lipworth, 2012) and by in vitro work 
(Sutherland et al., 2008a). Sutherland and colleagues found that dexamethasone 
induced MKP1 suppression in PBMCs taken from mild asthmatics was attenuated in 
subjects with a BMI ≥25 compared to those <25. 
 Leptin is produced mainly by white adipocytes, is positively correlated with 
increasing BMI and is viewed as proinflammatory (Kelesidis et al., 2010, Considine 
et al., 1996). Circulating levels in healthy humans are usually below 10 ng/ml, rising 
to between 10 to 60 ng/ml in obese individuals (Licinio et al., 1997). Serum levels 
increase following the administration of inflammatory stimuli such as 
lipopolysaccharide (LPS), or in experimental acute inflammation (Faggioni et al., 
1998, Iikuni et al., 2008). Decreased levels are linked to impaired immune function 
(La and Matarese, 2004) and humans with congenital leptin deficiency exhibit a 
higher mortality incidence related to infection (Ozata et al., 1999). This correlation 
appears to be multifactorial and related to both direct and indirect modulation of 
immune pathways with leptin playing an important role in innate immunity control 
(Procaccini et al., 2015).  Leptin up-regulates phagocytic function (Mancuso et al., 
2002), induces proinflammatory cytokine secretion (including TNF-α, IL-6 and IL-12) 
(Loffreda et al., 1998), stimulates the proliferation and activity of monocytes in vitro, 
induces neutrophils chemotaxis (Zarkesh-Esfahani et al., 2001) and plays an 




Three leptin receptors have been identified in humans: OB-Ra, OB-Rb and 
OB-Rc (Chua et al., 1997). OB-Rb appears to be the most important  and is 
expressed in high levels in the hypothalamus (De et al., 2007b) and has been 
identified on macrophages, monocytes, natural killer (NK) cells, neutrophils, dendritic 
cells and subpopulations of T and B cells (Iikuni et al., 2008).  
Leptin’s pro inflammatory activity appears to be via Jak2, MAPK, ERK, PI3K, 
Akt and STAT1, 3, 5 and 6 (Martin-Romero and Sanchez-Margalet, 2001). PBMCs 
pre-treated with leptin exhibit increased phosphorylation of both ERK-1 and ERK-2 in 
a concentration dependent manner (Martin-Romero and Sanchez-Margalet, 2001) 
and additionally a sustained phosphorylation of p38 MAPK  (Procaccini et al., 2009).  
Adiponectin is generally viewed as an anti-inflammatory adipokine. It is 
produced predominantly by adipocytes and is the most abundant adipokine, 
accounting for 0.01% of total plasma protein (Hu et al., 1996). Adiponectin plasma 
concentrations range between 3 and 30 µg/ml (Folco et al., 2009).  It is negatively 
correlated with increasing BMI (Lara-Castro et al., 2007) and levels increase with 
weight loss (Kern et al., 2003). Other cell types, including brown adipocytes, colonic 
mucosa cells, foetal tissue (Corbetta et al., 2005), salivary gland epithelial cells 
(Katsiougiannis et al., 2006), osteoblasts (Berner et al., 2004), myocytes (Pineiro et 
al., 2005) and myofibroblasts (Matsunaga et al., 2008) are able to produce small 
quantities, 
There are six isoforms of adiponectin. These include globular adiponectin 
(gAPN), full length adiponectin (fAPN or monomeric), low molecular weight 
adiponectin (LMW or trimeric), medium weight adiponectin (MMW), high molecular 
weight adiponectin (HMW), and the serum albumin bound LMW form (Alb-LMW). 
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Monomers can form trimeric isoforms via hydrophobic interactions and subsequently 
other isoforms via disulphide bonds. 
Four adiponectin receptors have been identified: Adipo R1, Adipo R2, T-
Cadherin, and calreticulin (Takemura et al., 2007, Hug et al., 2004, Yamauchi et al., 
2007). Adipo R1 and R2 is expressed in multiple cell types, including bronchial 
epithelium,  T cells, monocytes, B cells and NK cells (Pang and Narendran, 2008).   
In mice, adiponectin attenuates airway inflammation and AHR (Shore et al., 
2006) whilst APN-/- mice display more eosinophilic airway inflammation in a chronic 
model of asthma (Medoff et al., 2009).  Pre-treatment of human monocyte derived 
macrophages (MDMs) (Kumada et al., 2004) and AMs (Ohashi et al., 2010) with 
adiponectin has been shown to significantly increase IL-10 secretion and suppress 
LPS induced inflammation via IĸB (Folco et al., 2009).  Furthermore, adiponectin 
appears to stimulate the expression of M2 markers in human MDMs, resulting in 














Subjects underwent spirometry with reversibility testing, a methacholine 
challenge test (to assess the degree of bronchial hyper-responsiveness), skin prick 
tests and IgE levels (to assess atopic status), and measurement of exhaled nitric 
oxide (as a non-invasive marker of inflammation). All subjects had blood taken to 
obtain PBMCs. In addition, asthmatic subjects completed an Asthma Control 
Questionnaire. A full description of the methods can be seen in Chapter 2.  
Adipokine availability meant that some experiments were conducted at 
different time intervals. Therefore sub-groups of the overall cohort (table 6.1) were 
used for leptin (6.2), resistin (6.3) and adiponectin (6.4). CXCL8 was chosen as the 
primary cytokine response. CXCL8 induces the migration of neutrophils, monocytes 
and eosinophils to sites of infection, injury or inflammation (Govindaraju et al., 2006) 
with increased levels in sputum (Gibson et al., 2001), BAL fluid (Chanez et al., 1996) 














6.3.1 Overall demographics  
Baseline data for all subjects recruited are presented in table 6.1. All groups 
were of a similar age (mean 44.7 years for healthy subjects versus 44.1 years and 
48.7 years for mild/moderate and severe asthma subjects respectively) and smoking 
history. The severe group had a greater proportion of female subjects than the 
mild/moderate asthma or healthy cohort (71.4% versus 42% and 39%, p=0.039). 
Although all groups were of a similar BMI, the severe group had a higher body fat % 
calculated by BEI (35.6% IQR [21.1 – 44.6] versus 25.5% [14.1 – 34.6] and 27.1 
[13.0 – 40.5], p=0.044). 
As expected, the severe group were on higher doses of ICS and just under 
half (46.4%) were taking maintenance OCS. They were also more likely than the 
mild/moderate group to be receiving additional therapies such as LTRA (50% versus 
15.8%, p=0.0001) and aminophylline (42.9% versus 0%, p>0.0001). 
FEV1, FVC and the FEV1/FVC ratio were reduced in the asthmatic groups and 
to a greater degree in the severe cohort. Greater bronchodilator reversibility was 
seen in the severe compared to the mild/moderate group. The asthmatic groups 
were more likely to be atopic (71.4% severe, 84.2% mild/moderate and 30.4% 
healthy, p=0.0007) and report GORD symptoms (35.7%, 10.5% versus 8.7%, 
p=0.037). Asthma related quality of life in terms of ACQ (2.2 [1.6 – 3.1] compared to 
(1.0 [0.4 – 1.4], p<0.0001) and AQLQ (total AQLQ 4.7 [4.5 – 6.0] compared to 6.2 
[5.8 – 6.3], p=0.005) were significantly worse in the severe compared to the 
mild/moderate cohort.  
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Table 6.1: Demographics of subjects recruited. 
     
  Healthy subjects Mild/mod asthma Severe asthma P value 
N 23 19 28   
     
Age (yrs) 44.7 ± 10.7 44.1 ± 14.9 48.7 ± 12.2 0.34 
M/F 14/9 11/8 8/20 0.039 
Smoking History 
    
  Never 20 18 24 0.6 
  Ex 3 1 4 
 
Height 172.5 (160.5 - 179.3) 174 (166 - 180) 164.5 (161.3 - 172.8) 0.06 
Weight 76.4 (63.6 - 101.1) 76.5 (66.1 - 89.2) 73.8 (64.1 - 93.4) 0.87 
BMI 27.3 (20.8 - 33.1) 25.3 (21.1 - 30.0) 26.8 (22.6 - 34.9) 0.26 
BEI fat % 27.1 (13.0 - 40.5) 25.5 (14.1 - 34.6) 35.6 (21.1 - 44.6) 0.044 
Skin fold fat % 34.8 (23.8 - 40.1) 33.4 (22.5 - 35.7) 34.3 (27.8 - 40.0) 0.39 
waist/hip ratio 0.89 (0.87 - 1.0) 0.87 (0.81 - 0.99) 0.90 (0.81 - 0.99) 0.71 
BDP equiv dose (µg) 0 400 (200 – 1000) 2000 (1600 – 4000) <0.0001 
Oral corticosteroid (%) 0 0 13 (46.4) <0.0001 
OCS dose (mg) 0 0 10 (9 – 20)  <0.0001 
Aminophylline (%) 0 0 12 (42.9) <0.0001 
LTRA (%) 0 3 (15.8) 14 (50) 0.0001 
FEV1 (l) 3.4 (2.6 - 3.8) 2.7 (2.0 - 3.5) 1.6 (1.3 - 2.4) <0.0001 
FEV1 % 98.8 (91.7 - 105.1) 82.4 (71.7 - 89.0) 72.2 (41.9 - 72.2) <0.0001 
FVC 4.2 (3.0 - 4.7) 3.9 (3.3 - 4.3) 2.6 (2.2 - 3.5) 0.0003 
FVC % 100.4 (91.8 - 106.7) 95.7 (90 - 107.4) 79.6 (67.5 - 88.6) 0.0001 
FEV1/FVC % 81.9 (78.6 - 85.8) 72.9 (65.2 - 73.6) 65.7 (54.4 - 72.9) <0.0001 
BDR (n) 1 (-2 - 4) (11) 13.1 (9.9 - 19.1) (14) 20.3 (12.3 - 27.6) (24) <0.0001 
PC20 (n) >16 (23) 0.96 (0.43 - 5.7) (15) 1.0 (0.4 - 1.6) (2) <0.0001 
Atopic (n, %) * 7 (30.4) 16 (84.2) 20 (71.4) 0.0007 
IgE kU/l 64 (23 – 89) 221 (127 – 367) 108 (75 – 301) 0.038 
Blood eos count x 109/l 0.1 (0.1 – 0.2) 0.3 (0.2 – 0.5) 0.3 (0.1 – 0.6) 0.047 
GORD (n, %) 2 (8.7) 2 (10.5) 10 (35.7) 0.037 
PPI (n, %) 0 2 (10.5) 8 (28.6) 0.013 
ACQ 
 
1 (0.43 – 1.43) 2.2 (1.57 – 3.11) <0.0001 
AQLQ  
    
  Activities 
 
6.3 (5.8 – 6.6) 5 (4 – 6.2) 0.0038 
  Symptoms 
 
5.8 (5.5 – 6.4) 4.9 (4 – 5.9) 0.0058 
  Emotional 
 
6.4 (5.5 – 6.8) 5.4 (4.7 – 6.4) 0.017 
  Environmental 
 
6 (5.5 – 6.5) 5.4 (4.3 – 5.9) 0.028 
  Total 
 
6.2 (5.8 – 6.3) 4.7 (4.5 – 6.0) 0.005 
     
Data are presented as mean ± SD or median (IQR). Between group comparisons for continuous variables were made using 
Kruskal-Wallis test and for categorical variables using χ2 exact testing. 
BMI, body mass index  BEI, bioelectrical impedance  BDP, beclomethasone dipropionate  OCS, oral corticosteroid   LTRA, 
leukotriene receptor antagonist   FEV1, forced expiratory volume in 1 second   FVC, forced vital capacity   BDR, bronchodilator 
response  PC20, concentration of methacholine (mg/ml) required to produce a 20% fall in FEV1 from baseline  GORD, gastro-
oesophageal reflux disease   PPI, proton pump inhibitor  OCS, oral corticosteroid  ACQ, asthma control questionnaire   AQLQ, 
asthma quality of life questionnaire.   
*The data presented are for subjects with either a positive RAST or skin prick test. 
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Table 6.2: Demographics of subjects recruited for leptin studies. 
          
 Healthy subjects Mild/moderate asthma Severe asthma P value 
N 16 10 12   
     
Age (years) 42 (36 - 49.3) 44 (33.3 - 56) 49 (42.3 - 58.5) 0.36 
M/F 11/5 7/3 5/7 0.27 
Smoking History     
  Never 12 9 11 0.41 
  Ex 4 1 1  
Height 174 (166.3 - 179.8) 179 (172.3 - 182.8) 164 (160.3 - 175.8) 0.16 
Weight 70.3 (61.7 - 101.8) 73 (64 - 83.5) 86 (74.6 - 108.2) 0.16 
BMI 24.3 (20 - 32.3) 22.6 (21 - 26.2) 30.7 (25 - 34.9) 0.03 
BEI fat % 19.4 (12.6 - 34.1) 18.1 (13.4 - 26.5) 38.8 (21.1 - 46.3) 0.05 
Skin fold fat % 32.8 (22.5 - 39.1) 28.1 (21.7 - 35.8) 37.2 (30.7 - 42.2) 0.12 
waist/hip ratio 0.89 (0.8 - 1) 0.87 (0.82 - 0.98) 0.9 (0.84 - 0.93) 0.85 
     
BDP equivalent dose (µg) 0 600 (0 - 1000) 1800 (1600 - 3600) <0.0001 
Oral corticosteroid (%) 0 0 7 (58.3)  
Oral corticosteroid dose (mg) 0 0 7.8 (0 - 13.8) 0.0001 
Aminophylline (%) 0 0 6 (50) 0.0004 
LTRA (%)     
FEV1 (l) 3.4 (3.2 - 4.2) 3.0 (2.2 - 3.6) 1.9 (1.6 - 2.7) 0.0006 
FEV1 % 98.6 (88.5 - 106.3) 83.7 (70.9 - 88.0) 68.1 (58.3 - 72.0) <0.0001 
FVC 4.2 (3.8 - 5.3) 4.0 (3.6 - 4.6) 2.8 (2.2 - 3.6) 0.02 
FVC % 100.9 (92.2 - 107.1) 92.6 (87.4 - 101.5) 79.6 (73 - 86.0) 0.01 
FEV1/FVC % 81.9 (78.7 - 85.5) 73.3 (67.5 - 78.1) 70.5 (64.9 - 73.7) <0.0001 
Atopic (n, %) * 6 (37.5) 7 (70) 9 (75) 0.09 
IgE kU/l 64 (27 – 228) 212 (29 – 519) 114 (90 – 207) 0.3 
Blood eos count x109/l 0.1 (0.1 – 0.2) 0.3 (0.1 – 0.6) 0.3 (0.1 – 0.5) 0.29 
          
     
Data are presented as mean ± SD or median (IQR).  
   
Between group comparisons for continuous variables were made using Kruskal-Wallis test and for categorical variables using χ2 exact testing 
BMI, body mass index   BEI, bioelectrical impedance  BDP, beclomethasone dipropionate   LTRA, leukotriene receptor antagonist   FEV1, forced 
expiratory volume in 1 second   FVC, forced vital capacity  IgE, immunoglobulin E. 









6.3.2 Subjects recruited for leptin studies 
 Baseline data of patients recruited for the leptin studies is presented in table 
6.2. Similar demographics were seen compared to the overall cohort (table 6.1) 
However, differences were noted in terms of BMI (30.7 [25 – 34.9] in the severe 
group compared to 22.6 [21 – 26.2] in the mild/moderate and 24.3 [20 – 32.3] in the 
healthy groups, p=0.03) 
 
6.3.3 Effect of leptin on PBMC viability 
 To establish whether leptin alters PBMC viability, cells were pre-treated with 
leptin, LPS, Dex (10-6 M) or a combination for 20 hours prior to performing the MTT 
assay. Leptin did not significantly influence the MTT signal, in isolation or in 








Figure 6.1: Leptin MTT assay. PBMCs were treated with (A) Leptin (10 pg/ml to 1 µg/ml), (B) 
Leptin and LPS (0.5 ng/ml), (C) Leptin and Dex (10-6 M), or (D) a combination of Leptin, LPS (0.5 
















6.3.4 Effect of leptin, LPS and Dex (10-6 M) on CXCL8 release from PBMCs 
To examine the effects of leptin on CXCL8 release from PBMCs and the 
interaction of LPS and Dex, cells were pre-treated with increasing concentrations of 
leptin and Dex (10-6 M) ± LPS for 20 hours prior to collecting supernatant. Leptin 
induced CXCL8 release at the highest concentration of 1 µg/ml in severe, 
mild/moderate asthma and healthy subjects (3.9, 2.8 and 3.5 fold increase when 
normalised to untreated cells, respectively). At concentrations between 100 pg/ml to 
100 ng/ml there was no significant increase in CXL8 release compared to untreated 
PBMCs (figure 6.2). 
CXCL8 release in response to LPS was lower in the severe cohort compared 
to mild/moderate asthmatics and healthy subjects (13248 pg/ml [SD 6402] versus 
20036 [12505] and 17425 [10610], respectively, p=0.34) although this did not reach 














Figure 6.2: The effect of leptin, LPS, Dexamethasone, or in combination on 
CXCL8 release from PBMCs. Healthy (n=16), Mild/Moderate asthma (n=10), Severe asthma 
(n=12). PBMCs treated with (A) Leptin (10 pg/ml to 1µg/ml), (B) Leptin and Dex (10-6 M), (C) Leptin 
and LPS (0.5 ng/ml), or (D) a combination of Leptin, Dex (10-6 M) and LPS (0.5 ng/ml) for 20 hours 
prior to collection of supernatant. CXCL8 release was measured by ELISA. Data represent mean ± 









6.3.5 Subjects recruited for resistin studies 
Baseline data of patients is presented in Table 6.3. Similar demographics 
were seen compared to the overall cohort (table 6.1) However, differences were 
noted in terms of weight and BMI (23.6.7 [20.8 – 25.4] in the mild/moderate group 
compared to 30.8 [21 – 35.8] in the healthy and 32.7 [27.9 – 37.9] in the severe 
cohorts, p=0.03). 
Table 6.3: Demographics of subjects recruited for resistin studies. 
          
 Healthy subjects Mild/moderate asthma Severe asthma P value 
N 10 7 10   
     
Age (years) 45 (39.5 – 53.5) 55 (50 - 59) 49 (44.8 – 59.5) 0.29 
M/F 8/2 3/4 4/6 0.15 
Smoking History     
  Never 7 7 9 0.2 
  Ex 3 0 1  
Height 178.5 (168.5 – 182.3) 173 (160 - 177) 164 (160.8 - 177) 0.3 
Weight 98.3 (69.5 - 107) 66 (56 – 78.3) 86.2 (76.6 - 115) 0.036 
BMI 30.8 (21 – 35.8) 23.6 (20.8 – 25.4) 32.7 (27.9 – 37.9) 0.033 
BEI fat % 30.4 (12.5 – 40.5) 25.5 (16.4 – 32.4) 40.9 (23.8 - 47) 0.19 
Skin fold fat % 37 (23 – 40.9) 33.5 (29.7 – 35.3) 38.5 (35.4 - 43) 0.18 
Waist/hip ratio 0.98 (0.9 – 1.1) 0.84 (0.74 - 0.99) 0.9 (0.84 - 0.99) 0.23 
     
BDP equivalent dose (µg) 0 400 (0 - 1000) 1800 (1600 - 2800) <0.0001 
Oral corticosteroid (%) 0 0 5 (50) 0.005 
Oral corticosteroid dose (mg) 0 0 10 (8.8 -22.5) 0.007 
Aminophylline (%) 0 0 4 (40) 0.0019 
LTRA (%) 0 1 (14.3) 7 (70) 0.0016 
FEV1 (l) 3.5 (3 - 4.4) 2.5 (1.6 – 2.9) 1.9 (1.5 - 2.6) 0.0022 
FEV1 % 104.8 (91.7 – 107.6) 78.4 (71.5 - 86.0) 64.8 (56.9 - 71.4) 0.0002 
FVC 4.6 (3.4 - 5.6) 3.7 (2.5 - 4.1) 2.8 (2.2 - 3.6) 0.019 
FVC % 104.4 (94 - 108.1) 92.6 (90 - 103.4) 77.5 (70.5 - 83.9) 0.013 
FEV1/FVC % 82.8 (77.1 - 86.1) 70.2 (63.7 – 73.5) 71.7 (63.9 - 74.9) 0.0009 
Atopic (n, %) * 3 (30) 4 (57) 8 (80) 0.079 
IgE kU/l 63.5 (38.3 – 80.5) 189 (18 – 358) 108 (76.5 – 156) 0.22 
Blood eos count x 109/l  0.1 (0.1 – 0.2) 0.3 (0.2 – 0.5) 0.2 (0.1 – 0.3) 0.16 
          
     
Data are presented as mean ± SD or median (IQR).  
   
Between group comparisons for continuous variables were made using Kruskal-Wallis test and for categorical variables using χ2 exact testing. 
BMI, body mass index   BEI, bioelectrical impedance   BDP, beclomethasone dipropionate   LTRA, leukotriene receptor antagonist   
FEV1, forced expiratory volume in 1 second   FVC, forced vital capacity   IgE, immunoglobulin E. 




6.3.6 Effect of resistin on PBMC viability 
 To establish whether resistin alters PBMC viability, cells were pre-treated with 
resistin, LPS, Dex (10-6 M) or a combination for 20 hours prior to MTT assay. 
Resistin did not significantly influence the MTT signal, in isolation or in combination 
with Dex (10-6 M), LPS or both (figure 6.4). This indicates that resistin did not affect 














Figure 6.3: Resistin MTT assay. PBMCs treated with (A) Resistin (10 pg/ml to 
1µg/ml), (B) Resistin and LPS (0.5 ng/ml), (C) Resistin and Dex (10-6 M), or (D) a 











6.3.7 Effect of resistin, LPS and Dex (10-6 M) on CXCL8 release from PBMCs 
To examine the effects of resistin on CXCL8 release from PBMCs and the 
interaction of LPS and Dex, cells were pre-treated with increasing concentrations of 
resistin and Dex (10-6 M) ± LPS for 20 hours prior to collecting supernatant.  
CXCL8 release was greater at the two highest concentrations of resistin (100 
ng/ml and 1 µg/ml) in all groups. The mild/moderate asthmatics exhibited lower 
CXCL8 release, in terms of absolute and normalised data, compared to the healthy 
and severe cohorts at concentrations of resistin ranging from 10 ng/ml to 1 µg/ml 
(figure 6.4, panel A).  
Release of CXCL8 in response to LPS was not significantly different between 
groups (11676 pg/ml [SD 8152] for the severe cohort versus 13917 [6866] 
mild/moderate and 20244 [4025] healthy subjects, p=0.2) (figure 6.4, panel C). The 
pre-treatment of PBMCs with resistin was not associated with an increase in CXCL8 
release following stimulation with LPS (figure 6.4, panel D).  
PBMCs in the presence of Dex (10-6 M) released a similar amount of CXCL8 
in all groups (90.4 [88.2] for the severe cohort versus 122.5 [92.6] mild/moderate and 
156.8 [135.9] healthy subjects, p=0.74). In the presence of the highest 
concentrations of resistin (100 ng/ml and 1 µg/ml), the mild/moderate cohort 
exhibited the lowest CXCL8 release. At the highest concentration of resistin (1 µg/ml) 
PBMCs in all cohorts released greater amounts of CXCL8 compared to control (Dex 
10-6 M). However, only the severe cohort had a significant increase (p=0.012) (figure 







Figure 6.4: Effect of resistin, LPS, Dexamethasone, or in combination on 
CXCL8 release from PBMCs. Healthy (n=10), Mild/Moderate asthma (n=7), Severe 
asthma (n=10). PBMCs treated with (A) Resistin (10 pg/ml to 1 µg/ml), (B) Resistin 
and Dex (10-6 M), (C) Resistin and LPS (0.5ng/ml), or (D) a combination of Resistin, 
Dex (10-6 M) and LPS (0.5 ng/ml) for 20 hours prior to collection of supernatant. 








6.3.8 Subjects recruited for adiponectin studies 
Baseline data of patients is presented in Table 6.4. Similar demographics 
were seen in the subgroup of patients taken from all recruited subjects compared to 
the overall cohort (table 6.1). As expected, significant differences were noted in 
terms of asthma medication requirements, lung function, and asthma symptoms in 
















Table 6.4: Demographics of subjects recruited for adiponectin studies. 
          
       Healthy subjects Mild/mod asthma Severe asthma P value 
N 11 12 14   
     
     
Age (yrs) 43 (36 – 48) 51 (35.5 – 58.8) 56 (45 – 61) 0.14 
M/F 5/6 4/8 3/11 0.44 
Smoking History     
  Never 9 12 12 0.32 
  Ex 2 0 2  
Height 172.0 (155 - 180) 169 (161.5 - 175.3) 164.5 (160 - 169.8) 1 
Weight 70.5 (61.1 - 87.5) 77.0 (60.0 - 88.8) 66.5 (61.9 - 94.1) 0.41 
BMI 25.3 (20.5 - 32.5) 26.6 (21.9 - 30.5) 24.5 (22.5 - 35.4) 0.79 
BEI fat % 25.4 (13 - 40.2) 31.6 (23.8 - 38.7) 37.7 (27.2 - 46.6) 0.14 
Skin fold fat % 35.0 (28.5 - 39.3) 33.4 (29 - 37.1) 35.9 (25.7 - 40.9) 0.78 
waist/hip ratio 0.88 (0.79 - 0.96) 0.84 (0.75 - 0.98) 0.91 (0.84 - 0.96) 0.45 
     
BDP equiv dose (µg) 0 400 (250 - 700) 2400 (2000 - 2800) <0.0001 
Oral corticosteroid (%) 0 0 5 (35.7) 0.0087 
OCS dose (mg) 0 0 14.5  
Aminophylline (%) 0 0 7 (50) 0.0008 
LTRA (%) 0 1 (8.3) 7 (50) 0.0042 
FEV1 (l) 3.3 (2.3 - 4.2) 2.3 (1.7 - 2.9) 1.5 (1.1 - 1.8) 0.0001 
FEV1 % 100.5 (95.9 - 107.5) 82.1 (71.6 - 88.3) 61.4 (40.1 - 72.2) <0.0001 
FVC 4.1 (2.7 - 5.3) 3.6 (2.6 - 4.1) 2.6 (2.1 -3.3) 0.005 
FVC % 13.5 (97.7 - 107.1) 98.9 (90.2 - 109.9) 79.1 (64.3 - 88.1) 0.0024 
FEV1/FVC % 82.8 (78.3 - 85.5) 70.6 (64.0 - 73.5) 59.4 (49.2 - 70.1) <0.0001 
BDR (n) 1 (-2 - 4.0) 15.3 (9.9 - 19.1) 19.6 (12.2 - 27.7) <0.0001 
PC20 (n) >16 0.9 (0.2 - 1.9) *  
Atopic (n, %) * 3 (27.3) 11 (91.7) 10 (71.4) 0.0044 
IgE kU/l 64 (25.5 - 376) 316.5 (162.5 - 399.5) 94.5 (65.5 - 532.3) 0.23 
Blood eos count x109/l 0.25 (0.1 – 0.33) 0.3 (0.2 – 0.4) 0.2 (0.1- 0.43) 0.38 
History of GORD (n, %) 0 2 (16.7) 10 (71.4) 0.0003 
PPI (n, %) 0 2 (16.7) 6 (42.9) 0.031 
     
ACQ  8.5 (4 – 10) 14 (10.5 – 21.5) 0.038 
AQLQ      
  Activities  6.3 (6 – 6.6) 4.8 (3.8 – 6.3) 0.056 
  Symptoms  5.8 (5.6 – 6.3) 4.5 (3.8 – 6.1) 0.029 
  Emotional  6.4 (5.2 – 6.6) 5.4 (4.90 – 6.6) 0.15 
  Environmental  6 (5.5 – 6.5) 5.3 (4.4 – 6.4) 0.15 
  Total  6.1 (5.9 – 6.3) 4.7 (4.4 – 6.3) 0.091 
          
Data are presented as mean ± SD or median (IQR). Between group comparisons for continuous variables were made using Kruskal-
Wallis test and for categorical variables using χ2 exact testing. 
 
BMI, body mass index   BEI, bioelectrical impedance  BDP, beclomethasone dipropionate   LTRA, leukotriene receptor antagonist   
FEV1, forced expiratory volume in 1 second   FVC, forced vital capacity  IgE, immunoglobulin E   GORD, gastro-oesophageal reflux 
disease   PPI, proton pump inhibitor   ACQ, asthma control questionnaire   AQLQ, asthma quality of life questionnaire.   
*The data presented are for subjects with either a positive RAST or skin prick test. 
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6.3.9 Adiponectin: concentration response 
A concentration response for adiponectin (100 pg/ml to 10 µg/ml) can be seen 
in figure 6.5. Adiponectin was pro-inflammatory in a concentration dependent 
manner. The mild/moderate cohort had a lower baseline response to LPS compared 
to the severe and healthy cohorts (4455 [791] compared to 5089 [3865] and 6460  
[3291] respectively, p=0.74) although this was not statistically significant.  
 A similar pattern was seen when the cohort was subdivided into healthy, 
mild/moderate and severe asthma groups (figure 6.5, panels B, C and D). 
Concentrations of adiponectin including and above 10 ng/ml led to a greater release 














Figure 6.5: Release of CXCL8 as a function of concentration of adiponectin in 
the presence or absence of LPS. Healthy (n=4), Mild/Moderate asthma (n=4), 
Severe asthma (n=10). PBMCs treated with adiponectin (100 pg/ml to 10 µg/ml) for 
18 hours prior to stimulation with LPS (0.5 ng/ml) for 20 hours in (A), the overall 







B C D 
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6.3.10 Prokaryote versus eukaryote derived adiponectin  
A comparison between the effects of prokaryote derived adiponectin 
(Escherichia coli; E. coli) and eukaryote derived adiponectin (human embryonic 
kidney; HEK) in terms of CXCL8 release is presented in figure 6.6. Both samples of 
adiponectin were pro-inflammatory in a concentration-dependent manner with no 
significant difference noted at adiponectin concentrations of 100 pg/ml to 10 µg/ml. 
Similar response in terms of CXCL8 release was noted in PBMCs pre-treated with 
adiponectin prior to LPS stimulation. No significant differences were seen for the 
















Figure 6.6: Prokaryote (E.Coli) and eukaryote (HEK) derived adiponectin. 
Healthy (n=3). PBMCs treated with (A) adiponectin (100 pg/ml to 10 µg/ml) for 18 
hours, (B) adiponectin prior to stimulation with LPS (0.5 ng/ml) for 20 hours, (C) 
adiponectin and Dex (10-6 M), or (D) adiponectin, Dex (10-6 M) and LPS (0.5 ng/ml). 






6.3.11 Adiponectin: time course 
A time course using 100 ng/ml of adiponectin or 0.5 ng/ml LPS and in 
combination can be seen in figure 6.9. PBMCs were left for between 0.5 and 40 
hours prior to the collection of supernatant and measurement of CXCL8. Adiponectin 
and LPS induced a similar response of CXCL8 release over the 40 hour time course. 
There is a time-dependent increase in CXCL8 release from PBMCs reaching 
significance at 4 hours post stimulation with maximal response achieved at 16 hours 
for all combinations of stimuli. This was maintained over 40 hours and adiponectin 
did not attenuate LPS induced CXCL8 release. From these data, a 20 hour time 
course was chosen for subsequent studies to analyse the effects of these 












                                                 
 
 
Figure 6.7: Adiponectin time course. 
Severe asthmatics (n=4). PBMCs treated with adiponectin (red bar; 100 ng/ml), LPS 
(blue bar; 0.5 ng/ml) or both in combination (orange bar) for 0.5 to 40 hours prior to 
collection of supernatant. CXCL8 release was measured by ELISA. Data represent 







6.3.12 Effect of adiponectin on PBMC viability 
 To establish whether adiponectin alters PBMC viability; cells were pre-treated 
with increasing concentrations of adiponectin, LPS (0.5 ng/ml), Dex (10-6 M) or all in 
combination for 20 hours prior to the MTT assay. Adiponectin did not significantly 
influence the MTT signal, in isolation or in combination with Dex (10-6 M), LPS or 


















Figure 6.8: Adiponectin MTT assay. PBMCs treated with (A) adiponectin (100 
pg/ml to 10µg/ml), (B) adiponectin and LPS (0.5 ng/ml), (C) adiponectin and Dex (10-
6 M), or (D) a combination of adiponectin, LPS (0.5 ng/ml) and Dex (10-6 M) for 20 
hours prior to collection of supernatant. CXCL8 release was measured by ELISA. 








6.3.13 Effect of adiponectin on CXCL8 release from PBMCs 
 Adiponectin induced a similar amount of CXCL8 release from PBMCs taken 
from healthy subjects, mild/moderate and severe asthmatics (8736 [SD 9134], 8673 
[9763] and 9088 [5843] respectively, p=0.72). The mild/moderate cohort exhibited 
greater suppression of CXCL8 release compared to the healthy and severe asthma 
groups for Dex concentrations of 10-7 M (780.7 [SD 225] compared to 2327 [1450] 
and 4188 [4166] respectively, p=0.054) and 10-6 M. (1184 [1102] compared to 5993 
[1807] and 4008 [1071], p=0.094) (figure 6.9). 
 The pre-treatment of PBMCs with adiponectin did not significantly alter 
CXCL8 release following stimulation with LPS or the response to increasing 
















Figure 6.9: Effect of adiponectin, LPS, Dexamethasone, or in combination on 
CXCL8 release from PBMCs. Healthy (n=11), Mild/Moderate asthma (n=12), 
Severe asthma (n=14). PBMCs treated with (A) adiponectin (100 ng/ml) ± Dex (10-10 
to 10-6 M) for 21 hours, (B) adiponectin (100 ng/ml) ± Dex (10-10 to 10-6 M) for 1 hour 
and stimulated with LPS (0.5 ng/ml) for 20 hours, (C) Dex (10-10 to 10-6 M) for 1 hour 
and stimulated with LPS for 20 hours. CXCL8 release was measured by ELISA. Data 
represent mean ± SEM. *** p<0.0001 for APN vs. UN; # p<0.05, ## p<0.01, ### 














6.3.14 Effect of adiponectin on CXCL8 release from PBMCs according to BMI.  
Data displayed in figure 6.9 was then subdivided for each cohort by BMI, 
separating subjects into two groups: obese with a BMI ≥ 30 and a normal BMI ≤ 25 
(figure 6.10). No significant difference was seen in terms of CXCL8 release 



















Figure 6.10: Effect of adiponectin, LPS, Dexamethasone, or in combination on 
CXCL8 release from PBMCs according to BMI. BMI ≥30: Healthy (n=5), Mild/Mod 
(n=6), Severe (n=6); BMI <25: Healthy (n=6), Mild/Mod (n=6), Severe (n=8). PBMCs 
treated with (A) adiponectin (100 ng/ml) with/without Dex (10-10 to 10-6 M) for 21 
hours, (B) Dex (10-10 to 10-6 M) for 1 hour and stimulated with LPS (0.5 ng/ml) for 20 
hours, (C) adiponectin (100 ng/ml) with/without Dex (10-10 to 10-6 M) for 1 hour and 







6.3.15 Suppressive effect of dexamethasone on CXCL8 release in PBMCs pre-
treated with adiponectin and/or LPS.  
Normalised data can be seen for adiponectin, adiponectin/LPS and LPS alone 
for each cohort (figure 6.11).  
The severe cohort (figure 6.11, panel C) exhibits a similar inhibition of CXCL8 
with increasing concentrations of Dex (10-10 to 10-6 M) for PBMCs treated with APN, 
APN/LPS and LPS alone. Approximately 50% suppression was seen at a 
concentration of 10-6 M. Although the inhibition curve for LPS alone was similar in all 
three cohorts (figure 6.13, panel B), differences were seen with adiponectin alone 
(figure 6.13, panel A) and in combination with LPS (figure 6.13, panel C) between 
the groups. Both the healthy and mild/moderate cohort exhibited a greater % 
suppression of CXCL8 for Dex at all concentrations but significantly different from  
10-10 to 10-6 M for APN and APN/LPS and from 10-8 to 10-6 M for LPS alone (figure 
6.11). At Dex concentrations 10-7 and 10-6 M there was an approximate 85% 
suppression of CXCL8 release. APN and LPS in combination appeared to increase 
the inhibition of CXCL8 at Dex concentrations of 10-9 to 10-7 M in the healthy and 
mild/moderate cohorts; although this did not achieve statistical significance.  
Whilst the severe cohort did not exhibit a difference between the treatments, 
the healthy and mild/moderate cohorts revealed greater Dex-induced suppression of 
CXCL8 release in PBMCs stimulated with APN compared to APN/LPS and LPS 
alone. The asthmatic cohorts did not exhibit significant differences comparing 
stimulation with LPS and APN/LPS. However, significant differences were seen in 
the healthy cohort at Dex (10-8 M) (mean 29.3% suppression versus 36% 
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respectively, p=0.0029), Dex (10-7 M) (46.3% versus 59.4%, p=0.0014) and Dex (10-6 
M) (49.9% versus 61.4%, p=0.003). 
Figure 6.12 displays the same data as figure 6.11 but divided by BMI into 
subjects with a BMI ≥ 30 and classified as obese and those with a normal BMI < 25. 


















Figure 6.11: Suppressive effect of dexamethasone on CXCL8 release in PBMCs 
of healthy subjects, mild/moderate and severe asthmatics. (A) Healthy (n=10), 
(B) Mild/Mod (n=12), (C) Severe (n=14). PBMCs treated with adiponectin (100 ng/ml) 
with/without Dex (10-10 to 10-6 M) for 2 hours prior to stimulation with LPS (0.5 ng/ml) 
for 20 hours. CXCL8 release was measured by ELISA. Data represent mean ± SEM. 































Figure 6.12: Effect of adiponectin, LPS, Dexamethasone, or in combination on 
CXCL8 release from PBMCs according to BMI. BMI ≥30: Healthy (n=5), Mild/Mod (n=6), 
Severe (n=6); BMI <25: Healthy (n=6), Mild/Mod (n=6), Severe (n=8). PBMCs treated with 
(A) adiponectin (100 ng/ml) with/without Dex (10-10 to 10-6 M) for 21 hours, (B) Dex (10-10 
to 10-6 M) for 1 hour and stimulated with LPS (0.5 ng/ml) for 20 hours, (C) adiponectin (100 
ng/ml) with/without Dex (10-10 to 10-6 M) for 1 hour and stimulated with LPS (0.5 ng/ml) for 






6.3.16 Suppressive effect of dexamethasone on CXCL8 release in PBMCs pre-
treated with adiponectin. 
 Figure 6.13 shows the same data represented in figure 6.11 but by treatment 
(adiponectin, adiponectin/LPS or LPS alone) allowing comparisons to be made 
between cohorts. No significant differences were seen in CXCL8 release in response 
to stimulation with LPS or with adiponectin and LPS in combination. However, in the 
latter there appears to be a difference with the severe group less responsive to 
suppression of CXCL8 by Dex.  
PBMCs treated with adiponectin alone were less responsive to Dex-induced 
suppression of CXCL8 release in the severe cohort with significant differences when 
compared to the mild/moderate and healthy cohorts at concentrations of 10-6, 10-7 












Figure 6.13: Suppressive effect of dexamethasone on CXCL8 release in PBMCs 
pre-treated with adiponectin, LPS, Dexamethasone, or in combination. Healthy 
(n=10), Mild/Mod (n=12), Severe (n=14). PBMCs treated with (A) adiponectin (100 
ng/ml) with/without Dex (10-10 to 10-6 M) for 21 hours, (B) Dex (10-10 to 10-6 M) for 1 
hour and stimulated with LPS (0.5 ng/ml) for 20 hours, (C) adiponectin (100 ng/ml) 
with/without Dex (10-10 to 10-6 M) for 1 hour and stimulated with LPS (0.5 ng/ml) for 20 
hours. CXCL8 release was measured by ELISA. Data represent mean ± SEM. * p<0.05, 
**p<0.01, *** p<0.0001 severe vs. mild/moderate and healthy cohort. 
A B 
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6.3.17 Effect of PI3K, JNK, ERK and p38 MAPK inhibitor on CXCL8 release 
from PBMCs treated with adiponectin.  
To investigate the cellular pathways involved in the action of adiponectin, 
PBMCs were pre-treated with PI3K, JNK, ERK and p38 MAPK inhibitors for 2 hours 
prior to the addition of adiponectin (figure 6.14).  
Adiponectin induced CXCL8 release from PBMCs was inhibited with GW-
856553 (a selective p38α/β inhibitor), with maximal suppression by 94% at 10-6 M 
(p<0.0001). U10126 (an inhibitor of MEK1/2-mediated ERK1/2 phosphorylation) 
inhibited CXCL8 release with 63% suppression at 10-6 M (p=0.0007). SP600125 (a 
JNK inhibitor that competes with ATP to inhibit the phosphorylation of c-Jun) and 
wortmannin (a PI3K inhibitor) did not affect CXLC8 release at concentrations up to 
10-6 M. 45% suppression was seen at 10-5 M for wortmannin PI3K (p=0.0009); 













Figure 6.14: Effect of PI3K, JNK, ERK and p38 MAPK inhibitor on CXCL8 
release from PBMCs treated with adiponectin. PI3K (green) n= 13; JNK (purple) 
n= 5; ERK (blue) n=5; p38 (red) n= 12. Cells were pre-treated with increasing 
concentrations (10-5 to 10-8 M) of the various inhibitors: GW-856553, U10126, 
SP600125 or PI3K wortmannin for 2 hours prior to treatment with adiponectin (100 
ng/ml) for 20 hours. CXCL8 release was measured by ELISA. Data represent mean 









Leptin and resistin were pro-inflammatory, in terms of CXCL8 release from 
PBMCs taken from healthy subjects, mild/moderate and severe asthma when used 
at a concentration of 1 µg/ml. However, no significant effects were seen in terms of 
LPS induced CXCL8 release or corticosteroid sensitivity. Adiponectin exhibited a 
pro-inflammatory effect at a concentration of 100 ng/ml and adiponectin-treated 
PBMCs taken from severe asthmatics were less responsive to steroid mediated 
suppression, suggesting a pro-inflammatory effect in this group. These findings 
follow the hypothesis that adipokines modulate inflammatory cytokine release and, in 
the case of adiponectin, they augment corticosteroid sensitivity. 
The severe asthmatics in this study were predominantly female (71%) and 
46% had a BMI in the obese range (median BMI 34.4). The majority were atopic and 
just over half reported GORD. This compares to other large cohorts of severe 
asthma such as TENOR (The Epidemiology and Natural History of Severe Asthma: 
Outcomes and Treatment Regimes), where the adult mean BMI was 30.4 and 71.2% 
were female, and SARP (Severe Asthma Research Program) where 41% of severe 
asthmatics had GORD (Moore et al., 2007). The majority of both asthmatic cohorts 
(84.2% in the mild/moderate and 71.4% in the severe cohort) were atopic which also 
compares well with SARP (81% - mild, 85% - moderate, 71% - severe). Just over 
30% of the healthy population were atopic which is similar to figures of about 33% 
seen in previous studies of healthy cohorts (Strachan et al., 1997).  
Leptin is pro-inflammatory and serum levels are positively correlated with 
obesity. It has been shown to cause AHR in mice (Shore et al., 2005) and induces 
phosphorylation of ERK-1, ERK-2 (Martin-Romero and Sanchez-Margalet, 2001) and 
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p38 MAPK in human PBMCs (Procaccini et al., 2009). In this study, leptin induced 
CXCL8 release only at the highest concentration of 1 µg/ml. This is in excess of the 
upper limit of physiological levels seen in humans (usually below 10 ng/ml and rising 
to between 10 ng/ml and 60 ng/ml in the obese state) (Licinio et al., 1997). Local 
leptin concentrations in vivo are unknown and the pro-inflammatory effect seen at 1 
µg/ml may reflect the high concentration exposure or potentially off target effects. No 
significant effects of leptin on LPS induced CXCL8 release or on steroid sensitivity 
were seen in this study. Other studies have noted pro-inflammatory effects of leptin. 
Faggioni et al found that LPS induced leptin induction, dependent of IL-1β, in mice 
(Faggioni et al., 1998). Shen et al found that leptin enhanced TNF-α production, with 
a concentration dependent increase in MAPK activity, in LPS stimulated Kupffer cells 
(Shen et al., 2005, Faggioni et al., 2000). Martín-Romero and Sánchez-Margalet 
found that PBMCs incubated with leptin activated PI3K and MAPK (Martin-Romero 
and Sanchez-Margalet, 2001) and Procaccini et al. noted sustained phosphorylated 
of p38 MAPK in PBMCs pre-treated with leptin (Procaccini et al., 2009). 
Furthermore, leptin has been shown to have a stimulatory effect on human 
circulating monocytes, inducing TNF-α and IL-6 production (Santos-Alvarez et al., 
1999). In subsequent studies, the same authors noted that PBMCs taken from 
patients with HIV displayed increased leptin receptor expression, suggesting a role 
of leptin in the immune response (Sanchez-Margalet et al., 2002).  
Resistin is also positively correlated with obesity (Al-Suhaimi and Shehzad, 
2013) and regarded as pro-inflammatory. I found that resistin was pro-inflammatory 
in all three cohorts at the highest concentration of 1 µg/ml and in the severe asthma 
and healthy cohorts for the second highest concentration of 100 ng/ml. These are 
both well above the normal physiological levels in serum of between 7 and 22 ng/ml 
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(Fadda et al., 2013). Previous studies have shown that resistin induces the secretion 
of TNF-α and IL-12 from macrophages through NFκB and MAPK via TLR4 (Silswal 
et al., 2005). There is a paucity of data regarding the cellular action in asthma and 
the majority of previous studies looking at resistin and asthma have focused on 
serum levels and disease, disease severity or response to corticosteroids. Whilst 
some studies have noted that low serum levels are predictive of developing asthma 
(Kim et al., 2008), others noted higher levels correlate to disease severity (Larochelle 
et al., 2007) and may even predict a good anti-inflammatory response to 
corticosteroid therapy (Leivo-Korpela et al., 2011). Although this study did not find 
that resistin influenced the inhibitory action of Dex, only CXCL8 release was 
analysed. Furthermore, other cell types such as AMs may be more representative. 
There are a number of limitations and considerations with both the leptin and 
resistin work. Only CXCL8 was assessed for both these cytokines and further work 
looking at a combination of cytokines may explore their inflammatory action on 
PBMCs in greater detail. The use of Western blotting to evaluate protein expression 
would also be useful to explore the effects of these cytokines on PBMCs. This study 
did not show a significant difference in CXCL8 levels for leptin and resistin when 
subdividing for obesity. This may reflect the low numbers available for comparison.  
Adiponectin is an abundant serum protein, accounting for 0.01% of total 
plasma proteins, and is generally viewed as an anti-inflammatory cytokine (Hu et al., 
1996). However, this study has found a pro-inflammatory effect in terms of CXCL8 
release from PBMCs. Adiponectin induced CXCL8 release from PBMCs at a 
concentration of 100 ng/ml. This is below the physiological levels of adiponectin seen 
in vivo of between 3 and 30 µg/ml (Folco et al., 2009).   
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The pro-inflammatory effects of adiponectin seen are likely to reflect a 
combination of factors. The predominant APN receptors found in PBMCs are 
adipoR1 and adipoR2. Other in vitro studies have noted that adiponectin induces IL-
6 and CXCL8 from hepatocytes (Suzuki et al., 2011); via ERK1/ERK2, p38 MAPK, 
NF-κB and STAT3 signalling pathways (Kuerschner et al., 2008).  
Adiponectin has been shown to be raised in some disease states such as 
rheumatoid arthritis, SLE, type 1 diabetes and inflammatory bowel disease; 
suggesting a potential pro-inflammatory role (Fantuzzi, 2008). In addition, previous 
studies have shown that adiponectin induces CXCL8 release from human 
chondrocytes (Gomez et al., 2011), human placenta and adipose tissue (Lappas et 
al., 2005) and induces TNF-α and IL-6 release from primary human peripheral 
macrophages (Tsatsanis et al., 2005). 
In addition, some studies have suggested that it is the length of time that cells 
are exposed to adiponectin that alters the cellular response. Cheng and colleagues 
noted that adiponectin induced a pro-inflammatory action in macrophages that 
preceded or mediated tolerance to further pro-inflammatory stimuli through 
mechanisms that remain unclear (Cheng et al., 2012). Tsatsanis and colleagues 
demonstrated that although globular adiponectin induced TNF-α and IL-6 release 
from primary human peripheral macrophages, their pre-treatment with low 
concentration of adiponectin for 24 hours prior to re-stimulation led to tolerance and 
suppression of TNF-α and IL-6 release (Tsatsanis et al., 2005). These studies 
suggest that short term in vitro experiments, such as those in this study, involving 
acute exposure to adiponectin are not representative of the chronic exposure 
encountered in vivo. Furthermore, the adiponectin used in this work is prokaryote 
derived and predominantly globular which has been suggested to be more 
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biologically active and pro-inflammatory than the other adiponectin isoforms 
(Richards et al., 2006).  
Adiponectin treated PBMCs taken from severe asthmatics were less 
responsive to steroid suppression, suggesting an exaggerated pro-inflammatory 
effect in this group. In contrast, PBMCs treated with adiponectin and LPS exhibited 
greater suppression of CXCL8 compared to LPS alone for Dex (10-8 to 10-6 M) in the 
healthy cohort. This suggests that APN potentiated the steroid response; a 
phenomenon not seen in the asthmatic groups. The reasons for this difference are 
not clear but may represent an anti-inflammatory action of adiponectin in the healthy 
population that is not present in asthma or diminishes with increasing disease 
severity. This is in contrast to population studies looking at circulating or lung levels 
of adiponectin and clinical disease outcome (Sood and Shore, 2013). 
This study did not find any significant difference in Dex suppression of LPS 
induced CXCL8 release between the cohorts. This is in contrast to a previous study 
which found PBMCs taken from patients with severe asthma exhibited diminished 
corticosteroid sensitivity when compared to non-severe asthma (Hew et al., 2006).  
Furthermore, I did not see a difference in the effect of adiponectin on CXCL8 
release from PBMCs when subdividing by BMI (comparing normal, BMI <25 with 
obesity BMI ≥30). This is surprising given that adiponectin levels negatively correlate 
with increasing adiposity and is in contrast to previous studies which have noted 
corticosteroid insensitivity in obesity-associated asthma. This stems from the post-
hoc analysis of clinical trial data, which have associated increasing BMI with a 
reduced response to ICS (Peters-Golden et al., 2006, Sutherland et al., 2008a, 
Boulet and Franssen, 2007) and by an in-vitro study on PBMCs, which found 
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overweight and obese asthmatics exhibited a reduced response to corticosteroids 
(Sutherland et al., 2008a).  
The pre-treatment of PBMCs with p38 MAPK and ERK inhibitors markedly 
attenuated adiponectin induced CXLC8 release indicating the involvement of these 
pathways. Previous studies looking at human chondrocytes found that p38 MAPK 
and ERK1/2 inhibition attenuated inflammatory pathways in terms of MMP-3 release 
and phosphorylation of AMPK (Tong et al., 2011, Kang et al., 2010). Other studies 
have noted that p38 MAPK and ERK1/2 are key signalling pathways involved in 
adiponectin induced inflammation in human placenta, adipose tissue (Lappas et al., 
2005), T cells (Cheng et al., 2012) and human phagocytes (Chedid et al., 2012). 
There are some important limitations and considerations relating to this study. 
Adiponectin is present in different oligomeric complexes that are likely to impact on 
its function. Different isoforms exert different effects and it may in fact be their 
relative proportions or ratio that influences the inflammatory response (Pajvani et al., 
2004). The adiponectin used in this study is fAPN, known as monomeric adiponectin. 
Although present in vivo, this is not representative of physiological adiponectin which 
contains a mix of the different adiponectin isoforms. The monomeric form has been 
reported as being more biologically active compared to other isoforms (Nishida et al., 
2007). Repeating this work using a physiological mix of adiponectin would allow for 
these differences and potentially be more representative.  
The derivation and manufacturing method of globular adiponectin may also 
play an important role in inflammatory activity. There are two commercially available 
sources of adiponectin; eukaryote or prokaryote derived. In the latter, E.coli inclusion 
bodies are used in the process and therefore there is the possibility of LPS 
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contamination. In addition, eukaryote derived adiponectin appears to be able to form 
HMW complexes whilst its prokaryote counterpart has inadequate folding of the 
collagen-like domain, meaning it tends to be in globular, trimeric or hexameric forms 
(Richards et al., 2006). This is a particularly significant factor given that different 
isoforms of adiponectin appear to have differing inflammatory actions. This study has 
compared HEK versus E.coli derived adiponectin (figure 6.6) and found no 
significant difference in terms of CXCL8 release in the presence of dexamethasone 
and stimulated with LPS. However, this was only with three matched subjects and 
only looked the release of one cytokine. Repeating this with additional cytokines and 
in a higher number of subjects would be useful to address this point. 
Serum adiponectin levels were not assessed in this study. Serum levels at the 
time blood was taken from subjects could have been correlated with the cellular 
outcome and in addition, serum adiponectin displays diurnal variation and tolerance. 
However, blood for this study was taken at similar times in the morning. Repeating 
the study with measurement of serum adiponectin levels at the same time as PBMC 
extraction would allow greater interpretation of the role of adiponectin in asthma. 
The adipokines assessed did not augment LPS-induced CXCL8 release from 
PBMCs. LPS is ubiquitous in the environment, is a potent inflammatory stimulant, 
can induce airway inflammation and exacerbate allergic responses – factors which 
led to LPS being chosen as a positive control for this study. The fact that all three 
adipokines were pro-inflammatory in terms of CXCL8 release from PBMCs meant 
that the inclusion of LPS in these experiments became largely redundant.  
Finally, PBMCs were used for this study and they may not be representative 
of the effects of adiponectin in asthma. Repeating this work using AMs, ASMCs and 
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bronchial epithelial cells would provide greater insight into the effects of adiponectin 
in asthma.  
In summary, leptin and resistin were pro-inflammatory at the highest 
concentration tested which is supraphysiological. Adiponectin was pro-inflammatory 
at a concentration below physiological concentrations and adiponectin treated 
PBMCs taken from severe asthmatics exhibited an attenuated corticosteroid 
response in terms of CXCL8 release compared to mild/moderate asthmatics and 
healthy subjects. However, no correlations were seen in relation to BMI. Adiponectin 
augments the steroid response of PBMCs taken from healthy subjects in cells 
stimulated with LPS. Further investigation is required to establish the mechanism of 
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Chapter 7: The effect of adiponectin on PBMCs: inflammatory response and 
corticosteroid insensitivity in severe asthma 
Hypothesis and aim 
 Adiponectin modulates inflammatory cytokine release and corticosteroid 
insensitivity in severe asthma. I will examine the role of adiponectin in obesity-related 
severe asthma through in vitro experiments involving peripheral blood mononuclear 
cell taken from asthmatics and healthy controls. The aims are to study the effect of 
adiponectin on PBMCs in terms of inflammatory response, corticosteroid insensitivity 
and their relationship with BMI. 
7.1 Introduction 
In general, adiponectin is viewed as an anti-inflammatory cytokine that is 
predominantly produced by adipocytes and is negatively correlated with obesity. 
Previous studies have shown that it exerts an anti-inflammatory action by inducing 
IL-10 and IL-1RA release and by decreasing the release of pro-inflammatory 
cytokines such as IL-6, IFN- γ and TNF-α (Wolf et al., 2004, Folco et al., 2009, 
Tsatsanis et al., 2005). MDMs pre-treated with adiponectin exhibit increased IL-10 
expression (Kumada et al., 2004) and adiponectin inhibits macrophage TNF-α and 
IL-6 mediated inflammation (Folco et al., 2009). In contrast, adiponectin has been 
shown to induce IL-1β, IL-6 and TNF-α release from human placenta and adipose 
tissue (Lappas et al., 2005). Furthermore, the pre-treatment of primary human 
macrophages induces the release of TNF-α and IL-6 (Lappas et al., 2005). 
Adiponectin has been discussed in Chapter 1 and the Introduction to Chapter 
6. This study is a continuation from Chapter 6 and uses the same patient cohort and 
samples. Although adiponectin is largely viewed as anti-inflammatory, results from 
Chapter 6 showed a pro-inflammatory effect, in terms of CXCL8 release from 
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PBMCs. In view of this and with the aim of clarifying whether adiponectin is 
beneficial in asthma, this study sets out to look at seven more cytokines (IL-6, IFN-γ, 
IL-10, IL-1RA, CCL2, CCL3 and TNF-α). These cytokines were chosen in view of the 
known cellular effects of adiponectin (figure 1.6). Adiponectin interacts with 
monocyte AdipoR1 and AdipoR2 receptors resulting in the suppression of IL-6, IFN-
γ, CCL2, CCL3 (Neumeier et al., 2011) and TNF-α, whilst increasing the production 
of IL-10 and IL-1RA (Wolf et al., 2004).  
IL-6 was measured in all of the original samples used for CXCL8 analysis and 
the remaining cytokines were measured using a multiplex assay. Two Dex 
concentrations (10-7 and 10-8 M) were chosen to look at steroid response for use with 
the multiplex assay.  
LPS was used to stimulate PBMCs for each cytokine assessed both in 
isolation and in combination with adiponectin. LPS is present within the cell wall of 
Gram-negative bacteria and acts as a strong stimulator of the innate immune 
reponse. It is known to activate monocytes via TLR4 resulting in the release of 
inflammatory cytokines. Our study group has previously used LPS to investigate 
relative corticosteroid insensitivity in asthma (Hew et al., 2006, Bhavsar et al., 2008). 
The use of LPS enabled a baseline response to be measured and comparison to the 









To examine the effects of adiponectin on cytokine release from PBMCs and 
the interaction of LPS, cells were pre-treated with adiponectin with/without Dex 10-7 
and 10-8 M for one hour prior to stimulation with LPS (10 ng/ml) and supernatant 
collected after 20 hours. A multiplex cytokine assay was used to assess the 
concentrations of six different cytokines. IL-6 was measured in all original samples 
using a DuoSet ELISA kit (R & D Systems, Abingdon, UK) according to the 



















Baseline data of patients can be seen in table 7.1. Similar demographics were 
seen in the subgroup of patients taken from all recruited subjects compared to the 
overall cohort (table 6.1). Significant differences were noted in terms of asthma 
medication requirements, lung function, and asthma symptoms in the severe asthma 
compared to the mild to moderate cohort. A more detailed description can be found 















Table 7.1 : Demographics for subjects recruited for adiponectin studies. 
          
       Healthy subjects Mild/mod asthma Severe asthma P value 
N 11 12 14   
     
     
Age (yrs) 43 (36 – 48) 51 (35.5 – 58.8) 56 (45 – 61) 0.14 
M/F 5/6 4/8 3/11 0.44 
Smoking History     
  Never 9 12 12 0.32 
  Ex 2 0 2  
Height 172.0 (155 - 180) 169 (161.5 - 175.3) 164.5 (160 - 169.8) 1 
Weight 70.5 (61.1 - 87.5) 77.0 (60.0 - 88.8) 66.5 (61.9 - 94.1) 0.41 
BMI 25.3 (20.5 - 32.5) 26.6 (21.9 - 30.5) 24.5 (22.5 - 35.4) 0.79 
BEI fat % 25.4 (13 - 40.2) 31.6 (23.8 - 38.7) 37.7 (27.2 - 46.6) 0.14 
Skin fold fat % 35.0 (28.5 - 39.3) 33.4 (29 - 37.1) 35.9 (25.7 - 40.9) 0.78 
waist/hip ratio 0.88 (0.79 - 0.96) 0.84 (0.75 - 0.98) 0.91 (0.84 - 0.96) 0.45 
     
BDP equiv dose (µg) 0 400 (250 - 700) 2400 (2000 - 2800) <0.0001 
Oral corticosteroid (%) 0 0 5 (35.7) 0.0087 
OCS dose (mg) 0 0 14.5  
Aminophylline (%) 0 0 7 (50) 0.0008 
LTRA (%) 0 1 (8.3) 7 (50) 0.0042 
FEV1 (l) 3.3 (2.3 - 4.2) 2.3 (1.7 - 2.9) 1.5 (1.1 - 1.8) 0.0001 
FEV1 % 100.5 (95.9 - 107.5) 82.1 (71.6 - 88.3) 61.4 (40.1 - 72.2) <0.0001 
FVC 4.1 (2.7 - 5.3) 3.6 (2.6 - 4.1) 2.6 (2.1 -3.3) 0.005 
FVC % 13.5 (97.7 - 107.1) 98.9 (90.2 - 109.9) 79.1 (64.3 - 88.1) 0.0024 
FEV1/FVC % 82.8 (78.3 - 85.5) 70.6 (64.0 - 73.5) 59.4 (49.2 - 70.1) <0.0001 
BDR (n) 1 (-2 - 4.0) 15.3 (9.9 - 19.1) 19.6 (12.2 - 27.7) <0.0001 
PC20 (n) >16 0.9 (0.2 - 1.9) *  
Atopic (n, %) * 3 (27.3) 11 (91.7) 10 (71.4) 0.0044 
IgE kU/l 64 (25.5 - 376) 316.5 (162.5 - 399.5) 94.5 (65.5 - 532.3) 0.23 
Eos 0.25 (0.1 – 0.33) 0.3 (0.2 – 0.4) 0.2 (0.1- 0.43) 0.38 
History of GORD (n, %) 0 2 (16.7) 10 (71.4) 0.0003 
PPI (n, %) 0 2 (16.7) 6 (42.9) 0.031 
     
ACQ  8.5 (4 – 10) 14 (10.5 – 21.5) 0.038 
AQLQ      
  Activities  6.3 (6 – 6.6) 4.8 (3.8 – 6.3) 0.056 
  Symptoms  5.8 (5.6 – 6.3) 4.5 (3.8 – 6.1) 0.029 
  Emotional  6.4 (5.2 – 6.6) 5.4 (4.90 – 6.6) 0.15 
  Environmental  6 (5.5 – 6.5) 5.3 (4.4 – 6.4) 0.15 
  Total  6.1 (5.9 – 6.3) 4.7 (4.4 – 6.3) 0.091 
          
     Data are presented as mean ± SD or median (IQR). Between group comparisons for continuous variables were made using 
Kruskal-Wallis test and for categorical variables using χ2 exact testing. 
 
BMI, body mass index   BEI, bioelectrical impedance  BDP, beclomethasone dipropionate   LTRA, leukotriene receptor 
antagonist   FEV1, forced expiratory volume in 1 second   FVC, forced vital capacity  IgE, immunoglobulin E   GORD, gastro-
oesophageal reflux disease   PPI, proton pump inhibitor   ACQ, asthma control questionnaire   AQLQ, asthma quality of life 
questionnaire.   
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7.3.2 Effect of adiponectin on IL-6 release from PBMCs 
 Similar amounts of IL-6 release were seen in all three cohorts from untreated 
PBMCs (7.6 pg/ml [6.3], 8.9 [5.7], 8.5 [4.7]) for healthy, mild/moderate and severe 
asthmatic cohorts, respectively, p=0.89). LPS induced a lower but non statistically 
significant amount of IL-6 release in the mild/moderate cohort (9676 [3923]) 
compared to the healthy and severe asthma cohorts (14893 [9494] and 12358 
[7628], p=0.37). Adiponectin appeared to induce a higher amount of IL-6 release 
from PBMCs taken from severe asthmatics (2883 [2896]) compared to the 
mild/moderate asthmatic and healthy cohorts (1245 [1050] and 1027 [680]). 
However, this did not achieve statistical significance (p=0.49).  
All cohorts exhibited Dex-induced suppression of IL-6 release in a 
concentration-dependent manner (figure 7.1). Significant decreases were seen at 
Dex 10-7 and 10-6 M. The pre-treatment of PBMCs with adiponectin did not 
significantly change IL-6 release following stimulation with LPS or the response to 












Figure 7.1: Effect of adiponectin, LPS, Dexamethasone, or in combination on 
IL-6 release from PBMCs. Healthy (n=11), Mild/Moderate asthma (n=12), Severe 
asthma (n=14). PBMCs treated with (A) adiponectin (100 ng/ml) with/without Dex 
(10-10 to 10-6 M) for 21 hours, (B) adiponectin (100 ng/ml) with/without Dex (10-10 to 
10-6 M) for 1 hour and stimulated with LPS for 20 hours, (C) Dex (10-10 to 10-6 M) for 
1 hour and stimulated with LPS for 20 hours. CXCL8 release was measured by 
ELISA. Data represent mean ± SEM. *** p<0.0001 vs control for APN vs UN; # 

















7.3.3 Suppressive effect of dexamethasone on IL-6 release in PBMCs pre-
treated with adiponectin and/or LPS  
Normalised data can be seen for adiponectin, adiponectin/LPS and LPS alone 
for each cohort in figure 7.2. Figure 7.3 displays the same data but grouping the 
treatments by cohort to allow direct comparison. 
All the cohorts exhibited similar patterns of IL-6 inhibition with increasing 
concentrations of Dex 10-10 to 10-6 M for PBMCs treated with adiponectin, 
adiponectin/LPS and LPS alone. For the adiponectin treated PBMCs approximately 
80% and 85% inhibition was seen at a concentration of Dex 10-7 and 10-6 M 
respectively (p<0.0001). However, only the mild/moderate cohort exhibited a 
significant inhibition in IL-6 release at dexamethasone 10-8 M (p<0.001).  No 
significant differences were seen comparing treatment types by cohort. Similar levels 
of Dex-induced inhibition of IL-6 release were seen in both the adiponectin/LPS and 
LPS alone groups with approximately 40% suppression at dexamethasone 10-7 M 
and 50% at 10-6 M. A significant difference in inhibition of IL-6 release was noted 
comparing LPS versus APN/LPS-stimulated PBMCs for Dex 10-8 M in the 
mild/moderate cohort (p=0.012) with the addition of adiponectin resulting in greater 
inhibition (99% of control versus 72% respectively). This difference was not seen in 








Figure 7.2: Suppressive effect of dexamethasone on IL-6 release in PBMCs of 
healthy subjects, mild/moderate and severe asthmatics. (A) Healthy (n=9), (B) 
Mild/Mod (n=11), (C) Severe (n=13). PBMCs treated with adiponectin (100 ng/ml) 
with/without Dex (10-10 to 10-6 M) for 2 hours prior to stimulation with LPS (0.5 
ng/ml) for 20 hours. IL-6 release was measured by ELISA. Data represent mean ± 





















Figure 7.3: Suppressive effect of dexamethasone on IL-6 release in PBMCs 
pre-treated with adiponectin, LPS, Dexamethasone, or in combination. Healthy 
(n=9), Mild/Mod (n=11), Severe (n=13). PBMCs treated with (A) adiponectin (100 
ng/ml) with/without Dex (10-10 to 10-6 M) for 21 hours, (B) Dex (10-10 to 10-6 M) for 1 
hour and stimulated with LPS (0.5 ng/ml) for 20 hours, (C) adiponectin (100 ng/ml) 
with/without Dex (10-10 to 10-6 M) for 1 hour and stimulated with LPS (0.5 ng/ml) for 






7.3.4 Effect of adiponectin on LPS-induced cytokines in PBMCs  
There was less spontaneous release of IFN-γ in PBMCs from healthy subjects 
compared to both asthmatic groups (0.33 pg/ml [1.1] compared to 2.79 [2.1] for the 
mild/moderate cohort and 3.0 [1.7] for the severe cohort; p=0.0014) (figure 7.4).  
Adiponectin induced a similar amount of IFN-γ in both asthma cohorts but a 
significantly lower amount in the healthy group (0.92 pg/ml [2.0] compared to 5.0 
[1.9] for the mild/moderate and 4.9 [1.8] for the severe cohort; p=0.0009). LPS and 
APN/LPS induced significant increases in IFN-γ in all three cohorts. However, no 
significant differences were seen between the groups.  
Spontaneous release of IL-10 was lower in the healthy cohort (3.4 [1.9]) 
compared to the mild/moderate and severe asthma cohorts (4.8 [1.7] and 5.1 [1.5], 
respectively; p=0.038) (figure 7.5). LPS and APN/LPS induced significant increases 
in IL-10 in all three cohorts. However, no significant differences were seen between 
the groups. Adiponectin induced a significant increase in IL-10 release in all cohorts 
(healthy 139 [110], mild/moderate 92.8 [93] and severe 180.4 [183]; p<0.05).  
Spontaneous IL1-RA release was lower in the mild/moderate (117 [81.7]) 
versus the severe asthma and healthy cohorts (170 [108] and 188 [148] respectively) 
but this did not reach statistical significance (p=0.34) (figure 7.6). APN alone induced 
a non-significant rise in IL1-RA release whilst LPS and APN/LPS induced significant 
IL1-RA release. However, no differences were noted between groups. 
Similar spontaneous release of CCL2 was noted from untreated PBMCs taken 
from all cohorts (figure 7.7). Adiponectin, LPS and APN/LPS treatment led to 
significant increases in CCL2 release in all cohorts. LPS and Dex 10-7 M induced 
less CCL2 in the mild/moderate cohort compared to the healthy cohort (p=0.042). 
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Spontaneous CCL3 release appeared to be higher in the healthy cohort (709 
± 1541) compared to the mild/moderate and asthmatic cohorts (100 [241] and 58 
[98]) (figure 7.8) but this did not reach statistical significance (p=0.11). All three 
cohorts exhibited a similar level of CCL3 release following stimulation with LPS, 
LPS/APN or APN alone. No significant difference was seen comparing groups. 
All three cohorts exhibited a similar amount of spontaneous TNF-α release 
(healthy 17.4 pg/ml [13.0], mild/moderate 23.0 [14.6] and severe 26.0 [22.4], p=0.48) 
(figure7.9). LPS and APN/LPS induced significant increases in TNF-α release but no 
significant difference was noted comparing the cohorts. APN alone induced greater 
TNF-α from the severe (777 [699]) compared to mild/moderate asthma cohort (390 






Figure 7.4: Effect of adiponectin, LPS, dexamethasone, or in combination on 
IFN-γ release from PBMCs. Healthy (n=10), Mild/Moderate asthma (n=12), Severe asthma 
(n=13). PBMCs treated with (A) adiponectin (100 ng/ml), LPS (0.5 ng/ml) or in combination (B) 
adiponectin (100 ng/ml) with/without Dex (10-8 and 10-7 M), (C) LPS (0.5 ng/ml) with/without Dex (10-8 
and 10-7 M), (D) adiponectin (100 ng/ml) and LPS (0.5 ng/ml) with/without Dex (10-8 and 10-7 M). IFN-γ 
release was measured by multiplex assay. Data represent mean ± SEM. * p<0.05, ** p<0.01, *** 
p<0.001 comparing groups; # p<0.05, ## p<0.01, ### p<0.0001 for APN and Dex vs. APN, LPS and 
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Figure 7.5: Effect of adiponectin, LPS, dexamethasone, or in combination on 
IL-10 release from PBMCs. Healthy (n=10), Mild/Moderate asthma (n=12), Severe asthma 
(n=13). PBMCs treated with (A) adiponectin (100 ng/ml), LPS (0.5 ng/ml) or in combination (B) 
adiponectin (100 ng/ml) with/without Dex (10-8 and 10-7 M), (C) LPS (0.5 ng/ml) with/without Dex (10-8 
and 10-7 M), (D) adiponectin (100 ng/ml) and LPS (0.5 ng/ml) with/without Dex (10-8 and 10-7 M). IL-10 
release was measured by multiplex assay. Data represent mean ± SEM.  # p<0.05, ### p<0.0001 for 
















Figure 7.6: Effect of adiponectin, LPS, dexamethasone, or in combination on 
IL-1RA release from PBMCs. Healthy (n=10), Mild/Moderate asthma (n=12), Severe asthma 
(n=13). PBMCs treated with (A) adiponectin (100 ng/ml), LPS (0.5 ng/ml) or in combination (B) 
adiponectin (100 ng/ml) with/without Dex (10-8 and 10-7 M), (C) LPS (0.5 ng/ml) with/without Dex  (10-8 
and 10-7 M), (D) adiponectin (100 ng/ml) and LPS (0.5 ng/ml) with/without Dex (10-8 and 10-7 M). IL-
1RA release was measured by multiplex assay. Data represent mean ± SEM. * p<0.05 comparing 
groups; # p<0.05, ## p<0.01, ### p<0.0001 for APN and Dex vs. APN, LPS and Dex vs. LPS or LPS 





























Figure 7.7: Effect of adiponectin, LPS, dexamethasone, or in combination on 
CCL2 release from PBMCs. Healthy (n=10), Mild/Moderate asthma (n=12), Severe asthma 
(n=13). PBMCs treated with (A) adiponectin (100 ng/ml), LPS (0.5 ng/ml) or in combination (B) 
adiponectin (100 ng/ml) with/without Dex (10-8 and 10-7 M), (C) LPS (0.5 ng/ml) with/without Dex (10-8 
and 10-7 M), (D) adiponectin (100 ng/ml) and LPS (0.5 ng/ml) with/without Dex (10-8 and 10-7 M). CCL2 
release was measured by multiplex assay. Data represent mean ± SEM. * p<0.05 comparing groups; 





























Figure 7.8: Effect of adiponectin, LPS, dexamethasone, or in combination on 
CCL3 release from PBMCs. Healthy (n=10), Mild/Moderate asthma (n=12), Severe asthma 
(n=13). PBMCs treated with (A) adiponectin (100 ng/ml), LPS (0.5 ng/ml) or in combination (B) 
adiponectin (100 ng/ml) with/without Dex (10-8 and 10-7 M), (C) LPS (0.5 ng/ml) with/without Dex (10-8 
and 10-7 M), (D) adiponectin (100 ng/ml) and LPS (0.5 ng/ml) with/without Dex (10-8 and 10-7 M). CCL3 
release was measured by multiplex assay. Data represent mean ± SEM. # p<0.05, ## p<0.01, ### 

















Figure 7.9: Effect of adiponectin, LPS, dexamethasone, or in combination on 
TNF-α release from PBMCs. Healthy (n=10), Mild/Moderate asthma (n=12), Severe asthma 
(n=13). PBMCs treated with (A) adiponectin (100 ng/ml), LPS (0.5 ng/ml) or in combination (B) 
adiponectin (100 ng/ml) with/without Dex (10-8 and 10-7 M), (C) LPS (0.5 ng/ml) with/without Dex (10-8 
and 10-7 M), (D) adiponectin (100 ng/ml) and LPS (0.5 ng/ml) with/without Dex (10-8 and 10-7 M). TNF-
α release was measured by multiplex assay. Data represent mean ± SEM. # p<0.05, ### p<0.0001 

















7.3.5 Suppressive effect of dexamethasone on cytokine release induced by 
adiponectin, LPS or in combination in PBMCs.  
PBMCs from all three groups exhibited suppression of IFN-γ release in the 
presence of Dex 10-7 M and 10-8 M following stimulation with LPS with significant 
reductions in IFN-γ release were noted at 10-7 M (figure 7.4). Healthy controls 
demonstrated greater suppression of IFN-γ release at Dex 10-7 M (4.0 [0.8] versus 6 
[1.1] for mild/moderate and 5.8 [0.8] for severe; p=0.003) and 10-8 M (4.9 [1.2] versus 
7.1 [2.1] and 6.1 [2.7]; p=0.019) compared to the asthmatic cohorts. Dex 10-7 M 
caused a reduction in IFN-γ release from asthmatic PBMCs. All cohorts exhibited a 
significant reduction in IFN-γ for Dex 10-7 M in PBMCs pre-treated with LPS and 
APN. PBMCs from healthy subjects demonstrated a greater suppression of IFN-γ 
release for both Dex 10-7 M (3.3 [1.9] versus 6.3 [1.1] for mild/moderate and 6.1 [0.9] 
for severe; p=0.0002) and 10-8 M (4.5 [1.9] compared versus 7.2 [1.7] for 
mild/moderate and 7.7 [2.2] for severe; p=0.0004) compared to the asthmatic 
cohorts.  
Stimulation with APN alone induced a greater, but not statistically significant, 
release of IL-10 in healthy subjects compared to the asthmatic cohorts. The 
mild/moderate cohort exhibited a significant suppression in IL-10 release for Dex  
(10-7 M) following stimulation with APN and for 10-8 M for PBMCs stimulated with 
APN/LPS (figure 7.5).  
Significant suppression in IL-1RA release was noted in all cohorts for all 
treatments at Dex 10-7 and 10-8 M (figure 7.6). Whilst the overall appearances were 
similar for all cohorts, significant differences were noted comparing PBMCs 
stimulated with LPS at Dex 10-7 M taken from mild/moderate compared to severe
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asthmatics (63 [18.1] versus 97 [34.3]; p=0.01). Similarly, PMBCs taken from 
mild/moderate asthmatics stimulated with APN/LPS at Dex 10-8 M exhibited a 
significantly lower amount of IL-1RA release compared to the severe asthma cohort 
(104.5 [67.5] versus 154 [63.2]; p=0.05).  
CCL2 release appeared to be lower in the mild/moderate compared to the 
severe asthma and healthy cohorts following stimulation with LPS (figure 7.7). A 
statistically significant difference was noted for PBMCs pre-treated with Dex 10-7 M 
(646 [630] for the mild/moderate cohort versus 3117 [3291] for the healthy cohort; 
p=0.027). APN induced a similar amount of CCL2 in the healthy and mild/moderate 
asthma cohort (mean 1213 pg/ml and 1245 pg/ml, respectively). A higher amount 
was seen in the severe asthma cohort (1756 pg/ml) although this was not statistically 
significant. All cohorts exhibited suppression of CCL2 release at Dex 10-7 M and 
although this appeared to be greater for the mild/moderate cohort (130 [102] versus 
410 [512] for severe and 339 [322] for healthy cohorts) it did not reach statistical 
significance. CCL2 release following stimulation with APN/LPS was lower in the 
mild/moderate cohort (826 [890] compared to 1034 [1231] for the severe asthma and 
1556 [1643] for the healthy cohort). Significant differences were noted for both Dex 
concentrations at 10-7 M (791 [895] compared to 1711 [2515] severe asthma and 
2072 [2033] for the healthy cohort; p=0.048) and 10-8 M (851 [920] compared to 
1619 [2234] and 1825 [1764]; p=0.046).  
All the cohorts exhibited a significant reduction in CCL3 release in the 
presence of Dex 10-7 M following stimulation with LPS but no differences were noted 
between cohorts (figure 7.8). Stimulation with APN appeared to result in greater 
CCL3 release in the asthmatic cohorts (2251 [1685] mild/moderate and 3197 [3508] 
severe asthma) compared to the healthy group (917 [1219]), however this did not
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reach statistical significance (p=0.09). Pre-treatment with Dex 10-7 M resulted in 
significant inhibition of CCL3 release for all cohorts. Although there appeared to be 
less release in the healthy (177 [146] compared to 637 [1316] mild/moderate and 
1414 [1876] severe) compared to the asthmatic cohorts, this was not statistically 
significant.  Stimulation with APN/LPS resulted in similar levels of CCL3 release with 
all cohorts exhibiting a significant reduction when pre-treated with Dex 10-7 M. 
Stimulation with LPS and APN/LPS produced similar levels of TNF-α release 
from PBMCs in all cohorts (figure 7.9). The addition of Dex 10-7 M (all cohorts) and 
10-8 M (mild/moderate only for LPS; mild/moderate and severe cohorts for APN/LPS) 
resulted in significant decreases in TNF-α release. Stimulation with APN alone 
resulted in greater, but non significant, release of TNF-α in the severe cohort (801 
[710] compared to 390 [409] mild/moderate and 191 [128] healthy; p=0.1). Similar 
findings were noted for PBMCs pre-treated with Dex 10-7 (348 [452] compared to 
138 [320] mild/moderate and 49 [45] healthy; p=0.15) and Dex 10-8 M (551 [627] 















The original hypothesis was that adiponectin would modulate inflammatory 
cytokine release and corticosteroid insensitivity in severe asthma. I found that 
adiponectin induced IL-6, IL-10, CCL2, CCL3 and TNF-α release from PBMCs taken 
from healthy controls, mild/moderate and severe asthmatics. Baseline release of 
IFN-γ and IL-10 were significantly lower in healthy subjects compared to the 
asthmatic groups. Adiponectin induced IFN-γ, IL-1RA, CCL2, CCL3 and TNF-α 
release was suppressed by Dex. The pre-treatment with adiponectin did not affect 
LPS induced cytokine release. The results follow the hypothesis in terms of 
inflammatory cytokine release but not in terms of corticosteroid sensitivity. 
These findings are supported by previous studies. Wolf and colleagues found 
that adiponectin induced IL-10 production in primary human monocytes, MDMs and 
dendritic cells (Wolf et al., 2004). The pre-treatment of MDMs with adiponectin has 
been shown to result in significant increases in IL-10 secretion (Kumada et al., 
2004). Other studies have found that adiponectin stimulates IL-6 and TNFα release 
from human placenta (Lappas et al., 2005) and from primary human blood 
macrophages (Tsatsanis et al., 2005, Song et al., 2009). In cultured astrocytes, 
globular adiponectin induced secretion of IL-6 and CCL2 with NF-κB, p38 MAPK and 
ERK1/2 pathways playing important roles (Wan et al., 2014). 
Adiponectin induced more IFN-γ in the asthmatic cohorts compared to healthy 
controls. Previous studies have noted raised IFN-γ in asthmatics compared to 
healthy controls (ten Hacken et al., 1998). Although this study did not look at the 
mechanism of adiponectin induced IFN-γ production, results from the previous 
chapter noted that adiponectin-induced CXCL8 release was attenuated by p38 
248 
 
MAPK and ERK inhibition. Cheng and colleagues noted that inhibition of p38 MAPK 
abrogates adiponectin induced IFN-γ production (Cheng et al., 2012). 
The pro-inflammatory effects of adiponectin seen in this study follow the 
suggestion that adiponectin may behave this way in particular diseases (Fantuzzi, 
2008). In rheumatoid arthritis (Li et al., 2015), SLE (De Sanctis et al., 2009), type 1 
diabetes (Schalkwijk et al., 2006) and inflammatory bowel disease (Karmiris et al., 
2006) high levels of adiponectin and inflammation have been reported. The reasons 
behind this apparent paradox remain unclear; it is possible that circulating levels may 
not accurately reflect interstitial levels.  
Baseline release of IFN-γ and IL-10 from PBMCs was significantly lower in the 
healthy compared to the asthmatic cohorts. This is in contrast to a previous study in 
PBMCs where no significant differences were noted comparing PBMCs taken from 
healthy controls, non-severe and severe asthmatics (Hew et al., 2006). The same 
study noted that patients with severe asthma demonstrated relative corticosteroid 
insensitivity for LPS induction of IL-1β, CCL3 and borderline significance for IL-6 at 
Dex 10-6 M – findings that were not replicated in this study. These differences may 
reflect the fact that Dex 10-7 and 10-8 M were assessed in this study whereas Hew 
and colleagues used Dex at the higher concentration of 10-6 M. 
Analysis of normalised data revealed that only adiponectin induced CCL2 
release demonstrated a significant difference in terms of Dex (10-7 M) mediated 
suppression; demonstrating relative corticosteroid insensitivity in the severe 
compared to the mild/moderate asthma cohort. BALF CCL2 has been shown to 
increase following an allergen challenge, implying a role in the regulation of cell 
trafficking in asthma in response to allergen exposure (Holgate et al., 1997). 
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This is the first time corticosteroid sensitivity in vitro has been assessed in 
response to stimulation with adiponectin. Fallo and colleagues demonstrated that 
intravenous hydrocortisone inhibited adiponectin production for healthy volunteers in 
vivo (Fallo et al., 2004). This work is supported by in vitro work demonstrating that 
the treatment of 3T3-L1 adipocytes with 100 nM Dex for 16 hours suppressed 
adiponectin gene expression by between 50 and 85% (Fasshauer et al., 2002). In 
contrast, Uchida and colleagues demonstrated that plasma levels of adiponectin 
were significantly increased in patients with IgA nephropathy following pulsed 
methylprednisolone (Uchida et al., 2006). The authors concluded that this 
discrepancy may be due to the anti-inflammatory action of pulsed glucocorticoid 
therapy in terms of IL-6 production, which is a potent inhibitor of adiponectin. They 
acknowledged that their findings may reflect a disease specific effect. These are 
important findings in relation to this study, particularly in view of the fact that 83 % of 
the mild/moderate and 100 % of the severe cohort were receiving ICS and that 35.7 
% of the severe asthma cohort were taking maintenance OCS therapy in addition to 
ICS. Future work incorporating the measurement of serum adiponectin levels in 
severe asthmatic patients before and after commencing OCS therapy would allow 
this relationship to be further explored. 
The pro-inflammatory effect of adiponectin, in terms of IL-6 release, appears 
to be very steroid sensitive for mild/moderate, severe asthmatics and healthy 
controls. This is in contrast for CXCL8, where the severe asthma cohort exhibited a 
reduced steroid response in terms of CXCL8 release following stimulation with 
adiponectin compared to the other groups, no significant differences were seen for 
IL-6. Dex suppressed adiponectin induced INF-γ, IL-1RA, CCL3 and TNF-α release. 
For IL-10, no significant suppression was noted other than the mild/moderate group 
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at Dex 10-7 M and CCL2 exhibited significant suppression for all groups at 10-7 M. 
These findings are consistent with the action of adiponectin partly investigated in the 
previous chapter.  
There are some important limitations and considerations relating to this study. 
As previously discussed, adiponectin is present in different isoforms that are likely to 
exert different effects and their relative proportions or ratio may influence the 
inflammatory response (Pajvani et al., 2004). Furthermore the two main 
commercially available types of adiponectin, prokaryotic and eukaryotic derived, may 
behave differently – in part relating to potential LPS contamination and the formation 
of the more biologically active globular adiponectin (Richards et al., 2006).  The 
monomeric adiponectin used in this study may not be representative of physiological 
adiponectin and has in fact been previously shown to be more biologically active 
(Nishida et al., 2007). Repeating this work using a physiological mix of adiponectin 
would allow for these differences and potentially be more representative. As 
previously noted, serum adiponectin was not assessed with this work and knowledge 
of their levels would have allowed correlation with the cellular effect. There is 
additionally likely to be a gender effect on adiponectin levels and activity with greater 
serum levels in adolescent girls compared to boys, a difference that persists to 
adulthood (Bottner et al., 2004). Furthermore previous studies analysing serum 
adiponectin levels in relation to asthma have noted no correlation in peri/postpubertal 
boys (Kim et al., 2008), potentially a harmful effect on men (Sutherland et al., 2009) 
but beneficial effects for peri/postpubertal girls (Nagel et al., 2009) and 
premenopausal women (Sood and Shore, 2013) (Sood et al., 2008). This is a 
relevant factor in this study where 79% of the severe cohort, 67% of the 
mild/moderate cohort and 55% of the healthy cohort were female. 
251 
 
In summary, adiponectin was pro-inflammatory and adiponectin treated 
PBMCs released more IFN-γ and IL-10 in the asthmatic cohorts compared to healthy 
controls. An attenuated corticosteroid response in terms of CCL2 release was seen 
in the severe asthma compared to the mild/moderate asthma cohort. Further 
investigation is required to establish the mechanism of these links and establish the 
































 This thesis forms part of the ever growing and important research into the link 
between obesity and asthma. Approximately 8% of the adult UK population has 
asthma and the BMI of the UK population has significantly increased since the 
1960s, when less than 20% were overweight or obese, to a figure of approximately 
70% (Asthma UK, 2006, Department of Health, 2011). This has a significant role in 
asthma in terms of asthma control, healthcare utilisation, comorbid disease, 
corticosteroid burden and quality of life. A greater understanding of this relationship 
will allow us to treat this often difficult to control group and pave the way for further 
mechanistic work that may lead to targeted therapies.  
My thesis has identified that overweight and obesity are common findings in 
severe asthma (77.6% of the study population). Severe asthmatics with a BMI in the 
obese range were noted to have greater medication use in terms of SABA use per 
day, nebulisers and oral steroid requirements (both maintenance and short burst 
therapy). These findings are in keeping with previous cohorts of severe asthmatics 
such as SARP, where cluster analysis identified a unique group with a higher BMI 
(58 % with a BMI ≥ 30) and predominantly older females (71% female, mean age 50 
years) (Moore et al., 2010).  In addition, I found that GORD was reported to be more 
frequent in the obese group and obese severe asthmatics were less likely to be in 
full time employment due to their asthma. This suggests that obesity-related severe 
asthma is associated with more severe symptoms, a significant societal impact and 
patients are at risk of developing many deleterious side effects associated with 
corticosteroid use. The role of adipocytokines, lipid laded macrophages and lipid 
droplets in asthma remains poorly understood. I have found that leptin, resistin and 
adiponectin are pro-inflammatory and adiponectin appears to have a role in 
corticosteroid sensitivity in severe asthma. The identification of perilipin expression in 
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epithelial cells and the submucosa is a novel finding that suggests lipid droplets may 
correlate with airway inflammation.   
Obesity in severe asthma can be a comorbidity, affecting pathophysiology and 
response to therapy, or secondary to disease driven inactivity and/or systemic 
steroid therapy. Two recent studies have noted a genetic link between obesity and 
asthma which suggest obesity is associated with the development of asthma. 
Genomewide association studies (GWAS) have identified 32 independent loci 
associated with BMI with an estimated 250 common variant loci yet to be discovered 
(Speliotes et al., 2010). A study looking at 4835 children and the 32 established 
independent loci, used Mendelian randomisation to investigate the causal effect of 
BMI, fat mass and lean mass on childhood asthma. A weighted allele score was 
strongly associated with BMI, fat mass, lean mass and childhood asthma. This 
strongly suggests that a greater BMI, fat mass and lean mass in mid childhood 
increases the risk of developing asthma (Granell R, 2013). 
High fat diet and raised BMI appear to be risk factors for the development of 
intracellular lipid droplets and lipid laden macrophages. This study noted a higher 
lipid laden macrophage (LLMI) scores in severe compared to the mild/moderate 
asthmatics. This is likely to reflect the greater levels of GORD seen in the severe 
asthma group but may relate to disease severity and the higher BMI encountered in 
severe asthma.  
I found that perilipin expression is a common finding in epithelial cells and the 
submucosa. Higher perilipin expression was seen in the subepithelial layer in 
asthmatic subjects compared to healthy controls, which may reflect underlying 
airway inflammation associated with a greater release of eicosanoid mediators and 
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phagocytic activity. The presence of lipid droplets in airway epithelial cells, as 
suggested by perilipin expression, is a novel finding. These droplets may play an 
important inflammatory role and augment macrophage function.  
The mechanistic relationship between asthma and raised BMI is bidirectional. 
It is increasingly clear that adipose cells play an important role in systemic 
inflammation. Adipocytes produce inflammatory cytokines, termed adipokines, which 
correlate to the development of asthma and play a role in its severity. This study has 
looked at three adipokines (resistin, leptin and adiponectin) and subsequently 
examined adiponectin in greater detail in terms of inducing cytokine release and its 
role in corticosteroid insensitivity in vitro. Leptin and resistin were pro-inflammatory in 
terms of CXCL8 release from PBMCs but no significant effects were seen in relation 
to asthma severity or corticosteroid sensitivity. Adiponectin was pro-inflammatory in 
vitro and potentiated the steroid response in healthy subjects and mild/moderate 
asthmatics but not in severe asthma. This indicates that PBMCs taken from severe 
asthmatics exhibit an attenuated response to adiponectin. These are novel findings 
in asthma.  
Previous studies have assessed serum levels of adipokines and noted 
correlations with asthma in terms of disease presence, severity and corticosteroid 
sensitivity. However, these findings were present in particular age groups and 
appear to be gender related. There is a paucity of data at the cellular level in terms 
of the inflammatory effects of adipokines and how this relates to asthma, disease 





There are some important overall limitations to consider: 
1) The recruitment of obese mild/moderate asthmatics and severe asthmatics 
with a normal BMI was challenging and further work incorporating larger 
numbers of subjects in these groups would enhance this study. This would 
allow comparisons between obese and non-obese subgroups of 
mild/moderate and severe asthma; providing further insights into the role of 
obesity on the inflammatory response and inhibitory effect of corticosteroids 
on PBMCs in the presence of adipokines. 
2)  A total of eight cytokines were assessed in the adiponectin study and initially 
only CXCL8 release was analysed. Future work incorporating other 
adipocytokines would provide further information on the actions of adiponectin 
and the potential role in corticosteroid insensitivity.  
3) The use of PBMCs does not allow the identification of particular cell types that 
are responsible for the effects seen. For example, the cellular studies could 
be repeated using alveolar macrophages. The work incorporating lipid laden 
macrophages and lipid droplets did not assess particular and potentially key 
aspects such as how they impact macrophage phagocytosis and the location 
of lipid droplets.  
The results and discussion presented in here indicate a number of directions 
for future research, either in the form of new work or to clarify existing controversies: 
1) Asthma as a cause or effect of obesity. A longitudinal study to look at the 
role of obesity in asthma and disease severity. Analysis and extended follow 
up of a large cohort of patients to look at BMI prior to at the point of and 
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subsequent to a diagnosis of asthma. This would need to be a large study via 
primary care over a prolonged period of time. Additionally, intervention studies 
incorporating bariatric surgery to induce weight loss provide further 
information in to the role of obesity in asthma. Weight loss in obese asthmatic 
patients who underwent bariatric surgery has been associated with significant 
improvements in asthma control, asthma quality of life and AHR (Dixon et al., 
2011, Boulet et al., 2012).  Incorporating the cellular studies from this thesis 
for patients before and after bariatric surgery would provide an interesting 
insight into the mechanistic basis of these factors. 
2) The effects of adipokines in asthma. i) extending this study to examine the 
effects of other adipokines (table 1.2) and other cell types such as monocyte 
derived macrophages, airway macrophages, airway smooth muscle cells, 
airway epithelial cells and adipocytes ii) measurement of adipokines in serum 
and bronchoalveolar lavage fluid and protein expression of adipokines via 
western blot – correlate to asthma, disease severity and to serum levels and 
cellular function  
3) Assessment of different types of adiponectin. A comparative study 
incorporating prokaryote and eukaryote derived adiponectin alongside 
‘physiological’ adiponectin (a mixture of different adiponectin isoforms). 
4) Mechanisms underlying the formation and effects of lipid droplets in 
asthma. The use of electron or light microscopy to assess location and 
quantify lipid droplets could be correlated to asthma, disease severity and 
cellular function. This could be extended to different cell types including 
airway epithelial cells, airway smooth muscle cells and airway macrophages. 
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Macrophage function could be correlated with lipid droplet presence using 
fluorescently-labelled polystyrene beads or labelled H. influenzae or S. 
Aureus. 
In conclusion, my thesis has shown that obesity is often encountered in severe 
asthma with important correlations in terms of disease severity, symptoms and 
corticosteroid use. This is the first time that the effect of adipokines on inflammation 
and corticosteroid response in PBMCs taken from severe asthmatics has been 
assessed. Leptin, resistin and adiponectin are pro-inflammatory and adiponectin 
appears to play a role in corticosteroid sensitivity. Lipid laden macrophages and lipid 
droplets are frequently found in asthma and their role in disease severity and obesity 
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